

**POLYNUCLEOTIDES FOR USE AS TAGS AND TAG COMPLEMENTS IN THE DETECTION OF
NUCLEIC ACID SEQUENCES**

FIELD OF THE INVENTION

5 This invention relates to the use of families of oligonucleotides for use as tags, for example, in the sorting of molecules, identification of target nucleic acid molecules or for analyzing the presence of a mutation or polymorphism at a locus of each target nucleic acid molecule.

10 **BACKGROUND OF THE INVENTION**

 Single-nucleotide polymorphisms (SNPs) are the most common form of genetic polymorphism. This, coupled with their potential as functional variants, has produced a great deal of interest in SNPs both as pharmacogenetic indicators and as markers for mapping genes for complex
15 diseases. A large number of SNPs have already been identified with >21,000 entries on the NCBI's SNP database alone. Many recent studies have focused on identifying polymorphisms that lie in the coding sequence of potential candidate genes for common diseases. The ability to genotype this abundant source of variation rapidly and accurately is becoming an ever more important
20 goal in the genetics community. A variety of technologies have the potential to transfer to high-throughput genotyping laboratories. These include 5' exonuclease assays, such as TaqMan (Livak et al. 1995), molecular beacons (Tyagi et al. 1996), dye-labeled oligonucleotide ligation (DOL) (Chen et al. 1998), oligonucleotide-ligation assays (OLAs) (Tobe et al. 1996),
25 minisequencing (Chen and Kwok 1997; Pastinen et al. 1997), microarray technology (Hacia et al. 1998; Wang et al. 1998), mass spectroscopy (Ross et al. 1998) and the scorpions assay (Whitcombe et al. 1999). However, no single chemistry has gained acceptance as the technology of choice. A suitable method for such applications must be accurate and homogenous,
30 develop a robust, easily interpretable signal, and be flexible enough to extend to novel foci with little optimization. These features will lend the technology to automation.

 Third Wave Technologies, Inc., has developed a new mutation detection method referred to as the Invader Assay. The Invader Assay is
35 based on a novel linear signal amplification technology that requires specific hybridization of two "overlapping" oligonucleotides and subsequent recognition and cleavage of this structure by the Cleavase enzyme. Cleavases are bacterial enzymes that cleave unpaired DNA strands or "flaps" near a

nick, for instance when the 5' end of a sequence is displaced by the 3' end of an elongating upstream oligonucleotide. Enzymes with this so-called flap endonuclease activity typically excise the redundant 5' "flap" of the downstream oligonucleotide, leaving a simple nick to be repaired by lipases.

5 The excised "flap" is subsequently detected by one of several methods commonly known in the art. Cleavases have stringent requirements relative to the structure formed by such overlapping DNA sequences, and can be used to specifically detect single base pair mismatches immediately upstream of the cleavage site on the downstream DNA strand. Thermostable cleavages permit

10 reactions to be performed at temperatures sufficiently high to promote turnover and consequent signal amplification without the need for temperature cycling.

While the Invader Assay offers exquisite specificity, its use in the detection of multiple distinct target nucleic acids in a single experiment

15 i.e., multiplexing, is limited. This is because if the Invader Assay is to be used in a high-throughput gene microarray format, the most efficient method of detecting the excised "flap" sequence is to capture the sequence by hybridization to its complementary nucleic acid sequence attached to a solid phase support.

20 Working in a highly parallel hybridization environment requiring specific hybridization imposes very rigorous selection criteria for the design of families of oligonucleotides that are to be used. The success of these approaches is dependent on the specific hybridization of a probe and its complement. Problems arise as the family of nucleic acid molecules

25 cross-hybridise or hybridise incorrectly to the target sequences. While it is common to obtain incorrect hybridization resulting in false positives or an inability to form hybrids resulting in false negatives, the frequency of such results must be minimized. In order to achieve this goal certain thermodynamic properties of forming nucleic acid hybrids must be considered.

30 The temperature at which oligonucleotides form duplexes with their complementary sequences known as the T_m (the temperature at which 50% of the nucleic acid duplex is dissociated) varies according to a number of sequence dependent properties including the hydrogen bonding energies of the canonical pairs A-T and G-C (reflected in GC or base composition), stacking free energy

35 and, to a lesser extent, nearest neighbour interactions. These energies vary widely among oligonucleotides that are typically used in hybridization assays. For example, hybridization of two probe sequences composed of 24 nucleotides, one with a 40% GC content and the other with a 60% GC content,

with its complementary target under standard conditions theoretically may have a 10°C difference in melting temperature (Mueller et al., Current Protocols in Mol. Biol.; 15, 5:1993). Problems in hybridization occur when the hybrids are allowed to form under hybridization conditions that include a single hybridization temperature that is not optimal for correct hybridization of all oligonucleotide sequences of a set. Mismatch hybridization of non-complementary probes can occur forming duplexes with measurable mismatch stability (Santalucia et al., Biochemistry; 38: 3468-77, 1999). Mismatching of duplexes in a particular set of oligonucleotides can occur under hybridization conditions where the mismatch results in a decrease in duplex stability that results in a higher T_m than the least stable correct duplex of that particular set. For example, if hybridization is carried out under conditions that favor the AT-rich perfect match duplex sequence, the possibility exists for hybridizing a GC-rich duplex sequence that contains a mismatched base having a melting temperature that is still above the correctly formed AT-rich duplex. Therefore, design of families of oligonucleotide sequences that can be used in multiplexed hybridization reactions must include consideration for the thermodynamic properties of oligonucleotides and duplex formation that will reduce or eliminate cross hybridization behavior within the designed oligonucleotide set.

The development of such families of tags has been attempted over the years with varying degrees of success. There are a number of different approaches for selecting sequences for use in multiplexed hybridization assays. The selection of sequences that can be used as zipcodes or tags in an addressable array has been described in the patent literature in an approach taken by Brenner and co-workers. United States Patent No. 5,654,413 describes a population of oligonucleotide tags (and corresponding tag complements) in which each oligonucleotide tag includes a plurality of subunits, each subunit consisting of an oligonucleotide having a length of from three to six nucleotides and each subunit being selected from a minimally cross hybridizing set, wherein a subunit of the set would have at least two mismatches with any other sequence of the set. Table II of the Brenner patent specification describes exemplary groups of 4mer subunits that are minimally cross hybridizing according to the aforementioned criteria. In the approach taken by Brenner, constructing non cross-hybridizing oligonucleotides, relies on the use of subunits that form a duplex having at least two mismatches with the complement of any other subunit of the same

set. The ordering of subunits in the construction of oligonucleotide tags is not specifically defined.

Parameters used in the design of tags based on subunits are discussed in Barany et al. (WO 9731256). For example, in the design of polynucleotide sequences that are for example 24 nucleotides in length (24mer) derived from a set of four possible tetramers in which each 24mer "address" differs from its nearest 24mer neighbour by 3 tetramers. They discuss further that, if each tetramer differs from each other by at least two nucleotides, then each 24mer will differ from the next by at least six nucleotides. This is determined without consideration for insertions or deletions when forming the alignment between any two sequences of the set. In this way a unique "zip code" sequence is generated. The zip code is ligated to a label in a target dependent manner, resulting in a unique "zip code" which is then allowed to hybridise to its address on the chip. To minimise cross-hybridisation of a "zip code" to other "addresses", the hybridization reaction is carried out at temperatures of 75-80°C. Due to the high temperature conditions for hybridization, 24mers that have partial homology hybridise to a lesser extent than sequences with perfect complementarity and represent 'dead zones'. This approach of implementing stringent hybridization conditions for example, involving high temperature hybridization, is also practiced by Brenner et. al.

The current state of technology for designing non-cross hybridizing tags based on subunits does not provide sufficient guidance to construct a family of relatively large numbers of sequences with practical value in assays that require stringent non-cross hybridizing behavior.

Thus, while it is desirable to have, at once in a gene microarray format, a large number of "flap" molecules incorporated into the Invader Assay, the "flap" molecules should each be highly selective for its own complement sequence. While such an array provides the advantage that the family of molecules making up the grid is entirely of design, and does not rely on sequences as they occur in nature, the provision of a family of molecules, which is sufficiently large and where each individual member is sufficiently selective for its complement over all the other zipcode molecules (i.e., where there is sufficiently low cross-hybridization, or cross-talk) continues to elude researchers.

SUMMARY OF THE INVENTION

The present invention relates to the use of one set of 210 and a second set of 1168 minimally cross-hybridizing oligonucleotide sequences for use in the Invader Assay. The incorporation of these sequences into one of the two probes, and subsequent structure dependent cleavage of the minimally cross-hybridizing sequences upon hybridization to the target nucleic acid molecule enables the Invader Assay to be used in the analysis of multiple gene sequences on a gene microarray.

Using the method of Benight *et al.* a family of 100 sequences was obtained using a computer algorithm to have optimal hybridization properties for use in nucleic acid detection assays. The sequence set of 100 oligonucleotides was characterized in hybridization assays, demonstrating the ability of family members to correctly hybridize to their complementary sequences with an absence of cross hybridization. These are the sequences having SEQ ID NOs:1 to 100 of Table I. This set of sequences has been expanded to include an additional 110 sequences that can be grouped with the original 100 sequences as having non-cross hybridizing properties, based on the characteristics of the original set of 100 sequences. These additional sequences are identified as SEQ ID NOs:101 to 210 of the sequences in Table I. How these sequences were obtained is described below.

Variant families of sequences (seen as tags or tag complements) of a family of sequences taken from Table I are also part of the invention. For the purposes of discussion, families of tag complements will be described.

A family of complements is obtained from a set of oligonucleotides based on a family of oligonucleotides such as those of Table I. For illustrative purposes, providing a family of complements based on the oligonucleotides of Table I will be described.

Firstly, the groups of sequences based on the oligonucleotides of Table I can be represented as follows:

Table IA: Numeric sequences corresponding to word patterns of a set of oligonucleotides

Sequence Identifier	Numeric Pattern					
1	1	4	6	6	1	3
2	2	4	5	5	2	3
3	1	8	1	2	3	4
4	1	7	1	9	8	4
5	1	1	9	2	6	9
6	1	2	4	3	9	6
7	9	8	9	8	10	9
8	9	1	2	3	8	10

Table IA: Numeric sequences corresponding to word patterns of a set of oligonucleotides

Sequence Identifier	Numeric Pattern					
9	8	8	7	4	3	1
10	1	1	1	1	1	2
11	2	1	3	3	2	2
12	3	1	2	2	3	2
13	4	1	4	4	4	2
14	1	2	3	3	1	1
15	1	3	2	2	1	4
16	3	3	3	3	3	4
17	4	3	1	1	4	4
18	3	4	1	1	3	3
19	3	6	6	6	3	5
20	6	6	1	1	6	5
21	7	6	7	7	7	5
22	8	7	5	5	8	8
23	2	1	7	7	1	1
24	2	3	2	3	1	3
25	2	6	5	6	1	6
26	4	8	1	1	3	8
27	5	3	1	1	6	3
28	5	6	8	8	6	6
29	8	3	6	5	7	3
30	1	2	3	1	4	6
31	1	5	7	5	4	3
32	2	1	6	7	3	6
33	2	6	1	3	3	1
34	2	7	6	8	3	1
35	3	4	3	1	2	5
36	3	5	6	1	2	7
37	3	6	1	7	2	7
38	4	6	3	5	1	7
39	5	4	6	3	8	6
40	6	8	2	3	7	1
41	7	1	7	8	6	3
42	7	3	4	1	6	8
43	4	7	7	1	2	4
44	3	6	5	2	6	3
45	1	4	1	4	6	1
46	3	3	1	4	8	1
47	8	3	3	5	3	8
48	1	3	6	6	3	7
49	7	3	8	6	4	7
50	3	1	3	7	8	6
51	10	9	5	5	10	10
52	7	10	10	10	7	9
53	9	9	7	7	10	9
54	9	3	10	3	10	3
55	9	6	3	4	10	6
56	10	4	10	3	9	4
57	3	9	3	10	4	9
58	9	10	5	9	4	8
59	3	9	4	9	10	7
60	3	5	9	4	10	8

Table IA: Numeric sequences corresponding to word patterns of a set of oligonucleotides

Sequence Identifier	Numeric Pattern					
61	4	10	5	4	9	3
62	5	3	3	9	8	10
63	6	8	6	9	7	10
64	4	6	10	9	6	4
65	4	9	8	10	8	3
66	7	7	9	10	5	3
67	8	8	9	3	9	10
68	8	10	2	9	5	9
69	9	6	2	2	7	10
70	9	7	5	3	10	6
71	10	3	6	8	9	2
72	10	9	3	2	7	3
73	8	9	10	3	6	2
74	3	2	5	10	8	9
75	8	2	3	10	2	9
76	6	3	9	8	2	10
77	3	7	3	9	9	10
78	9	10	1	1	9	4
79	10	1	9	1	4	1
80	7	1	10	9	8	1
81	9	1	10	1	10	6
82	9	6	9	1	3	10
83	3	10	8	8	9	1
84	3	8	1	9	10	3
85	9	10	1	3	6	9
86	1	9	1	10	3	1
87	1	4	9	6	8	10
88	3	3	9	6	1	10
89	5	3	1	6	9	10
90	6	1	8	10	9	6
91	5	9	9	4	10	3
92	2	10	9	1	9	5
93	10	10	7	2	1	9
94	10	9	9	1	8	2
95	1	8	6	8	9	10
96	1	9	1	3	8	10
97	9	6	9	10	1	2
98	1	10	8	9	9	2
99	1	9	6	7	2	9
100	4	3	9	3	5	1
101	5	11	10	14	12	1
102	7	12	4	13	3	2
103	5	5	4	4	12	9
104	2	13	13	11	13	13
105	10	2	5	4	12	7
106	11	7	4	11	6	4
107	12	12	1	9	11	11
108	12	9	4	14	12	6
109	12	7	13	2	9	11
110	9	11	3	4	1	3
111	10	5	12	11	4	4
112	4	13	7	12	1	5

Table IA: Numeric sequences corresponding to word patterns of a set of oligonucleotides

Sequence Identifier	Numeric Pattern					
113	9	13	10	11	11	6
114	10	14	14	10	1	3
115	2	14	1	10	4	5
116	10	12	12	7	11	10
117	9	11	2	12	8	11
118	2	8	5	2	12	14
119	1	8	13	3	7	8
120	9	4	7	5	4	2
121	13	2	12	7	1	12
122	11	10	9	7	5	11
123	8	12	2	2	12	7
124	5	2	14	3	4	13
125	1	8	8	1	5	9
126	14	5	11	10	13	3
127	14	1	4	13	2	4
128	4	4	5	11	3	10
129	10	9	2	3	3	11
130	11	4	8	14	3	4
131	5	1	14	8	11	2
132	14	3	11	6	12	5
133	13	4	4	1	10	1
134	6	10	11	6	5	1
135	5	8	12	5	1	7
136	4	5	9	6	9	2
137	13	2	4	4	2	3
138	11	2	2	5	9	3
139	8	1	10	12	2	8
140	12	7	9	11	4	1
141	12	1	4	14	3	13
142	11	2	7	10	4	1
143	3	4	12	11	11	11
144	3	3	4	2	12	11
145	1	5	9	4	2	1
146	6	1	12	2	10	5
147	10	5	1	12	2	14
148	2	11	7	9	4	11
149	7	4	4	5	14	12
150	12	5	2	1	10	12
151	5	9	2	11	6	1
152	12	14	3	6	1	14
153	5	9	11	10	1	4
154	2	5	12	14	10	10
155	4	5	8	4	5	6
156	10	12	4	6	12	5
157	4	2	1	13	6	8
158	9	10	10	14	5	3
159	6	14	10	11	3	3
160	2	9	10	12	5	7
161	13	3	7	10	5	12
162	6	4	1	2	5	13
163	6	1	13	4	14	13
164	2	12	1	14	1	9

Table IA: Numeric sequences corresponding to word patterns of a set of oligonucleotides

Sequence Identifier	Numeric Pattern					
165	4	11	13	2	6	10
166	1	10	7	4	5	8
167	7	2	2	10	13	4
168	8	2	11	4	6	14
169	4	8	2	6	2	3
170	7	1	12	11	2	9
171	5	6	10	4	13	4
172	5	10	4	11	9	3
173	3	11	9	3	2	3
174	8	15	6	20	17	19
175	21	10	15	3	7	11
176	11	7	17	20	14	9
177	16	6	17	13	21	21
178	10	15	22	6	17	21
179	15	7	17	10	22	22
180	3	20	8	15	20	16
181	17	21	10	16	6	22
182	6	21	14	14	14	16
183	7	17	3	20	10	7
184	16	19	14	17	7	21
185	20	16	7	15	22	10
186	20	10	18	11	22	18
187	18	7	19	15	7	22
188	21	18	7	21	16	3
189	14	13	7	22	17	13
190	19	7	8	12	10	17
191	15	3	21	14	9	7
192	19	6	15	7	14	14
193	4	17	10	15	20	19
194	21	6	18	4	20	16
195	2	19	8	17	6	13
196	12	12	6	17	4	20
197	16	21	12	10	19	16
198	14	14	15	2	7	21
199	8	16	21	6	22	16
200	14	17	22	14	17	20
201	10	21	7	15	21	18
202	16	13	20	18	21	12
203	15	7	4	22	14	13
204	7	19	14	8	15	4
205	4	5	3	20	7	16
206	22	18	6	18	13	20
207	19	6	16	3	13	3
208	18	6	22	7	20	18
209	10	17	11	21	8	13
210	7	10	17	19	10	14

Here, each of the numerals 1 to 22 (numeric identifiers) represents a 4mer and the pattern of numerals 1 to 10 of the sequences in the above list corresponds to the pattern of tetrameric oligonucleotide segments present in the oligonucleotides of Table I, which oligonucleotides have been found to be

non-cross-hybridizing, as described further in the detailed examples. Each 4mer is selected from the group of 4mers consisting of WWWW, WWWX, WWWY, WWXW, WWXX, WWXY, WWYW, WWYX, WWYY, WXWW, WXWX, WXWY, WXXW, WXXX, WXXY, WXYW, WXYX, WXYX, WYWW, WYWX, WYWY, WYXW, WYXX, WYXY, WYYW, WYYX, WYYY, XWWW, XWWX, XWWY, XWXW, XWXX, XWXY, XWYW, XWYX, XWYY, XXWW, XXWX, XXWY, XXXW, XXXX, XXXY, XXYW, XXYX, XXYX, XYWW, XYWX, XYWY, XYXW, XYXX, XXYX, XYYW, XYYX, XYYY, YWWW, YWWX, YWWY, YWXW, YWXX, YWXY, YWYW, YWYX, YWYY, YXWW, YXWX, YXWY, YXXW, YXXX, YXXY, YXYW, YXYX, YXYX, YYWW, YYWX, YYWY, YYXW, YYXX, YXYX, YYYW, YYYX, and YYYY. Here W, X and Y represent nucleotide bases, A, G, C, etc., the assignment of bases being made according to rules described below.

Given this numeric pattern, a 4mer is assigned to a numeral. For example, 1 = WXYX, 2 = YWXY, etc. Once a given 4mer has been assigned to a given numeral, it is not assigned for use in the position of a different numeral. It is possible, however, to assign a different 4mer to the same numeral. That is, for example, the numeral 1 in one position could be assigned WXYX and another numeral 1, in a different position, could be assigned XXXW, but none of the other numerals 2 to 10 can then be assigned WXYX or XXXW. A different way of saying this is that each of 1 to 10 is assigned a 4mer from the list of eighty-one 4mers indicated so as to be different from all of the others of 1 to 10.

In the case of the specific oligonucleotides given in Table I, 1 = WXYX, 2 = YWXY, 3 = XXXW, 4 = YWYX, 5 = WYXY, 6 = YYWX, 7 = YWXX, 8 = WYXX, 9 = XYYW, 10 = XYWX, 11 = YYXW, 12 = WYXX, 13 = XYXW, 14 = WYYY, 15 = WXYW, 16 = WYXW, 17 = WXXW, 18 = WYYW, 19 = XYYX, 20 = YXYX, 21 = YXXY and 22 = XXYX.

Once the 4mers are assigned to positions according to the above pattern, a particular set of oligonucleotides can be created by appropriate assignment of bases, A, T/U, G, C to W, X, Y. These assignments are made according to one of the following two sets of rules:

(i) Each of W, X and Y is a base in which:

(a) W = one of A, T/U, G, and C,

X = one of A, T/U, G, and C,

Y = one of A, T/U, G, and C,

and each of W, X and Y is selected so as to be different from all of the others of W, X and Y,

(b) an unselected said base of (i) (a) can be substituted any number of times for any one of W, X and Y.

or

(ii) Each of W, X and Y is a base in which:

(a) W = G or C,

X = A or T/U,

Y = A or T/U,

and X \neq Y, and

(b) a base not selected in (ii) (a) can be inserted into each sequence at one or more locations, the location of each insertion being the same in each sequence as that of every other sequence of the set;

In the case of the specific oligonucleotides given in Table I, W = G, X = A and Y = T.

In any case, given a set of oligonucleotides generated according to one of these sets of rules, it is possible to modify the members of a given set in relatively minor ways and thereby obtain a different set of sequences while more or less maintaining the cross-hybridization properties of the set subject to such modification. In particular, it is possible to insert up to 3 of A, T/U, G and C at any location of any sequence of the set of sequences. Alternatively, or additionally, up to 3 bases can be deleted from any sequence of the set of sequences.

A person skilled in the art would understand that given a set of oligonucleotides having a set of properties making it suitable for use as a family of tags (or tag complements) one can obtain another family with the same property by reversing the order of all of the members of the set. In other words, all the members can be taken to be read 5' to 3' or to be read 3' to 5'.

A family of complements of the present invention is based on a given set of oligonucleotides defined as described above. Each complement of the family is based on a different oligonucleotide of the set and each complement contains at least 10 consecutive (i.e., contiguous) bases of the oligonucleotide on which it is based. For a given family of complements where one is seeking to reduce or minimize inter-sequence similarity that would result in cross-hybridization, each and every pair of complements meets particular homology requirements. Particularly, subject to limited exceptions, described below, any two complements within a set of complements are generally required to have a defined amount of dissimilarity.

In order to notionally understand these requirements for dissimilarity as they exist for a given pair of complements of a family, a phantom sequence is generated from the pair of complements. A "phantom" sequence is a single sequence that is generated from a pair of complements by selection, from each complement of the pair, of a string of bases wherein the bases of the string occur in the same order in both complements. An object of creating such a phantom sequence is to create a convenient and objective means of comparing the sequence identity of the two parent sequences from which the phantom sequence is created.

10 A phantom sequence may thus be generated from exemplary Sequence 1 and Sequence 2 as follows:

Sequence 1: ATGTTTAGTGAAAAGTTAGTATTG

* •

Sequence 2: ATGTTAGTGAATAGTATAGTATTG

• ♦

Phantom Sequence: ATGTTAGTGAAAAGTTAGTATTG

15 The phantom sequence generated from these two sequences is thus 22 bases in length. That is, one can see that there are 22 identical bases with identical sequence (the same order) in Sequence Nos. 1 and 2. There is a total of three insertions/deletions and mismatches present in the phantom sequence when compared with the sequences from which it was generated:

20 ATGT-TAGTGAA-AGT-TAGTATTG

The dashed lines in this latter representation of the phantom sequence indicate the locations of the insertions/deletions and mismatches in the phantom sequence relative to the parent sequences from which it was derived. Thus, the "T" marked with an asterisk in Sequence 1, the "A" marked with a diamond in Sequence 2 and the "A-T" mismatch of Sequences 1 and 2 marked with two dots were deleted in generating the phantom sequence.

A person skilled in the art will appreciate that the term "insertion/deletion" is intended to cover the situations indicated by the

asterisk and diamond. Whether the change is considered, strictly speaking, an insertion or deletion is merely one of vantage point. That is, one can see that the fourth base of Sequence 1 can be deleted therefrom to obtain the phantom sequence, or a "T" can be inserted after the third base of the

5 phantom sequence to obtain Sequence 1.

One can thus see that if it were possible to create a phantom sequence by elimination of a single insertion/deletion from one of the parent sequences, that the two parent sequences would have identical homology over the length of the phantom sequence except for the presence of a single base
10 in one of the two sequences being compared. Likewise, one can see that if it were possible to create a phantom sequence through deletion of a mismatched pair of bases, one base in each parent, that the two parent sequences would have identical homology over the length of the phantom sequence except for the presence of a single base in each of the sequences being compared. For
15 this reason, the effect of an insertion/deletion is considered equivalent to the effect of a mismatched pair of bases when comparing the homology of two sequences.

Once a phantom sequence is generated, the compatibility of the pair of complements from which it was generated within a family of complements can be
20 systematically evaluated:

According to one embodiment of the invention, a pair of complements is compatible for inclusion within a family of complements if any phantom sequence generated from the pair of complements has the following properties:

Any consecutive sequence of bases in the phantom sequence which is identical to a consecutive sequence of bases in each of the first and second complements from which it is generated is no more $((3/4 \times L) - 1)$ bases in length;

The phantom sequence, if greater than or equal to $(5/6 \times L)$ in length, contains at least 3 insertions/deletions or mismatches when compared to the first and second complements from which it is generated; and

The phantom sequence is not greater than or equal to $(11/12 \times L)$ in length.

25

Here, L_1 is the length of the first complement, L_2 is the length of the second complement, and $L = L_1$, or if $L_1 \neq L_2$, L is the greater of L_1 and L_2 .

In particular preferred embodiments of the invention, all pairs of complements of a given set have the properties set out above. Under particular circumstances, it may be advantageous to have a limited number of complements that do not meet all of these requirements when compared to every other complement in a family.

In one case, for any first complement there are at most two second complements in the family which do not meet all of the three listed requirements. For two such complements, there would thus be a greater chance of cross-hybridization between their tag counterparts and the first complement. In another case, for any first complement there is at most one second complement which does not meet all of three listed requirements.

It is also possible, given this invention, to design a family of complements where a specific number or specific portion of the complements do not meet the three listed requirements. For example, a set could be designed where only one pair of complements within the set do not meet the requirements when compared to each other. There could be two pairs, three pairs, and any number of pairs up to and including all possible pairs. Alternatively, it may be advantageous to have a given proportion of pairs of complements that do not meet the requirements, say 10% of pairs, when compared with other sequences that do not meet one or more of the three requirements listed. This number could instead be 5%, 15%, 20%, 25%, 30%, 35%, or 40%.

The foregoing comparisons would generally be largely carried out using appropriate computer software. Although notionally described in terms of a phantom sequence for the sake of clarity and understanding, it will be understood that a competent computer programmer can carry out pairwise comparisons of complements in any number of ways using logical steps that obtain equivalent results.

The symbols A, G, T/U, C take on their usual meaning in the art here. In the case of T and U, a person skilled in the art would understand that these are equivalent to each other with respect to the inter-strand hydrogen-bond (Watson-Crick) binding properties at work in the context of this invention. The two bases are thus interchangeable and hence the designation of T/U.

Analogues of the naturally occurring bases can be inserted in their respective places where desired. Analogues can be defined as any non-natural base, such as peptide nucleic acids and the like.

Other aspects of the invention are described below, particularly numbered paragraphs at the end of this specification.

In another broad embodiment A family of 1168 sequences was obtained using a computer algorithm to have desirable hybridization properties for use in nucleic acid detection assays. The sequence set of 1168 oligonucleotides was partially characterized in hybridization assays, demonstrating the ability of family members to correctly hybridize to their complementary sequences with minimal cross hybridization. These are the sequences having SEQ ID NOS:1 to 1168 of Table II.

Variant families of sequences (seen as tags or tag complements) of a family of sequences taken from Table II are also part of the invention. For the purposes of discussion, a family or set of oligonucleotides will often be described as a family of tag complements, but it will be understood that such a set could just easily be a family of tags.

A family of complements is obtained from a set of oligonucleotides based on a family of oligonucleotides such as those of Table II. To simplify discussion, providing a family of complements based on the oligonucleotides of Table II will be described.

Firstly, the groups of sequences based on the oligonucleotides of Table II can be represented as shown in Table IIA.

Table IIA: Numeric sequences corresponding to nucleotide patterns of a set of oligonucleotides

Numeric Pattern																								Sequence Identifier
1	1	1	2	2	3	2	3	1	1	1	3	1	2	2	3	2	2	2	3	2	3	2	1	1
3	2	2	1	3	1	3	2	2	1	1	2	2	3	2	1	2	2	2	3	1	2	3	1	2
1	2	3	2	2	1	1	1	3	2	1	1	3	2	3	2	2	3	1	1	1	2	3	2	3
2	3	1	2	3	2	2	1	3	1	1	3	2	1	2	1	2	2	3	2	3	1	1	2	4
2	2	2	3	2	3	2	1	3	1	1	2	1	2	3	2	3	2	2	3	2	2	1	1	5
1	2	1	1	3	2	3	2	1	1	3	2	3	1	1	1	2	1	1	3	1	1	3	1	6
1	1	3	1	3	2	1	2	2	2	3	2	2	3	2	3	1	3	2	2	1	1	1	2	7
3	2	3	2	2	2	1	2	3	2	2	1	2	1	2	3	2	3	1	1	3	2	2	2	8
1	1	1	3	1	3	1	1	2	1	3	1	1	2	1	2	3	2	3	2	1	1	3	2	9
2	1	2	3	1	1	1	3	1	3	2	3	1	3	1	2	1	1	2	3	2	2	2	1	10
1	2	3	1	3	1	1	1	2	1	2	3	2	2	1	3	1	1	2	3	2	3	1	2	11
2	2	1	3	2	2	3	2	2	3	1	2	3	2	2	2	1	3	2	1	3	2	2	2	12
3	2	1	1	1	3	1	3	2	1	2	1	1	3	2	2	2	3	1	2	3	1	2	1	13
1	1	1	3	2	1	1	3	1	1	2	3	1	2	3	2	1	1	2	1	1	3	2	3	14
3	2	1	3	1	1	1	2	1	3	2	2	2	1	2	2	3	1	2	3	1	2	2	3	15
2	3	2	1	1	3	2	3	1	1	1	2	1	3	2	3	1	3	2	2	1	2	2	2	16
1	1	1	2	1	3	1	2	3	1	2	1	2	1	1	3	2	3	1	3	1	1	2	3	17
1	2	1	1	3	2	2	1	2	1	1	3	2	3	2	2	1	2	3	2	3	1	3	2	18
2	1	2	1	3	1	2	1	1	1	3	1	3	1	2	3	1	2	2	2	3	2	2	3	19
1	3	1	3	2	2	3	1	3	1	1	2	3	2	1	2	1	3	2	1	2	2	1	2	20
1	1	3	2	1	3	2	2	2	3	2	1	1	3	1	1	2	3	1	2	2	3	2	1	21
2	2	1	2	3	1	1	1	2	2	3	1	3	2	3	1	1	3	1	2	2	3	1	2	22

Table IIA: Numeric sequences corresponding to nucleotide patterns of a set of oligonucleotides

Numeric Pattern																							Sequence Identifier	
3	2	1	2	1	2	3	2	1	1	1	2	2	3	2	2	1	2	3	2	2	3	1	3	23
3	1	1	2	2	3	2	1	2	1	1	1	3	2	1	2	2	1	3	1	2	3	2	3	24
2	1	3	1	2	3	1	3	1	2	2	1	1	3	2	3	2	2	1	2	2	2	3	1	25
3	2	2	1	1	3	2	2	2	3	2	2	2	1	2	3	2	1	2	1	3	1	1	3	26
3	1	3	2	1	2	2	1	3	2	1	1	1	3	2	3	1	2	1	2	3	1	2	1	27
3	2	3	1	1	2	3	1	2	2	2	1	3	2	1	1	1	2	3	1	2	2	3	1	28
3	1	2	2	3	1	1	3	2	2	1	2	1	3	1	1	1	2	3	1	2	2	1	3	29
1	3	2	3	1	2	1	1	1	2	3	2	2	1	3	2	2	3	1	1	2	2	3	2	30
2	1	2	1	2	1	3	2	1	1	1	2	3	2	2	2	3	2	3	2	3	2	2	3	31
2	2	1	1	3	2	3	2	2	1	3	2	2	1	2	2	2	3	2	2	3	2	1	3	32
3	2	1	3	2	1	1	2	1	2	3	1	1	3	2	3	1	3	1	1	2	1	2	1	33
2	1	3	2	3	2	1	2	1	3	1	1	2	3	2	1	3	1	2	2	2	1	3	2	34
2	2	3	2	1	3	1	2	2	1	3	1	2	3	2	3	2	2	2	3	2	1	1	1	35
2	1	3	2	1	2	1	3	1	3	2	1	3	1	3	1	2	3	1	2	1	2	2	2	36
1	2	2	3	2	3	1	1	1	3	1	1	1	3	1	3	1	1	3	1	1	1	2	2	37
2	3	2	3	1	3	1	1	2	2	1	1	3	1	2	2	1	1	3	1	1	2	3	2	38
1	2	1	2	2	1	3	2	2	1	1	3	1	1	1	3	1	1	3	1	3	2	2	3	39
2	2	3	2	1	3	2	2	3	1	3	1	1	1	2	1	2	3	2	1	3	2	2	2	40
2	1	3	1	3	2	2	3	2	2	1	1	1	3	1	3	2	3	2	1	1	1	2	1	41
3	2	2	1	2	3	1	2	3	2	3	2	1	2	1	1	3	2	1	1	2	1	2	3	42
2	2	2	3	2	2	1	3	1	1	2	3	1	3	1	1	3	1	2	2	2	1	2	3	43
1	3	2	1	2	1	3	2	2	2	1	1	1	3	1	1	3	2	1	3	2	1	3	1	44
3	2	3	1	3	1	2	1	2	1	3	1	2	2	2	1	3	1	1	1	3	2	1	1	45
2	2	3	2	2	2	1	2	1	3	2	3	1	1	3	2	3	1	1	2	1	3	2	1	46
1	1	3	2	1	1	3	2	1	3	2	1	1	2	1	3	2	3	2	3	2	2	1	1	47
1	2	2	2	3	2	3	1	3	2	2	1	2	3	1	1	1	3	1	2	1	1	3	1	48
3	1	1	1	3	2	1	3	1	3	1	1	2	1	1	1	3	1	2	1	1	3	1	1	49
1	2	2	2	1	1	3	1	2	2	3	2	2	1	1	3	1	3	2	1	3	1	1	3	50
3	2	2	2	1	1	1	3	1	2	2	3	2	1	1	3	1	1	2	3	2	3	2	1	51
2	2	2	3	2	3	1	1	3	1	2	3	1	1	3	2	1	2	2	2	3	2	1	2	52
2	3	2	3	2	2	2	1	3	1	1	2	2	2	1	3	2	1	2	3	2	3	2	1	53
3	1	2	1	1	2	3	1	2	2	1	2	1	3	1	1	1	3	2	3	2	2	2	3	54
3	2	2	1	2	2	2	3	2	1	1	3	2	2	1	1	3	1	2	1	3	2	1	3	55
1	3	2	2	2	1	2	2	3	1	1	1	3	1	3	2	2	2	3	1	1	2	1	3	56
2	2	3	2	3	2	2	2	1	2	2	3	2	3	2	1	3	2	2	2	1	1	1	3	57
1	2	2	3	2	3	1	3	1	1	3	1	2	1	2	3	1	1	1	3	2	2	1	2	58
2	3	1	3	1	1	2	3	2	1	1	1	3	1	1	2	3	2	2	2	1	2	2	3	59
1	2	3	2	3	1	1	1	3	2	2	1	2	3	1	2	3	2	2	1	1	2	2	3	60
3	2	2	2	1	3	2	1	2	2	1	3	2	2	3	2	2	1	1	3	1	2	2	3	61
3	1	2	2	3	1	2	1	2	2	2	3	1	1	2	3	2	2	2	3	2	2	2	3	62
2	3	1	1	2	2	3	1	1	1	3	2	3	2	1	1	2	3	2	2	3	2	1	2	63
3	1	2	2	3	2	1	2	2	3	2	2	3	1	3	1	1	2	1	3	1	1	2	1	64
1	1	1	2	2	2	3	1	3	1	2	2	2	3	2	3	1	2	1	3	1	3	2	1	65
3	2	1	1	2	2	1	3	1	2	2	2	3	2	2	2	3	2	2	3	2	2	3	2	66
3	2	2	2	3	2	1	2	2	3	2	2	1	3	2	3	1	1	2	1	2	1	3	2	67
1	2	3	2	1	3	2	1	3	2	1	3	1	2	3	2	2	2	1	2	3	1	1	2	68
2	3	2	2	2	1	1	1	3	1	2	3	1	2	2	3	1	1	3	1	1	1	2	3	69
2	3	2	3	1	2	1	1	2	3	1	2	3	2	2	1	2	2	2	3	2	3	2	1	70
1	2	1	3	2	2	3	2	3	1	3	1	1	2	2	2	3	2	1	1	2	2	1	3	71
1	2	1	3	1	2	3	2	1	1	3	1	1	3	1	1	1	2	3	2	3	1	1	1	72
1	3	1	2	2	1	1	3	1	3	1	1	3	2	2	1	1	2	1	3	1	3	2	1	73
3	1	1	3	2	1	1	1	2	2	3	2	3	1	1	2	3	1	1	1	3	1	1	1	74
1	1	2	3	2	1	1	3	1	1	1	3	1	1	3	1	2	2	3	2	2	3	2	1	75

Table IIA: Numeric sequences corresponding to nucleotide patterns of a set of oligonucleotides

Numeric Pattern																							Sequence Identifier	
2	2	2	3	1	2	2	2	1	2	3	2	3	2	2	1	2	3	2	2	3	1	3	2	76
3	2	1	2	2	3	1	3	1	1	1	2	2	2	3	1	1	3	1	1	2	3	1	1	77
3	1	1	2	2	3	2	1	2	3	1	1	1	2	3	1	1	2	2	3	2	1	1	3	78
2	1	2	2	3	2	1	3	1	1	3	2	1	1	1	3	2	2	1	3	1	1	3	2	79
2	2	2	1	2	3	2	1	1	2	3	1	2	1	1	3	2	3	2	1	3	2	2	3	80
1	2	1	2	1	3	2	2	3	1	1	1	2	2	3	2	3	1	2	1	3	2	3	2	81
1	2	1	1	3	1	1	1	2	2	1	3	1	3	1	3	2	2	3	2	2	1	1	3	82
3	1	1	2	2	3	2	3	1	1	1	2	3	2	3	1	2	2	3	1	2	1	2	1	83
1	1	1	2	1	1	3	2	1	3	2	2	2	1	1	2	3	1	3	1	3	1	1	3	84
3	1	2	2	1	1	1	3	1	1	3	2	1	1	3	2	3	1	1	2	3	2	2	2	85
2	1	2	3	2	3	2	3	2	2	3	2	2	2	1	3	2	3	2	2	1	2	2	1	86
3	1	3	2	2	1	2	1	2	3	2	1	3	2	2	1	3	1	3	2	2	1	2	1	87
3	1	1	1	3	1	1	1	3	1	1	3	2	3	2	2	1	1	3	2	2	1	1	1	88
2	1	3	2	1	2	2	1	3	2	1	1	3	2	1	2	3	2	3	1	2	2	3	2	89
2	2	3	2	3	2	3	1	2	2	3	1	1	2	1	2	2	3	2	3	1	1	1	2	90
1	2	3	2	3	1	1	1	3	1	3	2	2	1	1	3	2	3	1	2	2	1	1	1	91
3	1	2	2	3	1	1	2	3	1	2	2	3	1	3	1	2	1	2	3	2	1	1	1	92
1	1	3	1	2	3	1	2	1	3	2	2	1	1	3	2	3	2	1	1	3	2	2	1	93
2	1	3	2	2	3	2	2	1	2	2	3	1	3	1	1	2	2	2	1	3	1	1	3	94
2	2	2	1	2	1	3	2	3	1	1	2	2	1	2	3	1	3	2	3	1	1	1	3	95
3	1	2	1	3	1	2	2	2	1	3	1	1	2	3	1	1	2	2	1	1	3	2	3	96
2	2	2	3	1	1	3	1	1	3	1	3	1	2	2	2	3	1	1	1	2	2	3	1	97
1	2	3	1	1	2	1	1	3	1	3	2	2	3	1	2	1	1	1	2	3	2	3	1	98
2	3	2	2	2	1	2	3	2	1	3	2	3	2	1	3	1	2	2	3	1	1	2	2	99
2	2	2	1	1	3	2	3	1	3	2	2	1	2	1	3	1	1	3	2	1	3	2	1	100
3	1	2	2	2	1	2	3	2	3	2	2	2	3	1	1	3	2	2	1	1	3	1	2	101
2	1	3	2	2	1	3	1	3	1	1	1	3	2	3	1	2	1	1	1	3	2	2	1	102
3	2	1	1	2	3	1	2	1	1	2	3	1	1	3	2	3	2	1	2	1	2	1	3	103
1	1	2	3	1	1	3	2	3	2	2	1	3	2	1	2	1	3	1	2	1	3	2	1	104
2	1	1	1	2	2	3	1	3	2	2	2	3	2	2	3	1	2	2	3	2	1	3	105	
2	1	1	2	3	1	1	3	1	1	2	1	1	3	2	1	2	3	1	3	2	3	2	2	106
1	1	1	2	3	2	1	1	2	1	3	2	3	2	2	3	2	2	1	3	2	2	1	3	107
1	3	1	3	2	2	1	3	2	3	1	1	1	2	3	1	2	3	2	2	2	1	1	2	108
3	1	1	1	2	1	3	1	1	1	2	3	2	1	2	2	3	2	2	2	3	2	3	1	109
1	3	2	2	1	2	1	1	3	2	2	2	3	2	3	1	3	1	1	2	2	1	1	3	110
3	1	3	2	2	2	1	2	1	3	2	2	1	3	1	1	2	1	2	3	2	2	3	2	111
1	3	1	3	2	2	1	2	2	1	3	1	1	3	1	1	3	1	2	2	2	1	1	3	112
3	1	3	2	2	1	1	2	3	1	1	1	2	1	1	3	2	1	2	2	2	3	2	3	113
1	2	3	1	2	3	1	1	2	1	3	2	2	3	1	1	3	2	1	2	1	2	1	3	114
1	2	1	3	1	2	1	2	3	1	3	1	1	2	3	1	1	1	3	2	2	1	3	2	115
2	1	2	3	2	1	1	1	3	1	1	1	3	2	3	1	1	1	3	1	1	3	1	1	116
2	3	1	1	2	3	2	1	3	1	1	1	2	3	1	1	2	3	2	2	3	1	1	1	117
1	1	2	2	3	1	1	2	1	3	2	3	2	3	2	3	1	3	2	2	2	1	1	2	118
1	3	1	2	1	2	2	3	2	2	2	3	1	2	2	1	1	2	3	1	1	3	1	3	119
1	1	1	3	2	2	3	2	1	1	1	3	2	2	3	1	1	3	1	2	1	1	1	3	120
3	2	2	1	1	3	1	3	1	2	2	1	2	3	1	3	1	2	3	2	1	2	2	1	121
1	3	1	1	3	1	2	1	2	1	1	3	1	1	3	1	2	2	3	1	1	2	2	3	122
3	2	1	3	1	1	1	2	2	2	3	1	1	2	2	3	1	2	3	2	3	1	1	1	123
1	1	3	1	3	2	1	3	1	2	2	3	1	2	1	1	3	2	1	2	1	2	3	1	124
2	3	1	2	1	2	1	3	2	1	3	2	3	1	1	3	1	1	1	2	1	1	3	2	125
1	3	1	2	1	1	2	3	1	2	3	1	3	1	1	1	2	3	1	1	3	1	2	1	126
1	2	3	2	3	1	1	1	3	2	1	2	2	2	3	2	3	1	2	1	2	1	3	2	127
1	1	2	1	1	3	1	3	1	1	2	2	3	1	2	1	2	3	1	1	3	1	2	3	128

Table IIA: Numeric sequences corresponding to nucleotide patterns of a set of oligonucleotides

Numeric Pattern																							Sequence Identifier	
2	1	1	3	2	3	2	1	2	2	2	1	3	2	1	3	1	1	2	3	1	1	3	2	129
2	1	2	3	2	2	1	3	1	2	2	2	3	2	2	3	1	3	1	2	2	3	1	2	130
1	3	2	2	2	3	2	1	2	3	1	1	3	1	3	1	2	1	3	2	1	2	2	2	131
3	1	3	1	1	1	2	3	2	2	1	2	3	2	1	2	2	2	1	3	2	1	3	2	132
2	1	2	3	2	3	1	3	1	1	2	3	2	3	2	2	2	3	1	2	2	2	1	1	133
3	2	1	2	3	2	2	2	3	2	2	2	1	2	1	3	1	1	2	3	2	1	2	3	134
3	1	3	2	1	2	1	2	1	3	1	1	3	1	1	1	3	1	1	1	2	2	2	3	135
1	2	3	1	3	2	3	1	1	3	2	1	1	1	2	3	2	1	3	2	2	1	2	2	136
2	2	1	1	3	1	1	3	2	3	1	3	2	2	1	2	2	3	2	3	1	2	1	2	137
1	2	3	1	1	1	2	3	1	3	1	1	2	1	2	2	3	2	2	3	2	2	2	3	138
3	1	2	2	1	1	2	3	1	2	2	1	2	3	2	3	1	1	2	2	3	1	2	3	139
3	1	1	1	2	3	2	2	1	1	1	3	1	2	1	2	3	1	1	1	3	2	1	3	140
2	1	2	2	3	2	2	3	1	2	2	2	3	1	2	1	2	2	1	3	2	3	2	3	141
2	2	2	1	2	3	2	2	2	3	2	3	2	1	2	3	2	1	1	3	2	1	3	2	142
1	1	2	2	3	1	1	1	3	1	1	2	2	3	2	3	2	3	1	1	2	2	3	1	143
2	3	1	3	2	2	2	3	1	1	2	2	2	3	2	2	2	3	1	3	2	1	1	2	144
3	1	2	3	2	1	2	1	1	2	3	1	2	3	2	3	2	3	2	1	1	1	2	2	145
1	2	3	2	3	1	3	1	3	1	1	3	1	1	2	2	2	3	2	2	2	1	2	2	146
3	2	3	1	2	1	1	1	3	2	1	2	2	3	2	2	3	1	2	1	3	1	1	1	147
3	1	1	3	2	1	3	1	1	2	1	3	1	1	1	3	2	2	1	1	2	1	3	1	148
2	2	3	2	3	2	1	3	2	2	1	1	3	1	3	2	2	3	2	2	2	1	1	2	149
2	1	3	2	1	3	2	1	1	3	2	2	3	2	2	1	3	1	1	2	1	3	2	2	150
1	1	2	2	2	3	1	1	3	2	1	2	1	1	2	3	1	1	2	3	2	3	2	3	151
2	1	3	1	1	1	2	2	3	2	1	3	2	1	2	2	2	3	1	3	1	3	1	1	152
2	3	2	1	2	1	2	3	2	2	1	1	2	3	1	3	1	2	3	2	2	3	2	1	153
2	1	2	2	2	3	1	2	1	1	3	1	3	1	1	2	3	1	1	3	1	1	3	2	154
2	2	3	1	1	2	1	3	2	3	2	1	1	2	3	1	1	2	1	2	3	1	2	3	155
3	2	1	3	2	2	2	3	2	3	1	1	2	1	3	1	1	2	2	1	3	2	2	2	156
1	1	1	3	1	2	3	1	2	2	3	2	1	1	2	2	2	3	2	3	2	3	1	1	157
3	1	1	3	1	2	2	3	2	2	3	1	3	2	2	1	1	2	1	3	1	2	1	1	158
1	3	1	2	2	1	2	3	2	1	3	2	3	1	2	3	2	1	1	1	2	3	2	2	159
3	1	1	2	2	2	1	3	1	2	3	2	1	3	1	2	1	2	3	1	1	2	3	2	160
3	1	2	1	3	1	1	3	2	3	2	1	2	2	1	1	3	2	1	1	3	2	2	1	161
2	1	2	3	1	1	2	2	1	2	3	1	3	1	1	3	1	1	2	1	3	1	3	2	162
2	2	2	3	2	2	1	2	3	1	1	3	2	3	1	2	2	2	3	2	2	2	3	2	163
3	2	1	1	1	3	1	2	2	3	2	3	2	2	1	2	1	2	3	1	1	1	2	3	164
2	2	3	2	3	1	2	1	3	2	1	3	2	2	1	3	1	2	1	2	2	2	3	2	165
3	1	1	2	2	1	1	3	1	2	1	1	1	3	1	1	3	1	3	1	1	3	2	1	166
3	1	2	2	3	2	1	3	1	1	2	3	1	1	2	2	2	3	2	1	3	2	1	2	167
1	1	1	2	1	1	3	1	3	1	3	1	3	1	1	2	3	1	2	2	2	1	3	2	168
1	1	2	2	1	2	3	2	3	1	1	2	1	3	1	2	2	3	2	2	3	1	1	3	169
2	2	1	1	3	1	2	2	2	1	2	3	2	3	1	2	1	3	2	1	3	1	3	2	170
2	2	1	1	1	3	1	2	1	3	2	3	2	2	2	3	2	2	3	2	3	2	2	1	171
2	1	2	2	3	1	2	2	2	1	2	3	1	1	3	1	3	2	1	2	1	3	2	3	172
1	1	1	2	2	2	3	1	2	3	1	3	2	1	3	2	2	2	1	1	3	1	3	1	173
1	2	1	1	1	3	2	2	3	2	2	2	3	1	2	3	2	2	2	3	1	1	2	3	174
3	1	2	2	3	2	3	1	2	3	1	1	2	1	1	2	3	2	2	1	2	2	3	1	175
3	1	2	3	1	1	3	1	1	1	2	1	2	3	1	2	1	2	3	1	1	2	1	3	176
2	2	1	1	1	3	2	2	1	2	2	3	1	1	3	2	3	1	1	3	2	2	3	1	177
2	2	3	2	1	1	3	1	1	1	2	1	3	1	3	1	2	2	2	3	2	3	2	2	178
3	1	3	1	2	2	3	1	3	2	2	2	1	1	3	2	1	2	2	1	3	1	2	2	179
1	3	2	3	1	2	1	1	2	1	3	1	1	2	3	1	2	1	1	1	2	3	2	3	180
3	1	2	1	1	2	1	3	2	3	1	1	2	2	2	3	1	3	2	2	3	2	1	2	181

Table IIA: Numeric sequences corresponding to nucleotide patterns of a set of oligonucleotides

Numeric Pattern																								Sequence Identifier
1	3	1	2	1	2	2	2	3	2	1	3	2	1	3	1	1	1	3	2	1	2	3	2	182
3	2	2	1	2	3	1	1	2	3	2	2	3	1	1	2	2	2	3	1	1	2	3	2	183
1	2	3	1	1	1	3	1	2	2	2	1	3	2	2	3	2	3	1	3	1	2	1	2	184
1	1	1	2	1	3	1	3	1	1	3	2	2	1	2	3	1	2	3	2	3	1	2	1	185
2	2	1	3	2	3	1	3	1	1	1	2	3	2	2	2	1	1	2	3	2	3	1	2	186
2	3	1	1	3	1	1	2	1	2	3	2	3	1	1	1	2	2	1	3	2	2	2	3	187
3	2	2	2	3	1	2	1	3	2	2	2	1	1	2	3	1	3	2	1	2	2	3	1	188
3	2	2	3	2	1	1	3	2	1	1	2	3	1	2	1	1	1	3	2	1	2	3	1	189
2	1	1	3	1	3	2	1	3	2	1	1	2	2	3	2	2	3	2	2	2	1	3	1	190
2	2	2	3	1	3	1	3	1	3	2	1	2	3	2	1	2	3	1	2	2	1	2	2	191
1	2	2	3	1	2	2	3	2	3	1	1	2	2	1	3	1	2	1	3	1	1	3	1	192
3	1	2	2	1	3	2	1	2	2	2	1	3	2	1	3	2	1	1	2	1	3	1	3	193
2	1	2	3	2	1	2	2	1	3	1	3	1	2	1	2	2	3	1	1	1	3	2	3	194
2	1	2	3	2	3	1	1	1	3	2	1	1	2	3	1	2	1	1	1	2	3	1	3	195
3	2	1	1	2	2	1	3	2	1	1	2	3	1	2	2	2	3	1	1	2	3	1	3	196
3	2	2	2	1	2	2	3	2	1	1	1	3	1	2	3	2	1	1	3	2	3	1	1	197
2	1	3	2	1	3	1	1	2	2	3	2	2	3	2	2	1	1	1	3	1	1	2	3	198
2	1	2	2	3	2	2	1	3	2	2	1	2	3	2	1	3	2	3	2	3	2	1	1	199
3	1	3	2	3	1	1	1	3	2	2	1	2	1	2	3	1	1	1	3	2	1	2	1	200
1	2	1	2	1	3	1	1	3	2	2	3	1	2	3	1	3	2	2	2	1	2	3	1	201
2	2	2	1	3	1	1	3	2	1	1	3	1	1	2	1	1	3	2	3	1	3	2	1	202
2	3	2	3	2	1	2	1	1	3	1	2	1	2	2	2	3	2	1	1	3	1	1	3	203
2	1	3	1	1	3	1	3	2	2	3	2	1	2	2	3	2	2	1	2	1	1	3	2	204
3	2	3	2	2	1	2	2	1	3	2	2	2	1	1	3	2	2	1	3	1	3	2	1	205
1	1	2	1	2	1	3	2	3	1	2	3	2	3	1	1	1	2	2	3	1	1	2	3	206
2	2	1	3	1	3	1	1	2	1	3	1	3	2	3	1	2	2	1	2	1	3	2	2	207
3	1	1	3	2	3	1	3	2	2	1	1	2	3	1	2	2	2	3	2	1	1	1	2	208
1	1	2	3	2	1	1	1	3	2	1	1	1	3	1	1	1	3	2	3	1	2	3	1	209
3	2	2	1	3	2	2	1	2	3	1	2	3	1	1	2	1	2	2	3	2	3	2	1	210
1	1	1	2	3	1	3	2	2	1	3	1	3	2	1	3	1	1	2	2	1	2	3	2	211
3	1	2	1	2	1	3	1	1	3	1	2	2	1	3	2	2	1	3	2	3	1	2	1	212
1	2	1	3	2	2	2	3	2	2	3	1	3	1	2	2	2	1	2	3	1	3	2	1	213
2	1	3	1	1	2	1	3	2	2	1	3	2	1	3	2	1	1	3	1	3	2	1	2	214
3	1	1	2	2	2	3	2	1	2	2	3	2	3	1	1	3	2	2	2	1	3	2	1	215
3	2	1	3	2	1	1	3	1	1	3	1	3	1	1	2	2	1	3	1	2	2	1	1	216
1	1	2	3	2	3	2	2	1	2	3	2	1	2	3	2	1	1	1	2	1	3	2	3	217
3	1	1	2	2	1	3	2	2	1	3	1	3	2	1	1	1	2	2	3	2	2	2	3	218
3	1	1	1	2	2	3	1	1	3	1	2	1	3	2	1	1	3	1	1	1	2	3	1	219
3	2	3	2	1	2	2	1	2	3	2	3	1	2	2	2	1	2	3	1	2	1	3	1	220
2	1	2	2	1	2	3	1	3	1	1	1	3	2	2	3	1	1	2	1	3	2	1	3	221
2	1	2	3	2	1	2	2	3	2	1	2	2	3	1	3	2	1	3	1	2	3	1	1	222
3	2	3	1	2	2	3	1	1	2	1	3	2	1	3	1	2	2	3	2	2	2	1	1	223
1	3	2	1	1	3	2	2	3	2	2	2	3	1	2	2	3	1	1	1	2	2	2	3	224
3	1	1	3	2	2	2	3	1	2	2	2	1	1	3	2	2	2	1	1	3	1	1	3	225
3	1	3	1	1	3	1	2	1	1	1	2	3	1	2	1	2	2	3	2	2	1	2	3	226
1	2	3	1	2	3	1	3	2	2	3	2	2	1	1	2	1	3	2	2	1	3	2	2	227
2	1	2	3	1	2	1	2	2	2	3	1	1	3	1	3	2	3	2	2	1	1	3	1	228
3	1	3	1	2	3	1	2	2	1	1	1	3	2	3	1	2	2	2	1	2	3	1	1	229
1	2	1	3	2	2	1	1	3	1	3	2	3	1	2	3	1	3	1	1	2	1	1	1	230
2	2	2	1	2	2	3	2	2	1	3	1	2	1	1	1	3	1	3	2	2	3	1	3	231
1	3	1	1	2	1	2	2	3	1	2	1	3	2	2	3	1	1	3	2	2	3	1	1	232
2	1	3	2	3	2	1	1	1	3	2	3	2	1	3	1	2	2	3	2	1	1	1	2	233
1	3	2	1	3	2	3	1	2	1	2	3	1	2	2	2	3	1	1	2	1	2	2	3	234

Table IIA: Numeric sequences corresponding to nucleotide patterns of a set of oligonucleotides

Numeric Pattern																							Sequence Identifier	
2	3	2	1	2	2	3	1	1	2	2	1	3	1	1	2	1	3	2	3	1	3	1	1	235
2	3	1	2	1	2	3	1	3	1	2	1	3	1	1	3	2	2	2	1	1	2	3	2	236
3	1	1	3	1	1	3	2	1	1	3	2	1	2	1	1	1	3	2	1	1	1	2	3	237
2	2	2	1	1	3	2	3	2	3	1	2	1	1	3	1	1	1	3	1	2	1	3	1	238
2	1	2	2	3	2	2	3	1	1	2	3	2	3	2	2	2	1	1	1	3	1	3	1	239
3	1	1	2	1	1	2	3	1	2	3	1	3	1	2	3	1	2	2	1	2	2	3	1	240
2	1	3	1	3	1	1	1	3	1	3	1	3	1	1	2	2	3	2	1	2	2	1	1	241
1	2	3	2	1	2	1	1	2	3	1	3	1	3	1	2	3	2	2	2	3	2	3	1	242
1	1	2	1	3	1	2	1	1	3	1	2	2	3	1	2	2	3	2	3	2	2	2	3	243
2	2	2	3	1	2	3	1	2	1	1	2	1	3	1	1	3	1	3	1	1	2	3	1	244
1	3	1	2	3	1	1	2	1	1	3	2	2	3	2	3	1	1	2	3	2	2	2	1	245
1	3	1	2	3	1	1	1	3	1	1	1	3	2	3	2	1	3	1	1	2	1	2	2	246
2	3	2	2	1	1	1	2	3	2	1	2	3	2	1	3	2	1	1	2	2	3	1	3	247
2	1	3	2	1	3	2	3	2	3	1	1	3	2	2	1	2	2	2	3	2	2	1	2	248
1	3	2	3	1	1	2	3	2	2	2	3	2	1	1	1	3	1	3	2	2	2	1	1	249
3	1	2	1	1	1	2	3	1	3	1	1	2	2	3	1	3	2	1	1	2	2	3	2	250
2	3	1	2	3	1	3	1	1	1	2	2	3	2	2	2	1	1	3	2	3	2	2	2	251
1	1	1	2	1	1	3	2	1	3	2	3	2	3	1	3	2	1	1	2	1	3	2	1	252
2	1	2	3	1	1	1	2	1	2	3	2	3	1	2	1	3	2	1	1	3	1	3	1	253
1	2	2	3	2	1	1	3	1	3	2	3	1	2	2	1	2	1	3	1	2	3	1	2	254
1	3	1	3	2	1	1	3	1	1	2	3	1	1	1	3	1	3	1	2	1	1	2	1	255
2	1	1	3	2	1	1	3	2	1	3	1	2	3	2	2	1	1	1	3	1	3	1	2	256
1	1	1	2	1	3	1	1	1	3	1	1	2	2	3	2	1	3	1	3	2	1	3	2	257
1	2	1	3	1	2	2	2	1	1	3	2	3	1	1	3	1	3	1	3	2	2	1	2	258
3	1	1	2	3	2	2	2	3	2	1	1	1	2	3	2	1	2	1	3	1	2	1	3	259
1	1	1	2	1	3	1	1	2	3	1	3	2	1	3	2	3	1	1	1	2	1	2	3	260
2	2	3	1	1	2	2	1	2	3	2	1	3	1	3	1	1	1	3	2	1	1	1	3	261
2	1	3	2	1	1	1	2	2	3	1	3	1	3	2	1	3	2	2	3	1	1	2	2	262
2	3	2	1	1	1	3	2	3	2	2	2	1	2	1	3	2	3	2	3	2	1	1	2	263
1	2	1	2	3	1	2	2	2	3	1	3	1	2	3	1	3	1	1	2	3	2	1	1	264
1	1	2	1	2	2	3	1	2	1	2	3	2	3	2	2	3	2	3	1	1	3	2	1	265
1	3	2	3	1	3	1	2	2	1	2	3	1	3	2	1	2	2	3	1	2	2	2	1	266
2	2	3	2	1	2	2	2	1	3	1	2	1	3	2	3	1	3	1	2	2	1	2	3	267
1	2	1	3	1	1	1	2	3	1	1	1	3	1	2	1	3	1	2	1	3	1	1	3	268
3	1	2	2	3	2	1	2	1	2	3	2	1	1	1	3	2	1	3	2	2	2	1	3	269
2	1	2	3	1	1	2	3	2	2	1	2	2	3	2	3	2	3	2	2	3	1	2	2	270
3	1	2	1	2	2	1	3	2	1	3	1	3	2	1	1	3	2	1	2	1	2	2	3	271
2	3	1	3	1	2	3	1	1	2	2	2	3	2	3	2	2	1	2	3	1	2	1	2	272
2	1	2	3	1	1	2	3	1	1	3	2	1	1	1	3	1	3	1	2	3	2	1	1	273
3	1	3	2	3	1	1	2	2	2	3	2	2	3	2	2	1	1	2	2	3	2	2	2	274
1	3	1	1	1	2	2	3	2	1	3	1	3	2	2	1	1	2	2	3	2	3	2	1	275
3	2	3	2	2	1	1	2	3	1	1	1	3	2	2	3	2	3	1	1	2	1	1	2	276
2	3	2	3	1	2	2	2	3	2	2	1	1	3	1	1	3	1	2	2	1	1	2	3	277
1	3	2	1	3	2	1	2	2	3	2	1	1	1	3	2	1	2	1	1	1	3	1	3	278
2	3	1	2	2	3	2	2	3	2	1	2	1	3	2	2	1	2	2	3	2	3	2	1	279
3	1	2	2	3	2	1	3	2	2	2	1	1	2	3	2	2	1	1	3	1	1	2	3	280
1	2	3	1	1	1	2	1	1	3	1	1	1	2	2	3	1	3	2	1	3	1	3	1	281
2	1	2	3	1	2	3	1	2	1	2	2	2	3	2	2	3	2	1	2	3	2	3	2	282
2	2	2	1	3	1	3	2	2	2	3	1	2	2	1	3	2	1	2	3	2	2	2	3	283
1	1	2	1	1	3	1	3	1	2	2	3	2	3	1	2	3	1	3	1	1	1	2	1	284
1	1	2	3	1	1	2	1	3	1	1	2	1	3	1	3	1	1	2	3	2	1	3	1	285
3	2	1	3	2	1	3	2	1	1	2	2	2	3	1	1	2	3	2	2	2	3	1	1	286
1	3	2	3	1	3	2	1	1	2	2	3	1	2	2	3	1	2	2	3	2	2	1	1	287

Table IIA: Numeric sequences corresponding to nucleotide patterns of a set of oligonucleotides

Numeric Pattern																				Sequence Identifier	
3	1	1	2	1	1	2	3	2	2	2	1	3	2	3	2	2	2	3	1	1	288
1	2	1	2	3	1	1	1	3	2	1	3	1	3	1	1	1	3	2	3	2	289
2	3	1	3	2	2	1	2	2	3	2	1	2	2	2	1	3	2	2	2	3	290
2	1	3	2	2	3	1	3	2	2	2	1	1	1	3	2	2	3	1	1	1	291
2	1	1	1	3	1	3	2	3	1	2	3	2	1	1	1	2	1	3	1	1	292
2	3	2	1	3	2	3	2	2	2	1	3	1	3	2	1	1	3	2	2	1	293
1	3	1	3	1	2	2	1	1	2	3	2	3	2	2	3	1	1	1	3	1	294
3	2	1	1	2	1	1	3	2	2	3	2	3	1	1	1	3	1	1	3	1	295
3	1	3	1	2	3	2	2	1	2	1	3	1	2	1	1	2	3	1	1	1	296
2	2	2	1	3	2	2	3	1	2	2	3	2	2	3	1	1	2	1	3	1	297
1	2	2	1	2	2	3	1	1	1	3	2	1	3	1	2	3	2	2	1	3	298
2	2	2	1	2	3	2	3	2	3	1	2	2	3	1	3	2	3	2	2	1	299
2	1	2	2	2	1	3	2	2	1	3	1	2	1	3	1	2	1	3	1	3	300
1	2	3	2	3	2	2	2	1	2	3	2	3	1	1	1	3	1	2	2	2	301
1	2	1	3	2	1	1	2	2	1	3	1	1	3	1	3	1	1	3	1	2	302
2	1	2	3	1	3	2	3	1	2	2	1	3	1	1	2	2	3	2	1	2	303
2	2	1	1	2	3	2	1	2	2	3	2	2	2	1	1	1	3	1	3	2	304
1	2	1	3	1	3	1	1	2	2	1	1	3	1	1	2	2	3	2	2	2	305
3	2	2	1	2	1	1	3	2	1	3	1	1	1	2	3	2	1	2	1	3	306
1	3	2	1	1	2	2	1	3	2	2	2	3	1	1	1	2	3	2	3	2	307
3	1	1	1	3	1	2	2	1	2	3	1	2	2	3	2	1	1	1	3	2	308
3	2	1	1	3	1	2	2	1	3	1	1	3	2	2	1	1	2	3	1	1	309
3	1	3	1	1	2	3	2	2	3	1	1	2	1	1	3	1	1	3	2	1	310
2	2	1	1	3	1	3	2	3	2	2	3	1	1	2	1	3	2	3	2	2	311
1	2	1	1	1	3	1	1	1	3	1	3	2	1	2	3	1	3	1	2	2	312
1	3	2	2	1	2	2	3	1	2	2	3	1	1	3	1	2	3	1	3	1	313
3	2	2	2	3	2	3	2	2	2	3	2	1	2	1	1	3	2	2	3	2	314
2	2	3	2	1	2	3	2	3	1	3	2	2	2	1	3	1	2	2	1	1	315
2	1	3	2	2	1	1	1	3	2	1	2	1	3	2	2	3	2	2	2	3	316
1	1	1	2	2	2	3	2	3	2	2	3	1	3	1	2	2	2	3	2	1	317
2	1	2	2	1	3	2	3	2	2	1	2	3	1	2	1	1	1	3	1	3	318
2	1	2	1	1	3	1	1	3	2	1	1	2	2	2	3	1	3	1	1	3	319
2	1	1	3	2	2	3	1	3	1	2	3	2	2	3	2	2	3	2	3	1	320
3	2	3	2	1	3	1	2	2	2	1	2	3	1	1	2	2	3	1	3	2	321
2	1	2	1	3	1	3	1	1	3	2	3	2	2	2	1	3	2	2	3	2	322
1	2	1	1	1	3	1	1	3	1	1	2	1	3	2	2	3	2	2	3	2	323
1	3	1	2	2	3	1	1	1	2	1	3	1	2	2	1	3	1	1	1	3	324
3	2	2	3	2	2	1	2	1	1	3	1	1	1	2	1	3	2	2	2	3	325
1	3	1	1	1	2	1	3	1	3	2	1	1	3	1	3	2	3	2	2	1	326
1	3	1	3	1	2	1	3	2	1	3	2	1	1	1	2	1	3	2	2	1	327
1	1	1	2	3	1	2	2	3	2	3	2	1	1	3	2	2	1	2	3	2	328
1	1	3	1	1	3	2	1	1	3	1	3	1	1	1	1	2	2	2	3	1	329
3	2	3	2	3	2	1	2	2	2	1	3	2	2	3	1	2	1	1	2	2	330
1	2	2	3	2	2	3	2	2	3	2	2	3	1	3	1	1	1	2	3	2	331
1	3	1	2	1	1	3	2	2	1	1	1	3	2	1	1	1	3	1	3	1	332
2	1	3	2	2	3	1	1	3	2	2	1	3	2	2	2	1	1	3	2	3	333
1	3	2	1	1	3	1	1	2	3	2	1	1	2	1	2	3	1	2	3	1	334
1	2	3	1	3	1	2	2	3	1	1	1	3	1	2	2	2	1	2	3	1	335
2	3	1	2	2	3	1	1	2	2	1	3	1	3	1	3	1	1	2	3	2	336
1	3	2	2	1	3	2	1	1	3	1	3	1	1	2	1	2	1	3	2	3	337
1	2	2	1	1	3	1	2	2	3	2	1	2	1	3	2	2	1	3	2	3	338
3	1	3	1	2	1	1	1	3	1	1	2	2	3	1	1	1	2	1	3	1	339
1	3	1	3	2	1	1	1	2	3	2	2	1	1	3	1	1	1	3	1	1	340

Table IIA: Numeric sequences corresponding to nucleotide patterns of a set of oligonucleotides

Numeric Pattern																							Sequence Identifier	
1	1	1	3	2	2	2	3	2	2	1	2	3	2	3	1	1	3	1	1	2	2		341	
1	2	2	3	2	3	2	2	2	1	1	3	1	1	1	2	1	2	3	1	2	3	1	3	342
2	1	2	2	3	1	1	1	2	3	1	3	1	2	3	2	1	2	3	2	1	3	2	2	343
1	2	2	2	3	2	3	2	3	1	2	3	2	2	2	3	1	1	1	2	1	2	3	1	344
2	1	1	3	1	2	1	1	2	1	3	2	3	1	3	1	3	1	1	1	2	2	3	1	345
1	2	2	2	1	2	3	1	2	2	1	3	2	3	2	1	1	3	2	3	2	2	3	2	346
3	1	2	2	1	1	3	1	1	2	1	1	1	3	2	3	2	3	1	1	3	1	1	2	347
3	2	1	1	2	2	3	1	2	3	1	1	3	1	3	2	2	1	3	2	2	2	1	2	348
2	3	2	3	2	2	1	2	3	2	2	1	2	1	1	3	1	1	3	2	3	1	2	1	349
1	3	1	3	1	1	1	2	2	3	1	1	2	2	2	1	3	1	1	1	2	3	2	3	350
2	2	1	2	2	3	1	1	2	3	2	3	1	3	1	1	1	3	2	1	2	2	2	3	351
2	3	2	2	1	1	2	3	1	3	1	1	3	1	2	1	1	2	3	1	2	1	3	2	352
3	1	1	1	3	2	1	2	2	2	3	2	2	3	1	2	2	1	2	2	3	2	2	3	353
2	1	3	2	2	2	1	2	3	2	1	3	2	2	1	1	2	2	3	2	2	3	1	3	354
3	2	2	3	1	1	1	3	1	2	1	3	2	2	2	3	1	2	1	2	3	2	1	2	355
2	2	1	3	1	1	3	1	2	1	3	1	2	2	1	2	2	3	1	3	1	1	1	3	356
1	1	2	1	1	2	3	2	2	3	2	3	1	1	1	2	1	3	1	2	3	2	3	1	357
1	3	2	1	1	3	1	1	1	3	2	2	2	1	3	2	2	2	1	3	2	2	1	3	358
2	1	3	2	2	2	1	1	2	3	1	3	1	2	3	2	2	2	3	1	2	1	2	3	359
2	2	1	1	1	3	1	2	3	2	2	1	1	1	3	1	1	2	3	1	3	2	3	1	360
1	1	1	3	2	3	2	3	2	1	2	1	2	3	2	2	1	3	1	1	1	3	2	1	361
1	2	2	1	1	3	2	2	1	2	3	2	3	2	2	2	1	2	3	2	3	2	2	3	362
2	2	2	3	1	1	3	1	1	3	2	3	2	2	2	3	2	1	2	2	1	2	3	2	363
2	3	2	2	1	1	3	1	1	3	2	2	2	1	3	2	2	1	1	1	3	2	2	3	364
2	2	2	1	1	3	2	1	2	1	1	3	1	2	2	3	2	3	2	3	1	3	1	2	365
1	3	1	2	1	2	2	2	3	1	2	1	3	1	2	1	3	1	1	3	1	1	1	3	366
1	2	2	2	1	3	1	3	2	2	3	2	1	1	3	1	1	3	1	2	1	2	2	3	367
3	1	3	1	1	1	2	2	3	2	1	1	2	2	3	2	2	1	3	1	3	2	1	2	368
3	1	1	3	2	1	2	1	2	3	2	2	1	1	3	1	2	3	2	1	1	2	1	3	369
1	1	2	1	2	2	3	1	1	3	1	2	3	2	1	3	2	3	1	3	2	2	1	2	370
3	1	3	2	2	2	1	3	1	1	1	2	3	1	2	1	1	1	3	1	1	2	2	3	371
2	1	1	3	1	1	1	2	3	1	3	2	2	1	2	1	2	3	2	2	3	1	3	1	372
2	2	3	1	2	1	2	1	1	3	1	1	3	2	2	3	2	3	1	2	1	1	3	2	373
1	1	3	2	3	2	2	2	1	1	2	3	2	1	1	3	1	3	1	1	2	3	1	1	374
3	2	2	3	2	3	1	3	1	1	2	2	1	3	1	1	1	2	1	3	2	1	2	1	375
2	2	2	1	3	2	2	2	3	1	2	3	2	3	2	2	2	1	2	3	1	3	1	2	376
3	2	1	1	2	2	3	1	1	1	3	2	1	2	3	1	3	2	1	3	2	1	1	2	377
2	1	3	2	2	3	1	1	2	1	1	3	1	2	2	3	1	3	1	3	1	1	1	2	378
2	2	1	1	3	2	3	1	1	3	2	3	2	2	3	2	2	2	1	2	2	3	1	1	379
1	2	2	3	1	2	2	2	3	2	2	3	1	1	1	2	1	1	3	2	3	2	2	3	380
2	3	1	1	2	2	3	2	2	3	1	2	1	1	3	2	2	1	2	3	1	1	3	1	381
3	2	2	2	3	2	2	1	2	2	3	1	3	2	1	1	3	2	2	3	1	1	2	2	382
2	3	1	2	2	2	1	3	2	1	2	3	2	1	2	2	1	3	1	3	2	2	3	1	383
2	1	1	1	2	1	3	1	3	1	2	3	1	3	1	1	2	1	1	3	1	1	1	3	384
1	3	1	1	2	3	2	2	1	2	1	2	3	2	1	3	1	3	1	1	1	2	2	3	385
1	2	2	2	1	2	3	2	1	3	2	2	3	1	3	1	3	2	3	1	2	1	1	1	386
3	2	1	1	1	3	1	2	1	3	2	2	2	3	1	3	2	1	1	2	2	2	3	1	387
3	1	1	1	2	1	3	2	1	2	1	1	2	3	2	2	1	1	3	2	3	1	3	1	388
1	2	2	3	2	1	2	1	2	2	3	2	3	2	2	3	1	1	3	1	1	1	3	2	389
3	1	3	2	2	1	1	3	2	3	2	1	1	1	2	3	1	1	1	2	3	2	1	1	390
1	2	1	3	1	2	2	3	2	3	2	3	1	1	1	3	1	1	1	3	1	1	2	2	391
2	2	1	1	2	1	3	1	1	3	2	2	2	3	2	1	3	2	1	2	3	1	2	3	392
2	2	3	2	1	2	3	2	3	1	3	1	1	2	1	1	1	3	2	2	2	1	3	2	393

Table IIA: Numeric sequences corresponding to nucleotide patterns of a set of oligonucleotides

Numeric Pattern																				Sequence Identifier				
3	2	3	1	2	2	1	3	1	2	1	2	3	1	2	3	1	2	3	1	1	2	394		
2	3	1	1	3	1	1	3	1	1	2	2	2	1	3	1	2	2	2	3	2	1	1	3	395
2	3	2	1	2	3	1	2	2	1	2	2	3	1	2	2	1	3	2	3	2	3	2	2	396
2	3	2	3	1	1	1	3	1	3	1	1	2	3	1	2	1	3	1	2	1	2	2	2	397
1	1	2	2	3	1	1	1	2	3	1	3	2	3	2	3	2	2	2	1	1	3	1	1	398
1	2	2	1	2	1	3	1	3	2	2	1	3	2	2	2	1	3	1	1	2	3	1	3	399
1	1	1	3	1	2	1	3	1	1	1	2	2	3	1	3	2	3	2	1	2	3	1	2	400
3	2	1	3	2	2	2	3	2	2	1	1	2	3	2	2	3	2	1	2	1	1	2	3	401
1	3	1	3	1	2	1	2	2	1	3	1	1	2	3	2	1	1	3	1	1	2	1	3	402
1	3	1	1	3	2	2	2	3	1	1	1	2	1	2	3	1	2	1	3	1	1	2	3	403
2	1	3	1	1	2	3	2	1	1	1	3	2	2	2	1	3	2	1	2	1	3	1	3	404
1	3	2	1	3	1	2	3	2	1	2	3	2	2	1	1	2	3	2	3	1	1	2	1	405
2	3	1	1	1	3	2	3	1	1	1	2	1	2	3	1	1	1	2	3	2	2	3	2	406
1	2	1	3	2	1	2	1	2	2	3	1	3	2	2	2	3	2	1	2	3	1	1	3	407
3	1	1	3	1	1	1	2	3	2	2	2	3	2	1	3	1	1	2	1	1	3	2	1	408
1	1	2	3	1	3	2	1	2	2	3	1	1	3	1	1	1	2	3	2	1	2	1	3	409
3	2	3	1	2	1	3	1	1	2	2	2	3	2	3	2	2	2	1	1	2	3	1	1	410
2	3	2	1	3	2	1	2	3	1	1	3	1	1	2	1	1	2	3	1	1	1	2	3	411
1	2	1	3	1	1	3	2	2	1	1	2	3	1	2	1	1	2	2	3	2	3	2	3	412
3	2	3	1	2	2	3	2	1	1	3	2	1	1	3	2	1	1	1	3	1	2	1	1	413
2	1	2	3	2	1	3	2	2	2	3	2	3	2	2	1	2	2	2	3	1	1	3	1	414
2	3	1	3	2	1	1	3	2	2	2	3	2	1	2	3	2	2	2	1	1	3	2	1	415
2	1	1	1	2	3	2	1	2	3	1	3	2	3	2	3	2	1	1	1	3	1	1	1	416
3	2	1	1	3	1	3	2	1	2	2	3	1	1	1	2	2	1	3	2	1	1	3	1	417
3	2	2	3	1	3	2	3	2	1	1	1	3	1	2	2	1	2	2	3	1	2	1	1	418
1	3	2	1	2	3	1	3	2	2	1	2	2	1	3	1	2	1	1	1	3	2	3	1	419
1	2	2	2	3	2	2	1	2	1	3	1	3	2	2	3	2	3	2	2	3	2	1	2	420
2	1	1	2	2	1	3	2	1	3	2	3	2	3	2	2	3	1	1	1	2	2	2	3	421
2	3	2	1	2	2	3	1	3	1	2	2	3	2	2	1	2	2	3	2	1	2	2	3	422
3	2	2	1	2	2	1	3	1	1	3	1	3	1	2	1	1	2	2	3	1	3	2	2	423
2	2	3	1	3	2	2	3	2	3	1	2	2	1	1	3	2	1	3	2	1	2	1	2	424
3	1	2	1	3	2	1	2	1	1	2	3	1	2	2	3	1	1	3	2	1	1	2	3	425
3	2	3	1	1	1	3	1	2	1	2	2	2	3	1	3	1	3	1	2	1	1	1	2	426
1	3	2	2	1	2	3	1	2	2	2	3	1	1	3	1	1	1	2	2	3	2	2	3	427
3	2	1	1	3	2	1	2	2	2	3	1	1	2	2	2	3	1	2	3	1	3	2	2	428
2	1	1	2	1	3	2	3	2	2	1	2	1	1	3	2	3	1	1	1	3	1	3	2	429
1	1	1	2	3	1	1	2	2	3	1	2	3	2	3	2	1	2	1	2	3	1	1	3	430
1	3	1	1	1	3	2	3	1	3	2	2	3	2	2	1	1	3	2	1	2	2	2	1	431
2	2	2	1	2	3	2	3	2	3	1	1	2	2	3	2	3	2	1	2	1	2	1	3	432
3	2	1	1	2	1	2	3	1	2	1	3	1	1	1	2	3	2	1	1	1	3	1	3	433
3	1	3	1	1	2	2	3	2	2	2	1	1	1	3	1	2	1	3	2	2	3	2	1	434
3	1	1	2	2	2	3	2	2	1	1	3	1	1	2	3	1	3	2	2	2	3	1	2	435
1	2	1	3	2	3	1	2	3	1	2	2	1	1	1	3	1	3	1	1	2	2	2	3	436
1	2	1	3	1	2	3	2	2	2	1	3	2	2	3	1	3	1	2	2	1	2	2	3	437
1	1	3	1	3	2	3	2	1	1	1	2	1	3	1	1	1	3	2	3	1	2	1	2	438
2	3	2	3	2	1	2	2	3	1	2	2	3	2	2	3	1	3	1	2	1	1	1	2	439
2	1	3	2	1	2	1	3	2	3	1	3	1	1	1	3	1	3	2	2	1	1	1	2	440
1	1	1	3	1	2	1	1	3	1	1	1	3	1	3	1	2	3	1	2	3	2	2	2	441
3	1	1	3	2	2	1	2	2	3	1	1	1	2	1	3	1	3	1	1	3	2	1	2	442
1	2	3	2	1	2	3	2	1	2	1	3	1	1	1	3	1	3	2	1	1	1	2	3	443
3	1	2	3	2	2	2	3	2	1	1	1	3	1	2	2	3	1	1	1	2	2	3	1	444
1	1	2	2	2	1	3	1	3	1	3	2	1	2	2	2	3	2	3	2	2	3	2	1	445
1	1	2	2	2	3	2	2	2	3	1	1	1	3	1	1	1	3	2	1	1	3	2	3	446

Table IIA: Numeric sequences corresponding to nucleotide patterns of a set of oligonucleotides

Numeric Pattern																							Sequence Identifier	
1	1	1	3	1	3	2	1	3	2	3	2	2	1	2	2	3	2	2	1	3	1	2	1	447
3	2	1	2	3	2	2	3	2	1	2	1	2	3	2	2	3	2	2	3	1	2	1	2	448
3	2	1	3	1	1	2	2	2	3	2	2	3	1	3	2	1	2	2	2	3	2	1	1	449
1	2	3	1	1	2	2	2	1	3	2	2	1	3	2	3	2	1	1	3	1	1	1	3	450
1	2	3	1	2	1	1	3	1	1	1	2	3	2	2	3	1	2	3	1	1	3	2	1	451
2	2	3	1	2	3	1	2	3	1	1	3	1	2	1	1	2	3	2	1	3	1	2	1	452
1	3	1	2	3	1	2	1	2	3	1	2	1	2	1	3	1	2	2	1	3	1	2	3	453
2	2	3	1	1	1	3	2	2	1	3	1	1	1	3	1	2	1	3	1	2	3	2	2	454
3	2	2	2	1	1	2	3	2	2	1	3	2	2	1	3	1	1	1	3	2	1	1	3	455
3	1	3	1	2	2	2	1	1	3	2	2	2	3	1	1	3	2	3	1	1	1	2	1	456
2	2	2	3	2	2	1	3	2	1	3	2	2	3	2	2	1	2	1	1	3	1	3	1	457
2	1	2	3	1	3	1	1	2	1	3	2	2	2	3	2	2	1	3	2	3	1	1	2	458
2	2	3	1	1	1	3	2	2	2	1	1	1	3	1	1	3	1	3	1	2	1	1	3	459
1	1	3	2	3	1	3	2	2	3	1	1	1	2	3	1	1	1	2	1	2	3	2	2	460
3	2	2	1	3	1	1	1	2	3	1	1	1	2	3	1	3	2	1	3	2	2	1	2	461
2	1	1	3	2	1	2	2	3	2	1	2	2	2	3	2	3	2	3	2	3	2	1	2	462
2	3	2	1	2	2	1	3	2	1	1	1	3	1	1	3	1	3	1	3	1	1	2	1	463
3	1	3	1	1	3	1	3	1	1	1	2	1	1	3	2	2	3	1	1	1	2	1	1	464
3	2	1	1	1	3	2	1	3	1	1	1	2	1	3	1	1	2	2	3	1	3	2	2	465
3	2	3	2	3	2	2	1	2	2	2	3	2	2	2	3	2	1	1	1	3	2	1	2	466
2	2	2	3	1	2	3	2	1	2	3	1	1	2	1	2	1	3	2	1	2	3	1	3	467
1	1	3	1	2	2	3	2	3	2	3	1	1	2	1	3	2	2	3	1	1	1	2	2	468
2	1	2	1	1	1	3	2	2	2	3	1	1	3	1	2	3	1	3	2	3	1	2	1	469
1	3	1	2	1	1	1	3	2	1	3	1	2	2	2	1	1	3	1	2	3	2	1	2	470
3	1	1	3	1	1	2	2	1	1	3	2	2	3	1	3	1	1	2	2	1	1	3	1	471
2	1	3	1	3	1	1	1	2	2	2	3	1	2	1	1	1	3	1	1	1	3	1	3	472
1	1	1	3	2	2	2	1	2	3	1	1	3	2	2	1	2	2	3	1	3	2	1	3	473
1	1	1	2	1	3	2	3	2	1	1	3	2	1	1	1	3	1	3	1	2	3	1	2	474
2	1	2	3	1	2	3	1	2	2	2	1	3	2	2	1	2	1	1	3	1	3	2	3	475
2	1	3	1	2	1	1	1	2	3	2	2	1	2	3	1	2	3	1	3	2	1	1	3	476
1	3	1	2	2	3	1	2	2	3	2	3	1	2	3	1	2	2	2	3	2	1	2	1	477
2	2	1	1	3	1	1	3	1	1	2	2	3	2	1	2	1	2	3	1	3	1	3	2	478
3	2	1	3	1	1	2	3	2	2	2	1	3	1	3	2	2	3	1	1	2	1	2	1	479
3	1	3	1	1	1	2	1	3	2	1	1	3	1	1	3	2	1	1	1	2	1	3	1	480
1	2	2	3	1	1	3	2	2	3	2	2	1	2	3	2	3	1	1	3	1	2	2	2	481
2	1	1	1	2	3	2	2	3	2	3	2	1	3	1	3	2	1	1	2	2	1	3	1	482
1	1	1	2	1	1	3	1	3	2	2	2	3	1	3	1	1	3	2	2	3	2	2	2	483
1	3	2	2	3	2	1	1	2	1	1	3	1	1	3	2	3	1	2	2	2	1	1	3	484
3	2	2	1	3	1	1	2	3	2	1	2	1	2	1	3	1	3	2	2	1	3	1	2	485
2	2	3	1	2	1	2	2	3	1	1	1	3	1	3	1	1	1	3	2	2	1	2	3	486
2	2	1	1	1	3	1	3	1	3	1	1	1	2	3	2	2	2	3	1	2	2	1	3	487
2	3	2	3	1	1	2	2	3	1	2	2	3	1	3	2	1	3	2	1	1	3	1	1	488
2	1	1	2	2	2	3	1	1	2	3	2	3	1	1	1	3	2	2	3	2	2	1	3	489
1	2	3	2	3	2	2	2	3	1	1	1	3	1	2	3	1	2	3	1	2	2	2	1	490
1	1	3	2	2	1	2	3	2	2	3	1	2	1	2	2	3	1	3	2	3	1	1	1	491
2	1	3	1	2	1	1	1	3	1	1	3	1	2	1	3	1	3	1	2	2	2	1	3	492
3	1	2	3	1	1	2	3	2	1	3	1	2	1	2	1	2	3	2	1	1	2	3	1	493
3	1	1	3	1	1	2	1	3	2	2	2	1	2	3	2	1	1	1	2	3	1	2	3	494
3	2	1	3	2	1	2	1	2	1	3	2	2	1	1	1	3	1	2	3	1	3	2	2	495
3	2	2	1	2	2	2	3	2	3	2	1	2	3	1	2	2	1	2	3	1	2	2	3	496
1	3	1	3	1	2	2	1	3	1	1	1	2	2	2	3	1	3	1	3	1	1	2	2	497
3	2	1	2	3	1	2	1	3	1	3	2	2	2	1	2	1	3	2	3	1	2	1	1	498
3	2	2	1	3	1	1	1	3	1	1	2	3	1	1	1	2	2	3	1	1	3	2	1	499

Table IIA: Numeric sequences corresponding to nucleotide patterns of a set of oligonucleotides

Numeric Pattern																				Sequence Identifier
1	1	3	1	1	2	3	1	3	1	1	2	1	2	1	3	1	3	1	2	500
1	1	1	3	1	3	1	1	2	1	3	2	3	2	2	2	1	1	3	1	501
3	1	2	3	2	3	2	2	1	2	2	3	1	2	1	3	1	1	2	2	502
2	1	3	1	3	2	2	1	2	1	3	1	3	1	2	1	2	2	3	2	503
3	1	3	1	3	2	2	3	1	1	2	1	1	3	2	2	1	1	1	3	504
1	3	1	2	1	2	3	1	1	1	2	1	3	1	2	2	3	2	2	1	505
3	1	3	2	3	1	1	2	1	3	1	1	1	3	1	2	1	2	3	2	506
1	1	1	3	1	3	1	2	1	2	2	3	1	1	3	1	3	1	1	2	507
3	2	2	1	2	1	3	1	1	2	1	1	3	2	2	3	2	1	1	1	508
2	3	1	2	1	3	2	1	2	3	1	2	1	1	2	3	2	3	2	2	509
2	2	2	3	2	2	3	2	2	1	1	3	2	1	2	3	2	3	1	2	510
2	1	1	1	3	2	3	2	2	3	2	3	2	2	1	1	1	3	1	2	511
2	3	2	3	2	2	2	3	1	2	2	3	1	2	2	1	1	2	3	2	512
1	2	2	1	1	2	3	1	1	2	3	1	3	2	3	2	2	3	2	1	513
2	1	3	1	2	3	2	2	2	3	2	3	1	3	2	2	2	3	1	2	514
3	1	1	2	3	1	1	2	1	3	2	1	1	2	1	3	1	2	3	1	515
1	1	2	1	3	2	3	2	3	2	2	3	2	2	1	2	1	2	3	1	516
2	1	3	1	2	2	1	3	1	1	3	1	2	3	2	2	3	2	3	2	517
1	1	2	3	2	3	2	3	2	3	2	2	1	1	1	2	3	1	1	2	518
3	1	1	2	2	1	1	3	2	1	2	1	2	3	1	3	2	3	2	1	519
2	2	1	2	2	3	2	3	2	3	2	1	1	3	2	1	3	2	3	2	520
3	2	1	3	2	1	1	1	3	1	3	1	1	2	2	3	2	2	2	1	521
1	1	3	2	2	2	3	2	1	1	3	1	1	3	2	1	3	2	2	3	522
1	3	2	2	1	2	1	3	2	1	2	1	3	2	1	3	2	1	2	1	523
3	1	1	1	3	1	1	1	2	3	2	3	2	1	2	1	3	2	2	1	524
2	2	3	2	3	1	3	2	1	1	2	3	1	1	2	3	1	2	3	2	525
3	2	1	3	1	3	2	2	3	2	1	1	1	2	1	3	1	3	1	1	526
1	2	2	1	1	2	3	2	1	3	1	2	2	3	2	1	1	3	1	3	527
2	2	1	3	2	3	2	3	2	2	2	3	2	1	3	1	2	1	3	1	528
1	3	1	3	1	3	2	2	2	3	2	3	2	1	2	1	2	3	2	1	529
2	2	1	1	3	2	2	2	1	3	2	3	1	3	1	2	2	2	3	2	530
1	2	3	1	1	3	2	2	2	1	2	2	3	1	1	2	1	3	2	1	531
1	2	1	2	2	2	3	2	3	2	2	3	2	1	2	3	2	2	2	3	532
1	1	1	3	2	3	2	2	2	1	2	1	3	1	1	3	1	2	2	2	533
1	1	3	1	3	1	2	1	2	3	1	2	2	2	3	2	2	1	3	2	534
1	1	3	1	1	3	1	1	1	2	3	1	3	2	3	1	2	1	1	2	535
2	1	3	2	3	2	2	2	3	1	2	1	2	3	2	2	1	1	3	1	536
3	2	1	3	1	1	1	3	2	3	1	2	1	3	1	2	2	1	3	2	537
3	1	2	1	1	1	2	3	2	2	1	1	3	2	2	1	3	2	1	2	538
1	3	1	2	2	1	3	1	1	3	1	1	2	2	3	2	2	2	1	3	539
1	2	1	2	2	2	3	1	3	1	1	3	2	3	2	3	1	1	1	2	540
2	3	1	3	2	1	1	1	2	1	3	2	2	2	1	2	3	1	3	2	541
2	2	1	3	1	3	1	3	2	1	3	1	2	1	1	1	3	1	2	2	542
1	2	2	3	2	2	2	1	1	3	2	2	3	2	2	3	1	2	1	1	543
3	2	2	3	2	1	1	1	3	2	2	1	1	1	3	2	3	2	3	1	544
1	2	1	3	1	2	2	3	2	3	2	3	2	2	2	3	2	2	1	2	545
3	2	1	1	3	2	2	1	2	2	3	1	3	1	1	2	3	1	2	1	546
2	1	3	1	2	2	1	3	2	2	3	1	2	1	1	3	2	3	2	1	547
1	1	1	2	3	2	1	1	1	2	3	1	1	3	1	3	2	3	2	2	548
3	1	2	1	3	1	1	3	1	1	1	2	3	2	1	2	1	2	1	3	549
2	1	2	1	3	1	3	2	3	2	1	2	3	2	2	1	2	3	1	1	550
2	1	2	3	1	1	3	2	3	1	2	1	1	3	1	2	3	1	1	2	551
2	3	2	2	3	1	3	1	1	2	1	3	2	1	1	3	1	1	2	2	552

Table IIA: Numeric sequences corresponding to nucleotide patterns of a set of oligonucleotides

Numeric Pattern		Sequence Identifier
2 1 3 1 2 1 1 2 3 2 3 1 1 3 2 1 1 2 1 1 3 2 3 1		553
3 2 1 2 2 1 2 3 1 2 3 1 2 1 3 2 1 3 2 1 1 3 2 1		554
1 3 1 2 1 2 3 1 2 2 2 1 3 2 1 2 2 3 1 1 2 3 2 3		555
1 1 2 2 1 1 3 2 2 2 3 2 1 3 1 3 2 3 1 2 2 2 3 1		556
1 1 3 1 1 1 2 1 3 1 2 3 2 1 3 2 1 1 3 1 2 3 2 2		557
2 2 3 1 3 1 1 3 2 2 3 2 2 3 2 1 1 2 1 1 3 1 1 2		558
1 3 2 3 2 3 1 1 1 2 1 3 2 3 1 1 1 3 2 2 2 1 1 1		559
2 2 2 1 2 3 2 1 3 2 1 3 1 2 2 2 1 2 3 2 3 1 1 3		560
1 2 2 1 1 2 3 1 3 1 1 1 2 2 1 3 2 3 2 3 2 2 1 3		561
1 2 3 2 2 1 1 2 1 3 2 3 1 2 1 3 2 1 1 1 3 2 3 1		562
2 1 2 3 2 2 3 1 2 1 1 1 2 3 1 2 2 1 2 3 1 3 2 3		563
2 2 1 2 2 1 3 1 3 2 2 3 2 3 2 3 2 3 1 2 1 2 1 2		564
2 3 2 2 3 2 2 1 2 3 1 2 2 3 1 3 2 2 1 3 1 1 2 1		565
1 1 2 2 2 3 1 3 2 2 1 1 3 1 1 3 1 1 3 2 3 2 1 1		566
1 1 1 3 1 2 1 1 1 3 2 2 1 1 3 2 3 2 2 2 3 2 1 3		567
2 3 2 2 3 1 3 1 2 3 1 2 1 2 2 3 2 1 2 1 1 3 2 2		568
2 1 1 1 2 1 3 2 3 1 1 2 3 1 3 2 2 1 2 1 3 1 3 2		569
1 2 1 3 1 2 3 2 2 1 2 3 1 2 1 3 2 2 1 3 2 2 1 3		570
3 2 2 1 1 3 2 3 1 1 3 1 2 1 2 3 2 1 2 2 3 2 2 1		571
2 1 1 3 1 1 1 3 2 1 1 1 3 2 2 2 3 2 1 3 1 2 3 2		572
1 1 3 1 3 1 1 1 3 2 2 2 3 1 2 2 3 1 1 2 1 1 1 3		573
1 2 1 2 2 1 3 1 2 3 2 3 1 3 2 2 1 2 1 2 3 2 3 2		574
1 3 2 2 2 3 1 3 2 2 2 1 3 2 1 2 2 3 2 3 1 1 2 1		575
1 2 3 2 2 1 1 1 2 3 1 3 1 3 1 2 2 3 2 3 2 1 2 1		576
2 1 1 1 2 3 2 2 3 2 3 1 2 2 1 2 2 3 2 3 1 3 1 2		577
2 1 1 3 1 1 2 2 3 1 1 3 2 1 1 3 1 3 2 2 1 2 2 3		578
1 3 1 3 1 2 1 3 1 1 2 2 1 1 3 2 2 2 3 2 2 3 1 2		579
3 1 1 3 1 1 2 3 2 2 1 1 3 1 1 1 2 1 2 3 2 1 1 3		580
2 1 2 2 2 3 2 3 1 2 2 1 1 3 1 1 3 2 2 3 1 3 1 1		581
1 3 2 2 1 3 1 1 2 2 2 3 2 3 2 1 3 2 1 3 1 1 2 2		582
1 1 3 2 2 2 1 2 2 3 2 2 3 1 2 3 2 2 3 2 1 2 2 3		583
3 1 1 2 3 1 3 2 2 2 1 1 3 1 3 2 2 2 1 2 1 3 2 1		584
1 3 2 3 1 1 3 1 2 2 3 2 1 2 3 2 1 3 2 1 2 1 1 1		585
1 3 2 2 3 1 1 1 2 3 1 3 2 1 2 2 1 1 3 2 1 1 2 3		586
1 2 3 2 3 2 2 1 2 2 2 3 1 3 1 2 3 1 3 2 1 1 2 2		587
1 1 1 2 1 3 2 3 2 2 3 2 2 3 1 1 3 2 2 3 2 2 1 2		588
3 2 1 3 1 3 1 1 1 3 1 2 1 2 1 2 3 2 1 3 2 2 2 1		589
3 1 3 1 3 2 1 2 2 2 3 1 2 3 1 1 2 3 1 2 2 1 2 1		590
3 1 3 2 1 2 1 1 3 2 2 2 1 3 2 3 2 1 2 1 2 2 3 1		591
1 2 1 1 2 3 2 3 1 2 2 1 2 2 3 1 2 2 3 1 3 1 3 1		592
2 2 1 3 2 2 3 2 2 1 2 3 2 3 1 3 1 3 2 1 1 2 1 1		593
1 1 1 2 3 1 3 2 1 2 1 2 2 3 1 1 2 2 3 2 3 1 2 3		594
1 1 2 2 1 3 1 1 3 2 1 1 3 2 1 3 1 3 2 2 2 1 1 3		595
2 3 2 1 1 3 2 2 2 1 1 1 3 2 1 1 3 1 1 1 2 3 2 3		596
3 1 1 1 2 3 1 2 1 1 3 2 2 3 1 2 1 2 1 1 3 1 1 3		597
1 1 2 3 1 3 2 1 3 2 2 2 3 2 1 2 2 2 3 1 3 2 2 2		598
1 3 2 3 1 1 2 3 2 1 1 3 1 2 2 1 2 3 2 1 2 2 2 3		599
3 2 1 1 2 2 3 1 1 2 2 3 1 1 1 3 1 2 1 1 3 2 3 2		600
2 1 2 3 2 2 2 1 1 3 2 1 3 2 3 1 1 1 2 1 3 1 3 2		601
3 2 1 2 2 3 1 1 1 2 2 3 1 1 2 2 1 3 1 1 3 2 1 3		602
1 1 2 1 2 3 2 1 1 2 3 2 1 3 2 2 3 1 1 1 3 2 3 1		603
2 3 1 1 2 1 2 2 3 1 3 1 1 2 2 1 2 3 1 3 1 3 2 2		604
2 1 3 2 3 2 1 1 1 2 3 1 2 3 1 1 3 1 1 1 3 2 1 2		605

Table IIA: Numeric sequences corresponding to nucleotide patterns of a set of oligonucleotides

Numeric Pattern																							Sequence Identifier	
3	2	1	2	3	2	3	2	1	1	1	3	1	1	1	2	2	2	3	1	2	3	2	1	606
1	1	2	2	3	2	2	2	3	1	1	1	3	2	2	2	3	2	2	3	1	3	1	1	607
1	1	2	2	3	2	2	2	3	1	3	2	1	3	2	1	2	2	1	3	2	1	3	2	608
2	1	1	2	2	3	1	3	2	2	2	3	1	1	2	1	1	3	1	3	1	3	2	2	609
2	3	2	2	3	1	2	2	3	2	1	1	3	2	3	2	2	2	1	2	2	3	2	2	610
3	1	1	1	2	2	2	3	2	3	1	3	2	1	2	3	2	1	2	2	2	3	1	1	611
2	1	1	3	1	1	2	3	1	1	2	3	2	3	1	1	3	2	3	1	1	2	1	2	612
2	1	1	2	3	2	3	1	1	3	2	2	2	3	2	3	1	1	1	3	1	2	1	2	613
2	2	3	2	1	2	1	2	3	1	1	1	3	2	1	1	3	1	1	3	1	1	3	2	614
2	1	3	1	3	1	3	1	1	3	1	1	3	1	1	1	2	1	1	3	1	1	2	1	615
1	2	2	2	3	1	1	1	2	3	2	2	1	1	2	3	1	3	1	3	1	3	1	2	616
2	2	3	2	3	2	3	2	1	2	1	2	1	3	2	1	2	2	1	3	1	1	2	3	617
1	2	2	3	2	2	1	3	2	1	2	2	3	1	2	3	2	3	1	1	3	2	2	1	618
2	3	2	2	2	3	2	1	2	2	2	3	1	1	2	3	1	1	1	2	3	1	1	3	619
2	3	2	2	1	3	1	2	2	3	2	3	2	2	1	1	1	2	3	2	1	3	2	2	620
2	1	2	1	3	1	3	2	1	2	2	3	2	1	2	1	3	1	3	1	3	1	1	1	621
1	1	1	2	1	3	2	1	1	3	1	1	2	3	2	1	3	2	2	3	2	2	3	1	622
2	3	1	3	2	3	2	3	1	2	2	2	1	2	3	1	2	2	1	1	3	2	2	1	623
1	3	1	1	2	2	2	3	2	2	3	2	1	3	2	3	2	2	1	2	3	1	2	2	624
3	1	2	2	3	1	1	3	1	1	1	3	1	1	1	2	1	3	2	2	2	3	1	1	625
3	1	2	1	1	2	1	3	1	3	1	1	2	1	3	2	1	3	1	3	2	2	1	1	626
3	1	2	2	3	1	1	1	2	2	2	3	2	1	3	2	2	1	2	1	3	2	3	1	627
3	1	2	2	2	1	1	3	1	1	3	1	2	3	1	1	2	1	1	2	3	2	1	3	628
2	2	2	3	1	3	1	3	1	1	1	3	2	1	3	1	1	2	1	1	3	1	2	1	629
3	1	2	2	1	1	3	1	3	2	1	1	1	2	3	1	3	2	1	2	1	1	3	1	630
2	2	2	3	1	2	1	3	1	1	2	2	3	1	1	1	2	2	2	3	1	3	1	3	631
2	3	1	1	3	1	1	3	1	3	2	3	2	2	1	2	1	1	3	1	2	2	2	1	632
3	2	3	1	1	1	2	3	1	2	2	2	1	3	1	3	2	1	1	2	1	1	3	2	633
1	1	1	2	1	1	3	1	1	2	1	3	1	3	1	3	1	3	1	1	1	3	2	2	634
3	2	2	3	2	1	1	1	3	2	1	1	2	1	3	1	3	1	1	1	2	2	1	3	635
1	3	2	3	1	2	2	2	1	3	1	2	2	1	2	3	2	3	1	2	3	1	2	2	636
1	3	1	3	2	1	2	1	3	2	2	2	1	3	1	2	2	2	1	2	3	2	1	3	637
1	2	3	1	2	2	1	3	1	2	1	3	2	3	1	1	1	2	2	3	2	2	1	3	638
1	2	3	1	1	1	2	3	2	1	2	2	1	3	2	2	2	1	3	1	3	2	2	3	639
1	2	1	2	2	3	1	3	2	3	1	3	1	3	2	2	1	2	2	3	2	2	1	1	640
1	3	1	2	3	2	3	2	1	2	2	3	1	1	2	2	1	1	3	1	1	3	2	2	641
2	1	1	2	3	2	3	2	2	3	1	2	1	3	1	1	2	1	3	1	3	1	2	1	642
1	1	1	2	2	1	3	2	2	3	1	1	1	3	2	1	2	3	1	3	1	1	1	3	643
2	2	2	1	3	1	3	2	2	3	1	1	3	1	1	1	2	3	2	2	1	1	2	3	644
3	1	2	2	3	2	2	3	1	2	2	1	2	2	3	1	2	3	1	1	2	2	2	3	645
2	3	2	2	3	2	2	3	2	2	3	1	1	2	2	3	1	1	3	1	1	2	2	1	646
1	2	2	1	1	3	2	1	1	3	1	1	2	2	3	1	3	1	3	2	2	2	3	1	647
3	2	1	2	3	2	2	3	2	1	1	2	3	2	1	2	2	1	1	3	1	1	1	3	648
2	1	3	2	2	3	2	3	1	2	2	2	1	2	3	2	1	1	2	3	1	2	2	3	649
2	3	1	2	1	1	2	3	1	1	1	3	2	2	2	1	2	1	3	1	3	1	3	1	650
3	2	1	1	3	1	2	2	3	2	2	2	3	2	1	2	3	1	2	1	1	3	1	2	651
2	2	3	1	1	2	2	1	1	3	1	3	2	1	1	3	1	2	3	2	2	2	1	3	652
1	1	3	2	3	2	2	2	3	2	2	2	1	3	1	3	2	1	1	1	3	1	2	1	653
1	3	1	3	1	3	1	2	1	1	1	3	2	1	2	1	3	1	1	3	2	2	1	1	654
1	2	2	1	2	3	1	1	2	1	3	2	2	1	3	1	1	1	3	1	3	1	3	2	655
2	2	3	2	2	3	1	2	1	2	2	1	3	1	3	1	1	2	3	2	3	2	2	2	656
2	2	2	1	2	2	3	1	3	1	3	2	2	2	3	2	2	1	2	2	2	3	2	3	657
1	3	2	3	2	2	1	1	3	1	1	3	2	2	3	1	2	2	1	2	2	3	1	2	658

Table IIA: Numeric sequences corresponding to nucleotide patterns of a set of oligonucleotides

Numeric Pattern	Sequence Identifier
3 1 3 1 1 1 2 3 1 2 2 3 1 1 2 3 2 2 3 1 2 1 1 2	659
3 1 2 1 1 3 2 1 2 2 1 3 2 1 2 3 1 3 2 3 2 1 1 2	660
2 2 2 3 1 2 2 2 1 1 3 1 3 2 3 2 2 3 1 1 2 3 2 1	661
1 1 3 2 2 1 3 2 1 1 1 2 1 3 1 3 2 1 3 1 1 1 3 1	662
3 2 1 1 1 3 2 1 2 3 1 1 2 1 2 3 2 3 1 1 1 2 3 2	663
2 1 1 2 1 1 3 2 3 2 3 2 2 3 2 3 1 1 2 3 2 1 1 2	664
1 1 1 3 1 2 2 2 1 3 1 3 2 1 3 1 1 1 3 1 3 1 1 2	665
2 2 1 3 2 2 2 3 1 3 2 2 3 1 1 1 2 1 3 2 1 1 1 3	666
2 1 1 2 1 3 2 1 2 3 1 3 2 1 1 3 1 2 2 3 1 1 1 3	667
3 1 1 3 1 2 2 1 3 1 2 2 3 1 2 3 2 2 1 3 2 2 1 1	668
2 1 1 1 3 1 3 1 3 1 1 3 2 2 1 3 2 1 1 2 1 3 1 1	669
2 1 1 3 2 1 2 3 1 3 1 1 1 2 3 1 2 3 2 3 2 2 1 2	670
3 1 3 2 2 2 3 2 2 2 3 2 2 1 3 2 2 1 2 2 3 1 2 1	671
1 1 3 2 1 1 1 3 1 1 1 2 3 2 2 1 1 3 1 3 2 1 3 2	672
1 2 3 1 3 1 1 2 2 3 2 2 3 2 2 3 1 1 1 2 3 2 1 1	673
2 2 1 3 1 2 2 1 3 1 3 2 1 3 2 1 3 1 1 3 1 1 2 1	674
2 1 3 2 3 1 2 3 1 1 3 1 1 3 2 2 1 3 1 1 1 2 2 1	675
2 1 1 2 3 2 1 3 2 1 1 2 3 2 3 1 2 3 1 2 1 1 3 2	676
2 2 3 1 3 1 1 1 3 1 1 2 1 1 3 2 1 3 2 3 2 1 1 1	677
2 1 1 2 3 1 3 2 3 1 3 1 2 2 1 2 1 3 1 2 2 3 2 2	678
3 2 1 2 1 1 3 1 1 1 2 3 2 3 2 2 2 3 1 2 2 1	679
3 2 3 1 1 2 3 2 3 2 2 1 1 2 3 1 1 3 1 2 1 2 1 2	680
3 1 1 1 3 2 2 1 2 2 1 3 2 1 3 2 2 1 1 1 3 1 2 3	681
2 1 3 1 1 2 2 3 2 3 2 2 2 3 1 2 1 1 3 2 3 1 2 1	682
2 3 1 2 2 2 1 3 1 2 2 3 1 3 1 3 2 2 1 1 1 2 3 1	683
1 2 2 1 2 2 3 1 3 2 2 2 3 1 1 2 3 2 2 3 1 2 1 3	684
1 2 1 3 2 1 3 2 2 1 2 3 2 2 2 3 1 2 2 2 1 3 2 3	685
1 2 1 3 1 1 3 1 1 3 1 1 2 1 1 1 3 2 2 1 3 1 3 1	686
3 1 2 3 2 2 3 1 1 1 3 2 1 1 2 3 1 1 2 2 2 3 2 1	687
3 1 3 1 2 2 3 1 2 1 3 2 1 3 1 1 1 2 3 1 2 1 1 1	688
2 3 1 3 1 3 1 1 2 1 1 1 3 2 1 2 3 1 1 2 2 2 3 1	689
2 1 2 1 1 1 3 1 2 3 1 2 3 2 3 1 1 2 2 1 3 2 1 3	690
2 2 1 2 3 2 1 1 3 1 1 2 3 2 2 2 3 1 3 1 3 1 1 1	691
1 3 2 1 1 1 2 3 1 2 3 1 1 2 3 1 2 1 2 3 1 2 3 1	692
3 1 1 1 2 2 2 3 2 3 2 2 1 1 1 3 2 2 3 1 1 2 3 1	693
3 1 2 3 1 1 2 3 1 2 2 3 2 3 2 2 2 1 1 3 2 1 2 1	694
3 1 1 1 2 1 1 3 2 3 1 3 1 3 2 2 1 1 2 3 1 1 1 2	695
2 3 2 2 3 1 1 1 2 1 3 2 2 1 2 2 1 3 2 2 2 3 2 3	696
2 2 2 3 1 3 1 3 2 1 2 1 2 2 3 1 2 1 2 3 1 3 1 1	697
1 2 2 3 2 3 2 3 2 1 1 1 3 2 1 1 3 1 2 2 2 1 1 3	698
2 1 2 1 3 2 2 2 3 1 1 3 2 3 2 3 1 2 3 2 1 2 2 2	699
3 2 3 1 1 3 2 2 1 2 1 3 2 3 2 1 2 1 1 1 3 1 1 2	700
3 2 1 2 3 2 2 3 1 1 2 1 3 2 1 1 1 2 1 3 1 2 2 3	701
2 2 1 3 1 1 1 3 2 3 2 3 1 2 2 2 3 2 3 2 1 2 2 2	702
2 2 2 1 3 2 1 1 2 1 2 3 2 1 1 3 1 3 1 2 3 2 3 1	703
1 3 2 1 2 3 2 1 2 1 3 1 2 3 1 2 3 2 2 2 3 2 2 2	704
1 2 2 2 1 1 3 2 1 1 1 3 2 3 2 1 3 1 3 1 2 1 1 3	705
1 2 2 2 3 2 3 2 2 3 1 1 2 2 3 2 1 1 1 3 2 3 1 1	706
1 2 3 2 2 1 2 2 1 3 1 2 2 3 2 3 1 2 3 1 1 2 3 1	707
2 1 3 2 1 3 2 1 3 1 1 2 1 2 3 1 1 1 2 2 1 3 1 3	708
2 2 2 1 1 2 3 1 3 1 1 3 1 3 2 2 1 3 1 3 2 1 2 1	709
1 1 1 3 2 2 2 1 3 2 1 3 1 3 2 3 2 1 2 3 2 1 1 1	710
1 2 1 2 1 2 3 1 2 1 3 2 1 3 1 3 2 1 3 1 2 2 1 3	711

Table IIA: Numeric sequences corresponding to nucleotide patterns of a set of oligonucleotides

Numeric Pattern		Sequence Identifier
2 3 1 3 1 1 3 2 2 1 1 2 2 3 2 1 2 1 3 1 2 2 3 1		712
2 1 2 1 3 1 3 1 2 3 2 2 1 2 1 2 3 1 1 3 2 2 3 2		713
1 1 1 2 2 2 3 2 2 1 1 3 2 2 3 2 2 3 2 2 3 2 2 3		714
2 2 3 2 2 3 1 1 3 1 2 3 1 1 1 3 2 1 3 1 1 2 2 1		715
1 1 3 1 3 1 2 1 1 3 2 1 3 2 3 2 2 2 1 2 3 2 2 2		716
1 1 2 1 1 3 1 1 3 1 1 3 2 3 1 1 1 3 1 2 2 3 1 2		717
2 1 1 3 2 2 1 1 1 3 2 2 3 1 2 3 1 2 2 3 1 2 1 3		718
1 2 1 2 1 1 3 1 2 1 1 3 1 3 2 3 2 1 1 3 2 3 1 2		719
3 2 2 1 1 1 2 3 2 2 3 2 2 3 2 2 2 1 1 3 2 3 1 2		720
3 1 3 2 2 1 1 3 2 2 1 2 2 1 3 2 2 1 1 3 1 1 3 2		721
2 1 2 2 1 3 1 3 2 2 2 3 1 3 1 1 2 1 1 3 2 1 3 2		722
2 1 1 2 3 2 2 3 2 2 1 2 3 2 3 2 2 1 3 1 2 3 2 2		723
3 1 1 1 3 2 2 3 1 2 1 3 1 1 2 3 2 1 1 2 3 2 2 2		724
2 3 1 2 1 3 1 2 3 1 1 2 2 3 1 2 2 3 1 2 2 1 3 2		725
1 2 3 1 2 1 3 1 3 2 1 1 1 3 1 1 2 1 1 3 2 2 3 2		726
1 3 2 1 1 3 2 3 2 2 1 3 1 2 1 3 2 1 2 2 3 1 1 2		727
1 2 3 2 1 3 1 2 2 1 1 1 3 2 1 3 2 3 2 1 2 3 2 2		728
2 2 1 2 2 3 1 2 1 1 2 3 1 3 1 3 1 3 2 2 1 1 1 3		729
1 2 2 2 3 2 2 1 2 3 1 2 1 1 1 2 3 2 3 2 1 3 2 3		730
2 2 3 1 1 3 1 1 1 2 1 1 3 1 3 2 1 1 2 1 1 3 1 3		731
2 3 2 3 2 1 1 2 1 1 3 2 1 3 2 1 1 3 1 2 2 1 3 1		732
1 2 3 1 1 1 3 2 2 1 3 1 3 2 2 2 1 2 3 1 2 1 1 3		733
1 2 2 1 3 2 2 1 1 3 1 3 1 3 2 2 2 3 2 1 3 1 2 2		734
2 3 2 1 3 2 1 2 2 3 2 1 2 3 1 2 2 1 1 1 3 2 3 2		735
1 3 2 2 3 1 2 1 1 1 3 1 1 3 1 1 3 1 3 2 1 2 1 2		736
3 2 1 1 2 3 1 3 1 2 1 1 1 3 1 3 1 3 1 2 1 1 2 2		737
2 3 2 3 2 2 3 1 1 3 1 2 1 1 1 3 2 2 2 1 2 3 1 2		738
1 1 3 1 1 3 1 3 2 1 3 2 2 1 3 1 1 2 2 3 1 2 2 1		739
3 1 1 2 3 1 1 3 1 2 3 1 1 3 2 2 2 3 2 2 1 1 2 1		740
1 1 1 2 2 3 2 2 3 1 3 1 2 1 1 3 1 2 1 3 2 3 1 2		741
2 3 1 2 2 3 2 2 2 1 1 2 3 1 2 3 2 3 2 3 1 2 2 1		742
1 2 3 1 1 3 2 1 2 2 3 2 2 3 1 3 2 3 1 2 2 2 1 1		743
3 2 3 2 1 1 1 2 3 2 2 2 3 1 3 1 2 3 2 1 2 1 2 2		744
1 1 2 2 3 1 2 3 1 3 2 2 2 1 1 1 3 1 3 2 2 3 1 2		745
2 2 2 3 2 3 2 1 1 2 1 2 3 1 2 2 3 1 3 1 3 2 2 2		746
3 2 1 3 2 1 3 1 2 3 1 2 2 1 1 3 1 1 3 1 2 1 1 1		747
2 2 2 1 1 2 3 2 3 1 1 1 2 2 2 3 2 2 3 2 3 1 3 2		748
3 2 1 1 1 3 1 1 2 2 1 3 1 2 1 1 1 3 1 3 2 3 1 2		749
1 1 2 1 3 2 2 1 1 3 2 2 2 1 1 3 1 3 2 2 3 2 3 2		750
3 2 3 2 3 1 2 3 2 2 2 1 2 1 3 1 2 2 2 3 2 2 1 2		751
3 2 1 2 1 3 2 3 2 3 1 2 2 1 3 1 2 2 2 3 2 1 1 1		752
3 2 2 3 2 1 1 3 1 1 1 3 1 2 1 2 3 2 1 1 3 1 1 1		753
1 2 1 2 2 1 3 1 2 2 3 2 1 1 1 3 1 3 1 3 2 3 1 1		754
3 1 3 2 3 1 2 1 2 2 3 1 1 1 2 2 1 3 1 2 2 3 2 1		755
2 1 1 3 1 1 3 2 2 1 1 1 3 1 1 3 1 3 1 3 2 2 2 1		756
3 1 2 3 2 2 1 3 1 2 1 1 1 3 2 2 2 1 1 3 2 1 3 2		757
3 2 3 1 2 2 3 2 1 2 3 1 3 1 1 1 2 3 2 2 1 1 1 2		758
2 3 1 2 2 1 2 2 3 2 1 1 3 1 1 1 3 1 2 2 3 1 3 1		759
1 1 3 1 1 2 2 3 2 3 2 1 1 3 2 2 2 1 2 3 1 3 2 1		760
2 2 3 2 1 2 2 2 1 3 1 1 3 1 2 2 2 3 2 1 3 1 2 3		761
2 1 2 1 2 3 2 2 2 3 2 3 2 1 1 3 1 1 3 1 1 1 2 3		762
3 1 2 1 1 2 3 2 3 2 3 1 1 2 2 2 3 2 3 1 1 2 1 1		763
2 2 1 3 1 1 1 2 3 2 3 1 3 1 2 2 2 1 1 3 1 3 2 2		764

Table IIA: Numeric sequences corresponding to nucleotide patterns of a set of oligonucleotides

Numeric Pattern																							Sequence Identifier	
1	3	2	3	2	1	3	1	1	2	2	2	3	2	1	2	2	2	1	3	2	2	3	2	765
2	1	3	2	2	1	1	3	1	2	1	3	1	3	2	1	1	1	2	3	1	2	1	3	766
3	1	1	3	2	3	1	2	1	2	2	3	2	1	1	1	2	2	3	1	2	1	1	3	767
3	2	1	1	2	2	3	2	3	2	2	1	3	1	2	2	2	1	1	3	1	1	3	2	768
2	3	1	2	1	2	2	2	3	2	3	1	1	2	2	3	1	2	1	3	2	1	2	3	769
1	1	3	2	1	1	1	3	1	3	1	2	1	2	1	3	2	2	1	1	3	2	2	3	770
1	2	2	1	3	2	2	1	1	3	2	2	1	2	2	2	3	2	3	1	3	2	3	1	771
1	3	1	2	3	1	1	3	2	1	3	2	2	2	1	2	3	1	1	2	2	1	3	1	772
2	3	1	3	2	2	1	3	2	2	1	1	3	2	3	1	2	1	3	2	2	1	1	1	773
2	2	1	2	2	3	2	1	3	1	2	2	2	1	3	1	3	1	1	3	1	2	3	1	774
2	1	2	2	2	3	2	3	2	2	2	3	2	2	3	1	2	2	1	3	1	2	1	3	775
3	2	1	2	1	1	2	3	2	3	2	3	2	3	1	1	1	3	2	2	1	2	1	1	776
2	1	2	1	2	3	2	2	3	1	3	2	1	2	1	1	1	3	1	3	1	3	1	1	777
2	2	1	3	2	2	1	3	2	2	2	1	1	1	3	1	2	2	3	2	3	1	3	2	778
2	2	2	1	3	1	1	2	1	1	3	2	3	1	2	3	2	3	1	2	3	1	1	1	779
1	3	1	3	2	1	1	2	3	2	3	2	1	1	1	2	1	3	2	2	1	3	1	2	780
2	3	2	3	1	2	1	1	1	3	1	3	1	1	1	2	2	1	3	2	2	3	2	2	781
3	1	1	2	2	2	1	3	2	3	1	1	2	3	2	2	2	3	1	3	1	2	2	1	782
2	3	2	3	1	2	3	2	3	2	1	1	3	2	1	2	1	2	3	1	1	1	2	2	783
2	2	3	2	3	1	1	2	3	1	2	2	1	1	2	3	1	1	2	1	3	1	1	3	784
1	1	2	3	2	2	3	2	2	2	1	3	1	2	2	3	1	3	1	1	1	3	2	2	785
1	3	1	2	2	3	2	3	2	2	1	3	2	1	2	2	1	3	2	1	2	1	1	3	786
2	2	3	1	2	3	2	1	2	2	1	3	1	1	1	3	2	2	2	1	2	3	2	3	787
2	1	2	3	1	2	2	3	2	3	2	3	2	2	1	3	1	3	1	1	2	2	2	1	788
2	1	3	2	3	2	1	3	1	2	1	2	2	2	3	1	2	1	3	2	2	1	2	3	789
1	3	2	2	2	1	1	2	3	2	3	2	2	2	1	3	2	2	3	2	2	1	2	3	790
2	3	2	3	2	1	1	1	3	2	1	3	1	1	1	3	2	1	1	1	3	1	2	2	791
3	2	2	1	2	3	1	2	1	2	1	3	2	3	1	3	2	2	3	2	2	1	2	2	792
2	2	2	3	1	2	2	3	1	1	2	3	2	2	1	1	2	1	3	2	3	2	3	2	793
1	3	1	3	2	1	2	2	1	3	2	1	3	2	2	1	2	2	3	2	1	1	3	2	794
2	1	1	3	2	1	3	1	1	1	3	1	1	3	1	1	3	1	2	1	2	2	2	3	795
1	3	1	1	1	3	1	3	1	1	2	2	1	2	3	2	1	1	2	3	1	1	1	3	796
2	2	1	3	1	2	2	2	3	2	2	1	3	2	3	2	3	1	2	2	2	1	1	3	797
3	1	2	3	1	2	2	1	1	3	1	2	1	2	1	3	1	3	1	2	1	3	2	2	798
1	2	1	2	2	2	3	1	3	2	3	1	2	2	1	1	3	1	3	2	1	1	2	3	799
2	3	2	1	2	2	3	2	3	1	3	2	2	1	1	3	2	1	2	1	1	3	2	2	800
1	1	2	2	2	1	3	2	1	3	1	1	1	3	2	3	2	2	3	2	3	2	2	2	801
3	2	2	1	3	1	1	3	1	2	2	1	1	3	2	2	3	1	1	2	1	1	2	3	802
2	1	1	1	3	2	1	2	3	2	3	1	3	1	2	3	1	2	2	2	1	2	3	2	803
2	3	1	1	1	2	3	1	2	2	1	1	1	3	1	2	3	1	1	3	1	2	3	1	804
2	2	1	2	2	1	3	1	2	3	2	2	3	1	3	2	3	2	2	2	3	2	2	2	805
2	1	3	2	3	2	2	2	1	1	1	3	1	3	2	1	3	2	1	2	1	2	3	1	806
1	3	2	2	1	2	1	1	3	2	1	1	1	2	3	1	2	3	2	2	3	1	2	3	807
2	2	1	1	3	1	3	1	3	1	1	1	2	1	1	3	2	3	2	1	2	2	3	2	808
3	1	2	1	2	2	3	1	1	1	2	3	2	3	2	1	1	1	2	3	1	2	3	1	809
1	2	3	1	2	3	1	1	2	2	1	1	3	1	1	1	3	1	1	1	3	1	3	1	810
3	1	1	2	1	3	2	2	2	3	1	2	2	2	3	2	3	2	2	2	3	2	2	1	811
1	3	2	2	3	2	2	2	1	3	1	2	2	2	3	1	2	2	2	3	2	1	1	3	812
3	2	1	2	3	1	3	1	2	2	3	1	2	3	1	2	1	1	3	1	2	2	1	3	813
2	2	2	1	2	1	3	2	3	1	3	2	1	2	1	3	2	3	1	2	3	1	2	2	814
2	1	2	1	2	3	2	3	1	1	3	1	2	1	2	1	1	3	2	3	2	2	2	3	815
1	2	2	3	1	2	1	3	1	2	3	1	2	1	3	2	1	1	2	2	3	1	3	2	816
2	3	1	2	1	3	1	2	3	2	3	1	1	3	1	1	2	2	2	3	1	2	2	2	817

Table IIA: Numeric sequences corresponding to nucleotide patterns of a set of oligonucleotides

Numeric Pattern																								Sequence Identifier
3	1	1	3	1	2	1	2	2	3	1	1	1	3	1	1	2	2	2	3	1	2	3	2	818
3	1	2	3	2	2	2	1	3	2	3	2	1	3	1	2	1	2	1	3	1	2	2	2	819
3	1	1	2	1	2	2	3	1	3	2	2	1	2	1	1	3	2	1	3	2	1	3	2	820
1	3	2	3	1	3	2	1	1	3	2	1	1	2	1	3	1	1	1	3	1	2	2	2	821
3	2	1	3	1	1	2	1	1	3	2	1	1	2	2	2	3	2	3	1	3	1	2	1	822
3	1	3	2	2	1	2	2	2	3	1	3	1	2	2	2	1	3	1	2	3	2	2	2	823
3	1	1	1	2	3	1	2	3	1	2	2	3	1	1	2	2	2	1	3	1	3	1	2	824
1	1	1	2	1	3	2	3	2	3	1	3	1	1	2	1	3	2	2	1	1	3	2	1	825
1	2	3	2	3	2	2	1	1	3	2	2	3	2	1	3	1	1	3	1	1	2	1	1	826
1	2	1	1	2	3	1	3	2	2	1	1	2	1	3	2	3	2	1	1	3	1	1	3	827
1	2	1	1	3	1	3	1	2	3	2	2	1	1	3	2	2	1	3	1	1	1	1	3	828
2	3	2	2	1	3	2	3	2	2	1	3	1	1	1	2	1	2	3	1	1	1	3	1	829
2	2	2	1	3	1	1	3	1	2	2	3	2	2	1	3	1	2	1	1	3	2	2	3	830
3	2	3	2	1	1	2	3	2	1	2	1	1	3	1	2	1	3	2	2	1	1	3	2	831
2	1	2	2	1	3	1	3	1	3	1	1	1	2	2	3	2	1	3	1	3	1	2	2	832
2	1	3	2	3	1	3	1	2	1	1	1	3	2	1	1	1	3	2	2	2	1	2	3	833
2	2	3	2	3	1	1	1	3	2	2	1	1	3	2	1	1	3	2	2	1	3	2	2	834
1	1	1	3	2	3	2	1	1	3	2	2	3	1	1	3	1	1	2	1	2	2	3	1	835
3	1	1	2	1	3	1	3	2	3	2	2	1	2	2	2	3	1	1	1	2	1	3	1	836
2	1	2	1	1	3	1	3	1	3	1	3	1	2	1	1	3	2	1	1	2	1	1	3	837
2	3	1	3	2	3	1	1	1	2	2	3	1	2	1	3	1	3	2	1	1	1	2	2	838
3	1	2	3	1	1	2	1	1	3	2	2	2	1	1	3	2	3	1	3	1	1	1	2	839
3	2	3	2	3	1	2	1	2	3	2	2	2	1	2	2	3	1	2	2	1	1	3	2	840
2	1	1	1	3	2	3	1	3	2	3	2	1	1	1	2	3	1	2	1	1	2	3	1	841
3	2	1	3	1	3	2	2	2	3	1	2	2	2	3	1	1	1	3	1	1	2	1	2	842
3	1	1	2	1	2	2	3	2	2	1	2	3	2	2	2	3	2	2	1	2	3	1	3	843
3	2	3	2	1	1	2	1	1	3	1	2	3	2	1	2	2	3	2	2	3	2	2	2	844
2	1	1	1	2	2	3	1	2	2	3	2	3	1	3	2	2	3	1	1	3	1	1	2	845
2	3	1	3	1	2	1	3	2	2	1	2	1	3	2	2	1	1	3	2	2	2	1	3	846
1	3	2	2	2	3	2	2	1	1	3	1	2	2	1	2	3	2	1	3	1	1	1	3	847
3	1	1	2	3	2	3	2	1	3	1	1	2	1	1	3	1	3	1	2	2	1	1	1	848
3	2	1	2	2	1	2	3	1	1	1	3	1	1	3	2	2	3	2	2	3	2	2	2	849
3	2	3	2	2	1	2	1	3	1	1	3	2	2	1	1	1	2	3	2	2	1	1	3	850
2	2	1	1	3	1	3	2	1	3	2	3	1	1	2	1	2	3	1	2	1	3	2	1	851
1	1	2	3	2	2	1	2	1	1	3	1	2	3	1	3	1	3	2	2	2	1	3	2	852
1	2	1	2	1	1	3	1	2	2	2	3	1	2	3	2	1	3	2	3	2	1	3	2	853
2	1	2	3	2	2	2	3	2	2	3	2	2	3	2	2	1	1	3	2	2	2	3	1	854
3	1	2	1	3	2	2	2	1	3	2	1	2	1	3	1	1	3	1	2	1	1	1	3	855
3	2	2	3	1	1	2	1	2	1	3	1	3	1	2	1	3	2	1	1	1	2	1	3	856
1	3	1	3	1	1	3	1	2	2	2	1	3	2	1	1	3	1	1	2	3	1	2	1	857
2	3	1	1	2	3	1	3	1	1	1	3	1	2	1	2	2	3	1	3	2	1	2	2	858
2	3	1	1	3	1	2	2	1	2	1	3	2	1	3	2	2	3	2	1	2	1	3	1	859
3	1	2	2	1	3	2	1	3	2	1	2	2	3	1	1	3	1	2	2	1	2	3	2	860
2	3	1	1	1	2	3	2	3	2	1	2	2	2	3	2	1	2	3	2	2	2	1	3	861
1	2	2	1	1	1	3	2	2	3	1	2	1	2	3	1	1	1	3	1	1	3	2	3	862
1	1	2	3	2	1	3	1	3	1	2	2	3	2	1	3	2	3	1	1	2	1	2	2	863
2	2	1	2	2	2	3	2	2	3	1	3	2	3	2	1	1	1	2	3	2	3	1	2	864
1	2	3	2	1	1	2	2	3	2	3	1	1	2	1	1	2	3	2	1	2	3	2	3	865
3	1	2	2	2	3	2	1	2	1	3	1	3	1	2	2	1	3	2	1	1	3	2	1	866
1	1	2	1	2	2	3	2	2	3	2	2	2	1	3	1	3	1	1	1	3	1	1	3	867
1	2	3	1	2	3	1	2	3	2	1	2	2	2	3	2	1	1	1	3	1	3	2	1	868
1	1	2	3	2	1	2	2	2	3	2	3	2	3	1	2	2	3	2	3	2	1	1	1	869
1	3	2	3	2	2	1	2	3	1	1	3	1	1	2	1	3	2	1	1	3	1	1	2	870

Table IIA: Numeric sequences corresponding to nucleotide patterns of a set of oligonucleotides

Numeric Pattern																						Sequence Identifier			
3	2	2	1	2	3	2	1	3	1	3	1	2	3	1	1	1	3	1	1	1	2	2	1	871	
3	2	2	2	3	2	1	2	2	1	3	1	2	1	1	1	2	3	1	3	2	2	3	2	872	
2	3	1	2	2	2	1	2	3	1	3	1	2	2	1	1	3	1	3	1	1	1	3	1	873	
2	2	2	3	2	3	2	3	2	2	1	2	2	3	2	1	1	2	2	3	1	3	1	2	874	
3	1	2	3	2	3	2	3	1	2	1	2	3	1	2	2	1	1	1	3	1	1	1	2	875	
1	3	1	2	2	1	2	1	3	1	2	2	2	3	2	1	3	1	3	1	1	1	3	2	876	
3	1	1	3	1	3	2	1	2	3	2	1	1	2	1	3	2	1	2	2	3	2	1	2	877	
2	2	2	3	2	1	1	2	3	2	2	3	2	2	3	1	3	2	2	2	1	1	3	1	878	
1	3	2	1	1	1	2	1	3	2	1	3	2	1	2	3	1	1	2	1	1	3	1	3	879	
3	1	1	2	3	2	2	3	1	1	2	2	3	1	1	1	2	1	2	3	1	3	2	2	880	
1	3	2	1	3	2	2	1	1	2	2	3	1	2	1	3	2	1	1	3	2	2	2	3	881	
1	3	2	3	2	1	1	1	3	1	1	1	2	3	1	1	2	3	1	1	2	1	1	3	882	
2	3	2	2	1	3	1	2	1	2	2	2	3	2	2	3	1	1	1	2	3	2	3	1	1	883
2	3	2	1	2	3	2	2	3	1	3	2	2	2	3	1	1	2	2	3	2	2	1	2	884	
2	3	1	3	2	3	1	1	2	2	1	3	2	2	1	2	3	2	2	3	2	2	1	2	885	
3	1	1	3	1	1	1	3	1	1	1	2	3	1	3	1	1	1	3	1	2	2	1	2	886	
2	2	1	1	3	2	1	1	3	2	2	3	2	3	2	2	3	1	2	1	2	2	1	3	887	
1	2	3	1	2	3	2	3	2	2	2	3	1	2	2	2	3	1	1	2	2	3	1	1	888	
1	1	3	2	1	1	3	2	3	1	1	1	2	2	3	2	2	3	2	2	2	3	1	1	889	
1	2	3	1	1	3	2	3	2	1	1	1	3	2	2	2	3	1	1	1	3	1	1	1	890	
1	3	1	3	1	3	2	1	1	3	1	2	1	1	2	2	3	2	1	2	1	3	2	1	891	
2	2	2	1	2	3	1	3	1	2	1	3	1	2	3	1	1	1	2	1	1	3	2	3	892	
1	3	1	1	1	2	2	1	3	2	1	3	2	1	1	2	3	1	2	2	2	3	2	3	893	
3	1	2	2	2	3	1	3	1	2	2	3	1	1	2	3	1	3	1	1	2	1	2	1	894	
3	1	2	2	1	3	1	1	1	3	1	2	3	1	1	2	1	1	1	3	1	2	3	1	895	
2	1	3	1	2	1	3	1	1	1	3	2	1	2	1	2	3	2	2	3	2	1	3	2	896	
3	1	1	3	1	2	1	3	2	1	1	1	3	2	1	1	1	3	2	1	1	3	2	2	897	
1	1	1	2	3	2	3	2	3	2	2	2	1	3	2	1	3	2	2	3	2	1	1	1	898	
2	2	3	2	2	3	1	1	3	2	1	1	3	1	3	1	2	3	1	1	2	1	1	1	899	
2	1	2	2	2	3	1	3	1	3	1	1	1	3	1	1	1	3	1	3	2	2	2	1	900	
2	1	2	2	2	1	3	2	3	1	2	3	1	1	2	2	2	3	2	3	1	2	3	2	901	
2	2	1	2	1	3	2	3	1	2	3	1	2	3	1	2	1	1	3	2	2	3	1	2	902	
2	1	1	1	3	1	2	1	1	2	2	3	2	1	3	1	1	1	3	2	1	3	2	3	903	
3	2	2	2	1	3	2	1	2	2	3	1	2	1	2	2	3	2	3	2	3	2	1	1	904	
3	2	3	2	2	3	2	3	1	1	2	1	1	3	1	2	2	3	1	1	1	2	1	2	905	
1	1	1	3	1	1	1	3	2	1	2	1	1	1	3	2	3	1	3	1	2	1	3	1	906	
2	1	2	2	2	3	2	1	1	3	1	1	3	2	3	2	1	3	1	2	1	2	2	3	907	
2	1	3	1	1	3	1	2	3	1	1	1	2	2	3	2	3	1	2	2	2	3	2	2	908	
1	2	1	1	2	1	3	2	1	1	3	2	3	1	1	2	3	1	2	3	1	3	1	2	909	
1	1	2	3	2	3	1	1	2	1	1	3	1	2	1	1	1	3	2	3	2	3	2	1	910	
1	2	2	3	1	1	3	1	2	1	1	1	3	1	2	3	2	2	3	2	2	2	1	3	911	
2	3	1	1	1	2	1	3	1	1	3	2	3	1	3	1	2	2	1	2	1	3	2	1	912	
1	3	2	2	1	2	2	3	2	3	1	1	1	3	1	3	2	2	2	1	2	3	1	2	913	
1	1	1	2	1	3	2	1	3	2	3	1	2	1	3	1	3	1	1	3	1	2	2	2	914	
1	3	2	3	2	1	2	3	1	1	3	2	3	2	1	1	2	1	1	3	1	2	2	1	915	
2	3	1	2	2	1	1	3	1	2	2	3	2	3	2	1	3	2	3	2	2	1	2	1	916	
1	3	2	2	2	1	2	3	1	2	1	2	2	2	3	2	1	3	1	2	3	1	3	2	917	
2	1	2	3	2	3	2	1	2	3	1	1	3	1	2	2	1	2	1	3	2	2	1	3	918	
3	1	1	1	2	2	3	2	2	3	2	1	2	1	3	1	3	2	3	1	2	1	2	1	919	
2	1	3	1	1	1	2	1	3	2	2	2	1	1	3	2	1	2	1	3	2	3	2	3	920	
2	3	1	2	2	2	1	3	1	2	3	2	2	2	1	2	2	3	2	3	1	3	1	1	921	
1	1	3	2	2	3	1	2	1	2	2	2	3	2	2	3	2	2	1	3	1	2	3	1	922	
2	3	1	2	3	2	3	1	2	1	1	2	3	1	3	1	1	2	1	1	1	3	1	1	923	

Table IIA: Numeric sequences corresponding to nucleotide patterns of a set of oligonucleotides

Numeric Pattern																					Sequence Identifier			
1	1	1	3	2	2	2	1	3	2	2	2	3	2	1	2	2	1	3	2	1	3	1	3	924
1	3	2	2	2	3	1	2	3	2	3	1	2	1	3	2	1	1	1	2	1	3	1	1	925
1	1	3	2	3	2	2	1	2	2	3	1	1	2	3	2	3	1	2	3	2	2	1	2	926
1	1	1	2	2	3	1	1	3	2	3	2	3	1	2	1	1	2	3	2	2	2	3	2	927
3	2	2	2	1	3	2	3	1	2	2	1	1	1	3	1	2	1	3	1	2	2	1	3	928
1	2	1	1	3	2	3	2	1	2	1	1	3	1	3	1	1	3	2	3	2	2	1	1	929
1	2	3	1	1	2	2	2	3	2	2	2	3	2	3	1	2	3	1	1	3	2	2	1	930
1	1	1	3	1	1	2	2	3	1	3	1	1	1	2	3	1	1	1	3	2	2	1	3	931
1	3	2	3	2	1	1	3	1	3	2	1	2	1	1	1	3	2	1	2	2	2	3	1	932
3	1	1	2	2	1	1	3	1	2	2	3	2	2	1	2	1	2	3	2	3	1	3	2	933
2	1	2	3	1	1	1	3	2	3	2	2	3	2	2	2	1	1	3	2	1	1	3	1	934
2	1	1	1	3	2	1	1	1	2	3	2	2	1	2	3	2	3	1	3	1	3	1	1	935
1	1	1	3	1	2	1	2	2	3	1	2	2	3	1	3	1	2	1	3	1	3	2	2	936
1	1	3	2	3	1	2	1	2	3	1	1	2	1	2	3	2	3	1	3	1	1	1	2	937
1	1	1	2	1	3	1	3	2	2	2	3	2	2	1	1	2	3	2	1	1	3	2	3	938
3	1	2	2	2	1	3	1	2	3	1	3	2	2	1	1	3	1	1	2	2	2	1	3	939
2	2	3	2	1	1	1	2	3	1	3	2	3	2	3	1	1	2	1	2	2	3	2	1	940
1	3	2	1	3	2	3	2	1	2	2	2	3	1	3	1	2	1	1	2	1	3	1	1	941
2	3	1	3	2	2	1	1	1	3	1	3	2	2	3	2	2	3	1	2	1	2	2	2	942
1	1	1	3	1	3	2	3	2	1	2	2	1	3	1	1	1	2	1	3	2	2	2	3	943
3	2	2	2	1	3	2	2	1	2	2	2	3	1	2	3	1	3	1	2	1	1	2	3	944
1	1	3	2	3	2	1	1	1	2	3	1	1	2	1	1	1	3	1	3	2	2	3	2	945
1	1	2	1	1	1	3	2	3	1	3	2	1	3	1	1	3	2	3	2	1	1	2	2	946
2	1	2	2	3	1	3	2	2	2	3	2	3	2	1	1	1	3	1	1	3	1	2	1	947
2	2	2	1	2	1	3	2	2	3	2	2	3	2	3	2	2	3	1	1	1	3	2	2	948
1	2	3	1	1	1	2	1	2	3	1	2	2	3	2	3	2	2	2	3	2	2	3	2	949
1	1	1	3	1	3	1	2	3	2	1	1	1	3	2	3	1	3	2	2	1	2	2	1	950
2	2	3	1	1	3	1	1	1	3	2	2	1	3	1	2	3	1	2	3	1	1	2	2	951
1	2	3	2	2	1	2	2	2	3	2	2	2	1	3	2	2	2	3	2	3	2	3	1	952
1	1	1	2	1	2	3	1	1	2	2	2	3	1	1	3	1	3	1	1	3	2	3	1	953
3	1	2	2	1	3	1	2	1	2	1	3	1	1	2	1	2	2	3	1	1	3	1	3	954
2	2	1	3	1	1	2	1	1	3	1	3	1	1	1	2	3	2	1	2	3	2	3	2	955
2	2	2	1	2	3	1	1	1	3	1	3	1	1	3	2	3	2	1	2	2	1	2	3	956
3	2	1	1	3	2	1	2	2	1	1	3	2	3	2	3	1	2	2	2	1	3	2	1	957
1	2	1	1	1	3	1	3	1	1	3	2	1	1	1	3	1	3	2	1	1	1	3	2	958
1	2	2	3	2	2	1	1	2	2	3	1	1	3	2	3	2	1	2	3	1	1	1	3	959
2	1	2	1	2	1	3	2	2	3	1	3	2	2	3	1	3	2	1	1	3	1	2	2	960
2	1	3	1	2	3	1	3	1	2	1	2	1	2	3	1	1	1	3	1	2	1	3	2	961
1	2	1	1	3	1	1	3	1	2	3	1	2	2	2	3	2	3	2	1	1	1	2	3	962
2	2	1	3	2	1	1	2	1	1	3	1	1	1	3	1	2	3	1	1	3	1	3	1	963
3	1	2	2	2	3	2	3	1	3	2	1	1	1	3	2	1	1	1	2	1	3	1	1	964
1	1	1	2	1	3	1	2	3	2	1	3	1	1	2	2	2	3	2	3	2	3	2	2	965
3	1	1	1	2	2	1	3	2	3	2	2	2	3	2	3	2	3	2	1	2	2	1	2	966
1	2	2	2	3	1	3	2	1	2	3	1	2	1	3	1	1	3	1	2	2	3	2	2	967
1	2	1	3	1	3	2	2	3	1	1	3	2	1	2	3	2	1	1	1	3	2	2	2	968
2	1	1	2	2	2	3	2	3	1	1	2	3	2	2	3	2	2	1	2	2	3	2	3	969
2	2	1	3	2	2	2	1	2	3	1	3	1	3	2	3	1	3	1	2	2	2	1	1	970
3	2	2	3	2	2	1	3	1	3	2	3	2	2	2	1	2	3	1	1	1	2	2	2	971
2	2	2	1	2	2	3	2	3	1	2	3	2	3	1	1	1	2	1	1	3	1	3	1	972
3	2	1	1	3	2	1	1	2	1	2	3	1	2	1	3	2	3	1	2	2	1	1	3	973
2	3	1	3	1	2	3	1	2	3	2	1	2	1	2	3	2	1	3	2	1	1	2	1	974
1	1	2	2	3	1	3	1	1	1	3	1	3	1	2	1	1	1	2	3	1	2	1	3	975
2	2	2	3	1	1	3	2	3	1	2	3	2	2	1	3	1	1	2	3	2	2	2	1	976

Table IIA: Numeric sequences corresponding to nucleotide patterns of a set of oligonucleotides

Numeric Pattern																							Sequence Identifier	
1	3	2	2	3	2	2	3	2	3	2	1	1	2	2	3	2	2	1	3	2	1	1	1	977
1	2	1	3	2	3	1	3	1	1	3	2	3	1	2	1	1	3	1	2	1	2	2	2	978
3	2	3	2	3	1	2	1	1	3	2	1	1	2	2	3	1	3	2	2	1	1	1	2	979
2	1	3	2	2	1	2	2	3	2	2	2	3	2	3	1	1	2	2	2	3	1	3	1	980
1	2	1	3	2	2	3	1	1	2	1	3	2	1	1	2	2	2	3	1	1	3	1	3	981
1	2	3	2	2	2	3	2	3	2	2	2	3	1	1	2	1	3	1	3	1	1	2	1	982
2	3	1	2	1	1	1	3	1	2	1	2	3	1	3	1	3	1	2	2	3	2	1	1	983
2	1	1	1	3	1	2	3	1	3	1	2	3	2	2	3	2	2	1	1	1	3	2	2	984
1	1	3	2	3	1	1	1	2	2	2	3	2	1	1	3	1	1	2	2	1	3	2	3	985
3	1	1	1	2	3	1	3	1	3	2	2	1	2	2	3	1	2	1	3	2	2	2	1	986
2	2	2	3	2	1	1	1	2	3	1	3	1	2	1	2	1	3	2	3	2	2	1	3	987
3	2	2	1	1	2	2	3	2	3	1	2	1	2	2	2	3	1	2	2	1	3	2	3	988
1	3	1	3	2	3	2	2	3	1	2	1	1	1	3	1	2	3	2	2	2	1	2	1	989
1	1	2	2	3	2	3	1	3	1	1	1	2	2	3	1	2	1	1	3	1	1	3	1	990
2	2	1	1	1	3	1	3	1	1	2	2	3	1	3	1	1	3	1	3	1	1	1	2	991
2	2	3	2	2	1	3	1	1	3	1	1	2	2	3	1	1	2	3	2	1	2	3	2	992
1	3	2	2	1	1	3	1	2	1	2	3	2	3	2	3	1	2	3	2	2	2	1	1	993
2	3	1	3	2	2	1	2	3	2	2	3	2	1	1	2	1	3	1	1	1	2	2	3	994
2	2	1	3	1	2	1	1	3	2	2	2	1	3	1	3	1	2	2	3	1	3	1	1	995
1	2	3	1	3	2	1	1	2	1	1	3	1	3	2	1	2	2	2	3	1	1	3	2	996
2	3	2	2	2	1	1	3	2	3	2	1	1	2	3	1	2	2	2	3	2	2	1	3	997
2	2	3	1	1	3	1	1	3	1	2	2	3	2	2	1	2	2	3	2	2	3	1	1	998
2	1	2	1	3	1	1	1	3	1	2	2	1	1	1	3	1	3	2	3	1	1	2	3	999
2	1	1	1	2	2	3	2	2	1	3	1	1	1	2	2	2	3	1	3	2	3	2	3	1000
1	2	2	3	2	2	1	3	2	3	2	3	2	2	1	2	2	3	1	2	2	1	2	3	1001
3	1	3	1	1	2	2	1	2	3	2	3	2	3	1	1	2	1	2	1	3	1	1	1	1002
2	2	3	1	2	2	3	1	2	1	1	1	3	2	1	1	1	3	1	3	2	3	2	1	1003
3	2	3	2	3	2	1	1	1	2	2	3	1	1	2	1	2	3	2	2	1	1	2	3	1004
1	1	1	3	2	1	1	1	3	1	1	1	3	1	1	3	2	2	2	3	1	1	1	3	1005
2	2	2	1	3	2	2	3	1	1	3	1	1	2	1	3	1	1	1	3	1	1	1	3	1006
3	2	3	2	1	1	2	1	1	3	1	3	2	3	1	1	2	1	3	2	1	1	2	2	1007
2	1	2	2	3	1	1	1	2	1	1	3	1	3	1	3	1	2	2	2	3	2	3	1	1008
1	2	3	1	3	1	1	1	3	1	1	3	1	1	3	2	2	1	1	3	1	2	2	2	1009
1	1	3	1	3	2	3	1	3	2	1	2	1	2	2	3	2	2	1	1	1	3	1	1	1010
2	2	2	3	2	1	1	1	3	2	3	1	2	3	1	2	3	2	1	1	3	1	2	1	1011
3	1	2	3	2	2	1	2	3	2	3	1	2	3	1	1	1	2	1	2	3	2	1	2	1012
3	2	1	3	1	1	2	1	1	1	3	2	3	2	2	1	1	1	3	2	3	2	2	1	1013
1	1	1	3	1	3	2	1	2	3	2	3	2	3	2	1	2	3	1	2	1	2	2	2	1014
1	1	1	3	1	2	1	1	3	1	3	2	2	1	3	2	1	1	1	2	2	3	2	3	1015
1	1	3	1	1	2	2	1	3	1	3	1	1	2	1	1	3	2	3	2	3	1	2	1	1016
3	1	2	1	1	3	1	1	1	3	2	3	1	1	1	2	3	2	1	1	1	2	2	3	1017
3	1	2	3	1	1	1	3	1	2	3	2	2	2	1	1	1	3	2	2	2	3	2	2	1018
1	3	2	3	2	1	1	3	2	1	1	2	1	1	3	2	2	2	3	1	3	1	1	1	1019
3	2	2	3	1	3	1	1	2	2	1	3	1	1	2	2	2	3	1	2	1	1	1	3	1020
2	2	1	1	3	1	1	1	2	2	2	3	2	1	2	3	2	3	2	2	3	2	2	3	1021
1	3	1	1	3	1	2	2	2	1	3	1	2	3	1	1	1	2	3	1	3	2	2	2	1022
2	1	1	3	2	2	2	3	1	3	1	2	1	1	1	3	1	2	3	1	2	1	2	3	1023
2	3	1	3	1	2	1	3	2	2	2	3	2	1	1	2	1	2	3	2	2	2	3	2	1024
1	3	2	2	2	3	1	1	1	2	2	3	2	1	1	3	2	2	2	3	1	2	3	1	1025
2	1	3	1	1	2	2	3	1	2	2	1	1	2	3	1	2	3	1	3	2	1	3	2	1026
1	3	1	3	1	2	2	2	3	2	1	1	2	1	1	3	2	1	2	2	3	1	1	3	1027
1	2	1	1	2	3	1	2	3	2	1	1	2	3	2	1	1	3	2	1	3	2	3	2	1028
2	3	1	1	1	2	2	2	3	1	2	3	1	3	1	3	1	2	1	2	3	2	2	1	1029

Table IIA: Numeric sequences corresponding to nucleotide patterns of a set of oligonucleotides

Numeric Pattern		Sequence Identifier
2 3 2 3 2 1 1 1 3 2 1 2 1 3 2 2 2 1 2 3 2 2 1 3		1030
2 3 1 1 2 1 1 3 2 3 1 1 1 2 1 3 1 1 2 3 1 1 2 3		1031
1 1 1 3 1 1 1 3 1 2 2 3 2 1 1 2 1 1 3 2 1 3 1 3		1032
1 1 2 3 1 1 1 2 1 3 2 3 2 2 1 1 1 2 3 1 3 2 3 2		1033
3 2 1 3 1 2 1 1 1 3 1 2 3 2 3 1 1 2 2 1 2 3 1 2		1034
3 1 2 1 3 2 1 2 1 2 3 2 3 2 3 2 1 2 2 2 3 2 2 2		1035
1 2 3 2 2 2 3 2 1 3 1 1 1 2 3 2 2 2 3 1 1 3 1 2		1036
1 1 1 2 2 2 3 2 1 3 1 3 1 3 1 1 1 2 2 2 3 2 2 3		1037
2 1 3 1 1 2 1 1 3 1 2 2 1 3 2 1 1 3 2 3 2 1 3 1		1038
2 3 1 2 2 2 1 3 1 3 1 1 1 2 1 2 3 1 3 2 1 3 1 1		1039
1 1 2 1 3 1 3 2 1 2 3 2 2 3 2 2 2 1 2 3 1 3 1 1		1040
3 1 2 3 1 2 3 1 1 3 1 3 2 2 2 1 2 2 3 2 1 1 1 2		1041
1 1 3 2 1 1 1 3 1 1 3 1 1 3 1 1 1 2 3 2 3 2 2 1		1042
2 2 3 1 1 3 1 1 2 2 1 1 3 2 3 2 2 2 1 3 2 3 2 1		1043
1 3 1 1 1 3 1 1 2 3 2 2 3 1 2 2 2 1 2 3 1 2 3 2		1044
3 1 2 2 1 1 1 3 1 3 1 2 3 2 2 3 1 2 2 3 1 1 1 2		1045
1 1 2 3 1 2 1 1 2 2 3 2 2 3 1 3 1 3 1 3 2 1 1 2		1046
3 2 2 2 3 2 2 3 1 1 1 3 2 3 2 1 1 1 3 2 1 2 1 2		1047
2 3 1 3 2 2 1 2 1 2 3 1 3 1 1 1 3 2 3 2 1 1 2 2		1048
2 2 3 2 3 1 3 1 1 1 3 1 1 3 2 1 2 1 2 1 3 1 1 2		1049
3 2 1 1 3 2 2 2 1 3 1 3 2 2 1 2 1 3 1 3 2 2 2 1		1050
3 1 2 1 3 1 2 1 3 1 2 1 1 3 2 2 1 1 2 2 3 1 1 3		1051
1 3 1 3 1 2 3 1 2 2 3 2 2 2 1 2 3 2 1 2 2 1 2 3		1052
1 1 1 3 2 2 1 1 3 1 1 1 2 2 3 2 1 3 2 3 1 2 1 3		1053
2 2 2 3 1 2 1 2 2 3 2 2 2 3 2 3 1 3 2 3 2 1 2 1		1054
1 2 2 2 3 2 1 3 1 1 1 3 2 2 3 2 2 1 2 3 1 3 2 2		1055
3 1 2 2 2 3 1 3 2 1 1 3 2 2 2 1 2 1 3 1 2 3 1 1		1056
1 1 3 1 2 1 1 1 3 2 3 1 3 2 2 3 1 2 2 2 1 3 1 2		1057
3 1 2 1 2 2 3 2 1 1 3 1 2 1 2 3 2 2 3 2 1 1 1 3		1058
3 2 1 1 3 1 3 2 3 2 1 2 2 3 2 1 1 3 2 2 1 1 2 2		1059
3 2 3 2 3 1 2 2 1 3 2 1 1 2 3 1 1 3 2 1 2 2 2 1		1060
3 2 1 1 3 1 1 1 3 1 2 2 1 1 3 2 3 2 2 1 3 2 1 1		1061
1 3 2 1 3 1 1 1 3 2 2 3 1 1 1 2 2 3 1 2 2 1 2 3		1062
2 1 1 3 1 3 1 1 3 2 2 3 1 3 2 1 1 2 3 2 1 2 2 2		1063
3 2 2 1 1 3 1 1 1 2 1 3 2 1 3 1 2 1 1 3 2 3 1 1		1064
2 1 1 3 2 1 1 1 2 2 3 1 1 1 3 2 3 2 1 2 1 3 2 3		1065
1 1 3 1 2 3 2 1 2 3 2 2 2 1 2 2 3 2 2 3 2 3 2 1		1066
1 2 2 2 1 3 1 1 2 1 2 1 3 2 3 1 1 3 1 3 1 2 1 3		1067
3 2 2 1 2 3 1 1 1 3 1 3 2 1 2 3 2 3 2 2 1 1 1 2		1068
2 1 2 2 1 2 3 2 3 1 1 3 1 1 3 1 1 2 3 1 2 2 1 3		1069
2 1 1 2 1 1 3 2 2 3 1 1 3 1 1 2 2 3 2 2 3 2		1070
2 3 1 2 3 2 2 2 3 1 2 3 2 1 1 2 2 3 2 2 1 1 1 3		1071
3 2 3 1 1 1 3 1 2 2 2 3 1 3 2 2 2 3 2 1 2 1 1 2		1072
1 3 1 3 1 1 2 1 2 1 3 1 2 2 3 1 3 1 2 2 2 3 2 2		1073
2 2 2 3 1 3 1 2 3 2 3 1 2 3 1 2 1 1 1 3 2 2 1 1		1074
3 2 2 3 2 1 1 1 2 2 3 2 1 3 2 1 1 1 3 1 1 3 2 1		1075
3 2 3 2 2 1 2 3 1 2 3 2 2 3 2 2 2 3 2 1 2 2 1 2		1076
1 2 2 1 2 2 3 2 3 2 1 3 1 2 3 2 1 2 2 1 1 3 1 3		1077
3 2 2 1 3 1 1 1 3 1 2 2 2 1 3 1 1 3 2 2 1 3 2 2		1078
2 2 3 2 3 2 1 2 2 1 1 3 1 3 1 3 2 3 1 1 1 2 1 2		1079
3 2 2 2 1 1 3 1 2 1 3 1 1 1 3 1 3 2 3 1 2 2 2 1		1080
1 1 2 3 1 3 1 1 1 2 1 3 1 2 1 3 2 2 1 2 2 3 2 3		1081
2 3 1 1 2 2 3 1 1 2 1 1 3 1 1 2 2 2 3 2 2 3 2 3		1082

Table IIA: Numeric sequences corresponding to nucleotide patterns of a set of oligonucleotides

Numeric Pattern																							Sequence Identifier	
1	1	2	1	1	3	1	2	2	3	1	1	2	2	1	3	2	3	1	3	2	1	1	3	1083
1	1	2	3	2	2	2	3	1	3	1	3	1	2	2	2	1	3	2	1	1	1	3	1	1084
1	3	2	2	2	1	3	1	1	2	1	3	1	1	1	2	3	2	3	2	2	2	3	1	1085
2	1	2	1	1	3	2	1	1	3	2	3	2	2	1	1	3	1	2	2	2	3	1	3	1086
3	2	1	3	2	3	1	1	2	1	1	3	2	2	1	3	2	3	2	2	1	1	2	1	1087
1	1	3	2	3	2	3	2	2	1	1	1	3	2	1	1	1	2	3	2	1	3	1	2	1088
1	3	1	3	1	2	3	2	2	2	1	2	3	2	2	3	2	3	1	1	2	2	1	1	1089
1	3	2	2	3	1	1	2	1	2	2	3	1	2	3	1	2	1	1	3	1	1	3	1	1090
2	3	1	1	2	3	2	3	1	3	1	2	3	2	2	2	1	3	1	1	2	1	1	2	1091
1	1	2	1	1	2	3	1	2	3	2	1	1	3	2	2	2	3	1	3	2	2	2	3	1092
1	1	1	3	1	3	2	3	1	1	2	1	3	1	1	1	2	1	1	3	1	3	1	1	1093
1	1	2	1	1	1	3	2	2	1	2	2	3	1	3	1	3	1	3	2	2	2	1	3	1094
1	3	2	1	3	2	3	2	2	3	2	1	3	2	2	2	1	3	2	1	2	1	2	1	1095
3	2	1	1	3	1	1	2	3	2	1	2	2	1	3	1	2	1	2	2	3	2	2	3	1096
3	1	2	1	1	1	2	3	2	2	2	3	1	2	1	1	1	3	2	1	3	2	2	3	1097
1	2	1	3	2	1	2	3	2	1	2	3	2	3	2	3	1	1	3	1	2	2	2	1	1098
1	2	3	1	1	2	3	2	1	3	1	3	2	3	1	2	2	1	3	2	2	2	1	1	1099
3	2	1	3	2	1	2	2	2	1	3	2	3	1	2	3	2	1	1	3	1	1	2	1	1100
1	3	1	1	2	2	3	2	1	2	2	3	1	1	3	1	1	3	1	1	2	1	2	3	1101
2	2	2	1	2	1	3	1	1	2	2	3	1	3	1	3	1	1	3	2	2	1	1	3	1102
1	1	1	3	2	1	3	2	1	3	1	3	1	2	2	2	3	1	3	1	1	2	2	1	1103
2	2	2	1	1	1	3	1	1	1	3	2	1	2	2	3	2	1	1	3	1	3	2	3	1104
1	1	1	2	2	3	1	3	1	1	1	3	2	3	1	1	2	3	1	1	3	2	2	2	1105
1	1	3	1	1	1	2	1	1	3	2	1	2	3	1	2	1	3	2	1	3	2	1	3	1106
1	2	2	2	3	1	1	2	2	3	2	1	2	2	3	2	1	3	2	2	3	2	2	3	1107
1	1	3	1	3	1	1	2	1	1	2	3	2	1	3	1	3	1	2	1	2	1	1	3	1108
2	3	2	3	2	1	1	2	1	3	2	2	3	2	2	1	1	2	3	1	3	2	1	1	1109
2	1	2	1	3	2	2	3	2	1	3	2	2	2	1	3	1	2	3	1	1	2	3	2	1110
1	2	2	3	2	3	2	2	1	3	1	1	2	3	1	2	3	2	2	1	1	2	1	3	1111
3	2	2	2	3	2	1	2	1	3	2	1	2	2	2	3	1	2	2	3	1	2	3	2	1112
1	3	1	3	2	1	1	1	3	2	1	2	3	1	3	2	2	1	2	3	1	1	2	1	1113
3	1	1	1	3	2	2	2	1	1	3	2	3	1	2	3	2	1	2	1	2	2	3	2	1114
2	2	1	1	1	2	3	1	2	1	1	1	3	1	3	1	3	2	3	2	3	1	1	3	1115
2	2	1	1	1	2	3	2	3	2	3	1	3	1	1	3	1	2	3	1	1	2	1	1	1116
1	2	2	2	3	2	1	2	1	1	1	3	2	3	1	1	3	1	1	3	1	3	1	1	1117
2	3	1	2	2	1	3	2	1	2	2	2	3	2	3	1	1	3	1	3	1	2	2	2	1118
2	2	2	3	1	1	2	3	1	1	1	2	2	3	1	2	3	1	2	1	3	1	2	3	1119
1	3	1	3	2	1	1	3	1	2	2	1	1	3	1	1	2	1	1	3	1	1	1	3	1120
1	2	2	3	1	1	2	2	3	1	3	1	1	3	2	3	1	1	3	2	1	1	1	2	1121
2	2	2	1	3	1	3	1	1	3	2	1	2	2	3	2	2	2	3	1	1	1	3	1	1122
2	1	1	1	3	2	3	1	1	1	3	1	2	2	2	3	1	1	1	2	3	1	2	3	1123
3	1	1	1	3	2	2	1	3	1	3	1	1	1	2	3	2	1	3	1	1	1	2	2	1124
3	2	3	1	1	2	1	1	2	3	1	1	3	1	1	3	2	2	1	2	3	2	2	1	1125
2	2	3	2	3	1	1	2	1	1	1	3	2	1	3	1	2	3	2	3	2	2	1	2	1126
2	2	1	2	1	2	3	1	2	1	2	3	1	3	2	2	2	3	2	3	2	2	3	1	1127
2	2	3	1	2	2	2	3	2	3	2	3	1	3	2	1	2	2	1	3	2	2	1	2	1128
1	1	1	3	2	3	1	2	2	1	1	3	2	2	1	3	2	2	2	3	1	3	1	2	1129
2	2	3	2	1	2	2	2	3	2	1	2	1	1	2	3	2	2	3	1	1	3	1	3	1130
3	2	2	2	3	1	1	1	2	2	1	3	2	3	2	3	1	3	1	1	1	2	1	2	1131
1	1	2	3	2	2	3	1	3	1	2	2	3	1	2	1	1	2	3	2	2	3	1	1	1132
2	1	3	2	1	3	2	1	3	2	1	2	2	3	2	2	3	2	1	1	2	1	1	3	1133
3	2	2	3	2	1	1	2	2	2	3	1	3	2	3	2	2	1	3	2	2	1	2	2	1134
2	3	1	1	2	1	2	3	1	2	1	3	2	2	1	3	2	1	1	2	2	3	2	3	1135

Table IIA: Numeric sequences corresponding to nucleotide patterns of a set of oligonucleotides

Numeric Pattern																							Sequence Identifier	
2	3	1	2	1	3	2	1	2	3	2	2	2	3	2	3	1	2	2	1	1	1	3	1	1136
3	1	2	3	2	1	2	1	1	1	3	1	3	2	1	2	3	2	2	1	2	1	1	3	1137
1	3	2	3	1	3	1	2	2	2	1	3	1	1	3	1	2	3	2	2	1	2	2	1	1138
1	2	3	1	3	1	1	2	2	2	3	2	2	1	1	1	3	1	3	1	1	1	3	2	1139
1	1	1	3	1	1	2	2	1	3	2	1	2	3	1	2	1	3	1	2	3	1	3	1	1140
2	1	3	1	3	2	2	3	2	1	2	1	3	2	2	2	1	2	1	3	2	2	3	1	1141
3	2	1	3	1	1	2	3	1	2	2	3	2	2	2	1	3	1	1	3	1	2	2	2	1142
3	2	2	2	1	2	3	2	2	2	3	1	3	1	1	3	1	3	2	2	1	2	2	2	1143
2	1	3	1	1	3	2	2	2	3	1	1	1	3	2	2	1	2	2	3	1	2	2	3	1144
3	1	2	3	1	1	3	1	3	2	1	2	2	2	3	2	2	1	2	1	2	3	2	1	1145
3	1	2	3	1	1	2	1	2	1	3	2	1	1	3	2	1	2	2	3	1	3	2	1	1146
2	1	3	2	3	1	2	3	1	1	1	2	2	2	3	1	3	1	2	1	3	1	2	1	1147
3	1	1	1	3	1	1	1	2	2	3	1	1	3	1	3	2	2	2	3	1	2	1	2	1148
1	2	2	2	3	1	3	2	1	2	2	2	3	2	3	2	1	2	2	3	1	1	2	3	1149
1	2	3	1	3	2	2	3	1	1	1	2	2	2	3	1	1	3	2	1	2	2	3	2	1150
2	2	1	1	2	1	3	2	3	1	3	1	3	1	3	2	1	2	1	2	3	2	1	1	1151
1	2	2	1	1	3	1	3	1	3	2	3	1	3	2	1	1	1	2	3	2	1	1	1	1152
1	1	3	1	1	2	1	3	1	2	3	1	3	1	2	2	1	3	1	1	1	2	1	3	1153
1	3	2	2	2	1	1	1	3	1	3	2	2	1	3	1	1	2	2	3	1	1	1	3	1154
3	2	1	1	3	1	2	2	2	3	2	2	3	1	1	2	1	1	1	3	1	1	3	1	1155
1	3	1	3	1	1	1	3	1	1	3	2	2	1	1	1	3	2	3	1	2	1	2	2	1156
2	1	1	2	1	3	1	3	1	1	3	1	3	1	2	3	2	1	2	3	1	1	2	1	1157
2	2	1	2	2	1	3	2	3	1	2	1	1	3	2	3	1	1	3	2	2	2	1	3	1158
1	2	1	1	2	3	2	1	1	1	3	1	2	3	1	3	2	2	2	1	2	3	1	3	1159
2	2	3	1	2	2	2	3	1	3	1	3	2	2	3	1	2	1	1	3	1	2	2	2	1160
1	2	3	1	2	2	1	2	2	3	2	3	2	3	2	1	3	1	1	2	2	1	3	1	1161
2	1	2	1	1	1	3	1	2	1	2	1	3	2	1	3	1	2	3	1	2	3	2	3	1162
2	2	2	1	3	2	2	3	1	3	1	2	3	1	1	3	2	2	1	2	2	1	3	1	1163
1	2	2	3	1	1	2	2	3	1	2	1	2	1	3	2	3	2	1	1	1	3	2	3	1164
3	1	1	3	1	1	1	3	1	2	2	1	2	2	3	2	1	2	2	3	1	3	2	2	1165
1	2	2	3	1	3	2	3	2	1	3	2	3	1	2	2	2	1	3	1	1	1	2	1	1166
1	1	2	1	1	1	3	2	3	2	2	2	1	1	3	1	3	2	1	3	1	3	2	1	1167
3	2	1	3	1	3	1	2	1	1	2	2	3	1	2	3	2	3	2	1	1	2	2	2	1168

In Table IIA, each of the numerals 1 to 3 (numeric identifiers) represents a nucleotide base and the pattern of numerals 1 to 3 of the sequences in the above list corresponds to the pattern of nucleotide bases present in the oligonucleotides of Table II, which oligonucleotides have been found to be non-cross-hybridizing, as described further in the detailed examples. Each nucleotide base is selected from the group of nucleotide bases consisting of A, C, G, and T/U. A particularly preferred embodiment of the invention, in which a specific base is assigned to each numeric identifier is shown in Table II, below.

In one broad aspect, the invention is a composition comprising molecules for use as tags or tag complements wherein each molecule comprises an oligonucleotide selected from a set of oligonucleotides based on a group

of sequences as specified by numeric identifiers set out in Table IIA. In the sequences, each of 1 to 3 is a nucleotide base selected to be different from the others of 1 to 3 with the proviso that up to three nucleotide bases of each sequence can be substituted with any nucleotide base provided that:

for any pair of sequences of the set:

$M1 \leq 16$, $M2 \leq 13$, $M3 \leq 20$, $M4 \leq 16$, and $M5 \leq 19$, where:

M1 is the maximum number of matches for any alignment in which there are no internal indels;

M2 is the maximum length of a block of matches for any alignment;

M3 is the maximum number of matches for any alignment having a maximum score;

M4 is the maximum sum of the lengths of the longest two blocks of matches for any alignment of maximum score; and

M5 is the maximum sum of the lengths of all the blocks of matches having a length of at least 3, for any alignment of maximum score; wherein:

the score of an alignment is determined according to the equation

$(A \times m) - (B \times mm) - (C \times (og + eg)) - (D \times eg)$, wherein:

for each of (i) to (iv):

(i) $m = 6$, $mm = 6$, $og = 0$ and $eg = 6$,

(ii) $m = 6$, $mm = 6$, $og = 5$ and $eg = 1$,

(iii) $m = 6$, $mm = 2$, $og = 5$ and $eg = 1$, and

(iv) $m = 6$, $mm = 6$, $og = 6$ and $eg = 0$,

A is the total number of matched pairs of bases in the alignment;

B is the total number of internal mismatched pairs in the alignment;

C is the total number of internal gaps in the alignment; and

D is the total number of internal indels in the alignment minus the total number of internal gaps in the alignment; and

wherein the maximum score is determined separately for each of (i), (ii), (iii) and (iv).

5 An explanation of the meaning of the parameters set out above is given in the section describing detailed embodiments.

10 In another broad aspect, the invention is a composition containing molecules for use as tags or tag complements wherein each molecule comprises an oligonucleotide selected from a set of oligonucleotides based on a group of sequences as set out in Table IIA wherein each of 1 to 3 is a nucleotide base selected to be different from the others of 1 to 3 with the proviso that

up to three nucleotide bases of each sequence can be substituted with any nucleotide base provided that:

for any pair of sequences of the set:

$M1 \leq 19$, $M2 \leq 17$, $M3 \leq 21$, $M4 \leq 18$, and $M5 \leq 20$, where:

$M1$ is the maximum number of matches for any alignment in which there are no internal indels;

$M2$ is the maximum length of a block of matches for any alignment;

$M3$ is the maximum number of matches for any alignment having a maximum score;

$M4$ is the maximum sum of the lengths of the longest two blocks of matches for any alignment of maximum score; and

$M5$ is the maximum sum of the lengths of all the blocks of matches having a length of at least 3, for any alignment of maximum score; wherein

the score of an alignment is determined according to the equation

$(A \times m) - (B \times mm) - (C \times (og + eg)) - (D \times eg)$, wherein:

for each of (i) to (iv):

(i) $m = 6$, $mm = 6$, $og = 0$ and $eg = 6$,

(ii) $m = 6$, $mm = 6$, $og = 5$ and $eg = 1$,

(iii) $m = 6$, $mm = 2$, $og = 5$ and $eg = 1$, and

(iv) $m = 6$, $mm = 6$, $og = 6$ and $eg = 0$,

A is the total number of matched pairs of bases in the alignment;

B is the total number of internal mismatched pairs in the alignment;

C is the total number of internal gaps in the alignment; and

D is the total number of internal indels in the alignment minus the total number of internal gaps in the alignment; and

wherein the maximum score is determined separately for each of (i), (ii), (iii) and (iv).

In another broad aspect, the invention is a composition comprising molecules for use as tags or tag complements wherein each molecule comprises an oligonucleotide selected from a set of oligonucleotides based on a group of sequences set out in Table IIA wherein each of 1 to 3 is a nucleotide base selected to be different from the others of 1 to 3 with the proviso that up to three nucleotide bases of each sequence can be substituted with any nucleotide base provided that:

for any pair of sequences of the set:

$M1 \leq 19$, $M2 \leq 17$, $M3 \leq 21$, $M4 \leq 18$, and $M5 \leq 20$, where:

M1 is the maximum number of matches for any alignment in which there are n internal indels;

M2 is the maximum length of a block of matches for any alignment;

M3 is the maximum number of matches for any alignment having a maximum score;

M4 is the maximum sum of the lengths of the longest two blocks of matches for any alignment of maximum score; and

M5 is the maximum sum of the lengths of all the blocks of matches having a length of at least 3, for any alignment of maximum score, wherein:

the score of an alignment is determined according to the equation

$3A - B - 3C - D$, wherein:

A is the total number of matched pairs of bases in the alignment;

B is the total number of internal mismatched pairs in the alignment;

C is the total number of internal gaps in the alignment; and

D is the total number of internal indels in the alignment minus the total number of internal gaps in the alignment; and

In preferred aspects, the invention provides a composition in which, for the group of 24mer sequences in which 1 = A, 2 = T and 3 = G, under a defined set of conditions in which the maximum degree of hybridization between a sequence and any complement of a different sequence of the group of 24mer sequences does not exceed 30% of the degree of hybridization between said sequence and its complement, for all said oligonucleotides of the composition, the maximum degree of hybridization between an oligonucleotide and a complement of any other oligonucleotide of the composition does not exceed 50% of the degree of hybridization of the oligonucleotide and its complement.

More preferably, the maximum degree of hybridization between a sequence and any complement of a different sequence does not exceed 30% of the degree of hybridization between said sequence and its complement, the degree of hybridization between each sequence and its complement varies by a factor of between 1 and up to 10, more preferably between 1 and up to 9, more preferably between 1 and up to 8, more preferably between 1 and up to 7, more preferably between 1 and up to 6, and more preferably between 1 and up to 5.

It is also preferred that the maximum degree of hybridization between a sequence and any complement of a different sequence does not exceed 25%, more preferably does not exceed 20%, more preferably does not exceed 15%, more preferably does not exceed 10%, more preferably does not exceed 5%.

Even more preferably, the above-referenced defined set of conditions results in a level of hybridization that is the same as the level of hybridization obtained when hybridization conditions include 0.2 M NaCl, 0.1 M Tris, 0.08% Triton X-100, pH 8.0 at 37°C.

- 5 In the composition, the defined set of conditions can include the group of 24mer sequences being covalently linked to beads.

- In a particular preferred aspect, for the group of 24mers the maximum degree of hybridization between a sequence and any complement of a different sequence does not exceed 15% of the degree of hybridization between said
10 sequence and its complement and the degree of hybridization between each sequence and its complement varies by a factor of between 1 and up to 9, and for all oligonucleotides of the set, the maximum degree of hybridization between an oligonucleotide and a complement of any other oligonucleotide of the set does not exceed 20% of the degree of hybridization of the
15 oligonucleotide and its complement.

- It is possible that each 1 is one of A, T/U, G and C; each 2 is one of A, T/U, G and C; and each 3 is one of A, T/U, G and C; and each of 1, 2 and 3 is selected so as to be different from all of the others of 1, 2 and 3. More preferably, 1 is A or T/U, 2 is A or T/U and 3 is G or C. Even more
20 preferably, 1 is A, 2 is T/U, and 3 is G.

- In certain preferred composition, each of the oligonucleotides is from twenty-two to twenty-six bases in length, or from twenty-three to twenty-five, and preferably, each oligonucleotide is of the same length as every other said oligonucleotide.

- 25 In a particularly preferred embodiment, each oligonucleotide is twenty-four bases in length.

It is preferred that no oligonucleotide contains more than four contiguous bases that are identical to each other.

- It is also preferred that the number of G's in each oligonucleotide
30 does not exceed $L/4$ where L is the number of bases in said sequence.

- For reasons described below, the number of G's in each said oligonucleotide is preferred not to vary from the average number of G's in all of the oligonucleotides by more than one. Even more preferably, the number of G's in each said oligonucleotide is the same as every other said
35 oligonucleotide. In the embodiment disclosed below in which oligonucleotides were tested, the sequence of each was twenty-four bases in length and each oligonucleotide contained 6 G's.

It is also preferred that, for each nucleotide, there is at most six bases other than G between every pair of neighboring pairs of G's.

Also, it is preferred that, at the 5'-end of each oligonucleotide at least one of the first, second, third, fourth, fifth, sixth and seventh bases of the sequence of the oligonucleotide is a G. Similarly, it is preferred, at the 3'-end of each oligonucleotide that at least one of the first, second, third, fourth, fifth, sixth and seventh bases of the sequence of the oligonucleotide is a G.

It is possible to have sequence compositions that include one hundred and sixty said molecules, or that include one hundred and seventy said molecules, or that include one hundred and eighty said molecules, or that include one hundred and ninety said molecules, or that include two hundred said molecules, or that include two hundred and twenty said molecules, or that include two hundred and forty said molecules, or that include two hundred and sixty said molecules, or that include two hundred and eighty said molecules, or that include three hundred said molecules, or that include four hundred said molecules, or that include five hundred said molecules, or that include six hundred said molecules, or that include seven hundred said molecules, or that include eight hundred said molecules, or that include nine hundred said molecules, or that include one thousand said molecules.

It is possible, in certain applications, for each molecule to be linked to a solid phase support so as to be distinguishable from a mixture containing other of the molecules by hybridization to its complement. Such a molecule can be linked to a defined location on a solid phase support such that the defined location for each molecule is different than the defined location for different others of the molecules.

In certain embodiments, each solid phase support is a microparticle and each said molecule is covalently linked to a different microparticle than each other different said molecule.

In another broad aspect, the invention is a composition comprising a set of 150 molecules for use as tags or tag complements wherein each molecule includes an oligonucleotide having a sequence of at least sixteen nucleotide bases wherein for any pair of sequences of the set:

$M1 \leq 19/24 \times L1$, $M2 \leq 17/24 \times L1$, $M3 \leq 21/24 \times L1$, $M4 \leq 18/24 \times L1$, $M5 \leq 20/24 \times L1$, where $L1$ is the length of the shortest sequence of the pair, where:

$M1$ is the maximum number of matches for any alignment of the pair of sequences in which there are no internal indels;

M2 is the maximum length of a block of matches for any alignment of the pair of sequences;

M3 is the maximum number of matches for any alignment of the pair of sequences having a maximum score;

M4 is the maximum sum of the lengths of the longest two blocks of matches for any alignment of the pair of sequences of maximum score; and

M5 is the maximum sum of the lengths of all the blocks of matches having length of at least 3, for any alignment of the pair of sequences of maximum score, wherein:

the score of an alignment is determined according to the equation

$$(A \times m) - (B \times mm) - (C \times (og + eg)) - (D \times eg), \text{ wherein:}$$

for each of (i) to (iv):

$$(i) \quad m = 6, mm = 6, og = 0 \text{ and } eg = 6,$$

$$(ii) \quad m = 6, mm = 6, og = 5 \text{ and } eg = 1,$$

$$(iii) \quad m = 6, mm = 2, og = 5 \text{ and } eg = 1, \text{ and}$$

$$(iv) \quad m = 6, mm = 6, og = 6 \text{ and } eg = 0,$$

A is the total number of matched pairs of bases in the alignment;

B is the total number of internal mismatched pairs in the alignment;

C is the total number of internal gaps in the alignment; and

D is the total number of internal indels in the alignment minus the total number of internal gaps in the alignment; and

wherein the maximum score is determined separately for each of (i), (ii), (iii) and (iv).

In yet another broad aspect, the invention is a composition that includes a set of 150 molecules for use as tags or tag complements wherein each molecule has an oligonucleotide having a sequence of at least sixteen nucleotide bases wherein for any pair of sequences of the set:

$$M1 \leq 19, M2 \leq 17, M3 \leq 21, M4 \leq 18, \text{ and } M5 \leq 20, \text{ where:}$$

M1 is the maximum number of matches for any alignment of the pair of sequences in which there are no internal indels;

M2 is the maximum length of a block of matches for any alignment of the pair of sequences;

M3 is the maximum number of matches for any alignment of the pair of sequences having a maximum score;

M4 is the maximum sum of the lengths of the longest two blocks of matches for any alignment of the pair of sequences of maximum score; and

M5 is the maximum sum of the lengths of all the blocks of matches having a

length of at least 3, for any alignment of the pair of sequences of maximum score, wherein:

the score of a said alignment is determined according to the equation

$3A - B - 3C - D$, wherein:

A is the total number of matched pairs of bases in the alignment;

B is the total number of internal mismatched pairs in the alignment;

C is the total number of internal gaps in the alignment; and

D is the total number of internal indels in the alignment minus the total number of internal gaps in the alignment.

In certain embodiments of the invention, each sequence of a composition has up to fifty bases. More preferably, however, each sequence is between sixteen and forty bases in length, or between sixteen and thirty-five bases in length, or between eighteen and thirty bases in length, or between twenty
5 and twenty-eight bases in length, or between twenty-one and twenty-seven bases in length, or between twenty-two and twenty-six bases in length.

Often, each sequence is of the same length as every other said sequence. In particular embodiments disclosed herein, each sequence is twenty-four bases in length.

10 Again, it can be preferred that no sequence contains more than four contiguous bases that are identical to each other, etc., as described above.

In certain preferred embodiments, the composition is such that, under a defined set of conditions, the maximum degree of hybridization between an oligonucleotide and any complement of a different oligonucleotide of the
15 composition does not exceed about 30% of the degree of hybridization between said oligonucleotide and its complement, more preferably 20%, more preferably 15%, more preferably 10%, more preferably 6%.

Preferably, the set of conditions results in a level of hybridization that is the same as the level of hybridization obtained when hybridization
20 conditions include 0.2 M NaCl, 0.1 M Tris, 0.08% Triton X-100, pH 8.0 at 37°C, and the oligonucleotides are covalently linked to microparticles. Of course it is possible that these specific conditions be used for determining the level of hybridization.

It is also preferred that under such a defined set of conditions, the
25 degree of hybridization between each oligonucleotide and its complement varies by a factor of between 1 and up to 8, more preferably up to 7, more preferably up to 6, more preferably up to 5. In a particular disclosed embodiment, the observed variance in the degree of hybridization was a factor

of only 5.3, i.e., the degree of hybridization between each oligonucleotide and its complement varied by a factor of between 1 and 5.6.

In certain preferred embodiments, under the defined set of conditions, the maximum degree of hybridization between a said oligonucleotide and any
5 complement of a different oligonucleotide of the composition does not exceed about 15%, more preferably 10%, more preferably 6%.

In one preferred embodiment, the set of conditions results in a level of hybridization that is the same as the level of hybridization obtained when hybridization conditions include 0.2 M NaCl, 0.1 M Tris, 0.08% Triton X-100,
10 pH 8.0 at 37°C, and the oligonucleotides are covalently linked to microparticles.

Also, under the defined set of conditions, it is preferred that the degree of hybridization between each oligonucleotide and its complement varies by a factor of between 1 and up to 8, more preferably up to 7, more
15 preferably up to 6, more preferably up to 5.

Any composition of the invention can include one hundred and sixty of the oligonucleotide molecules, or one hundred and seventy of the oligonucleotide molecules, or one hundred and eighty of the oligonucleotide molecules, or one hundred and ninety of the oligonucleotide molecules, or two
20 hundred of the oligonucleotide molecules, or two hundred and twenty of the oligonucleotide molecules, or two hundred and forty of the oligonucleotide molecules, or two hundred and sixty of the oligonucleotide molecules, or two hundred and eighty of the oligonucleotide molecules, or three hundred of the oligonucleotide molecules, or four hundred of the oligonucleotide molecules,
25 or five hundred of the oligonucleotide molecules, or six hundred of the oligonucleotide molecules, or seven hundred of the oligonucleotide molecules, or eight hundred of the oligonucleotide molecules, or nine hundred of the oligonucleotide molecules, or one thousand or more of the oligonucleotide molecules.

30 A composition of the invention can be a family of tags, or it can be a family of tag complements.

An oligonucleotide molecule belonging to a family of molecules of the invention can have incorporated therein one more analogues of nucleotide bases, preference being given those that undergo normal Watson-Crick base
35 pairing.

The invention includes kits for sorting and identifying polynucleotides. Such a kit can include one or more solid phase supports each having one or more spatially discrete regions, each such region having a

uniform population of substantially identical tag complements covalently attached. The tag complements are made up of a set of oligonucleotides of the invention.

5 The one or more solid phase supports can be a planar substrate in which the one or more spatially discrete regions is a plurality of spatially addressable regions.

The tag complements can also be coupled to microparticles. Microparticles preferably each have a diameter in the range of from 5 to 40 μm .

10 Such a kit preferably includes microparticles that are spectrophotometrically unique, and therefore distinguishable from each other according to conventional laboratory techniques. Of course for such kits to work, each type of microparticle would generally have only one tag complement associated with it, and usually there would be a different oligonucleotide tag complement associated with (attached to) each type of microparticle.

15 The invention includes methods of using families of oligonucleotides of the invention.

One such method is of analyzing a biological sample containing a biological sequence for the presence of a mutation or polymorphism at a locus of the nucleic acid. The method includes:

- 20 (A) amplifying the nucleic acid molecule in the presence of a first primer having a 5'-sequence having the sequence of a tag complementary to the sequence of a tag complement belonging to a family of tag complements of the invention to form an amplified molecule with a 5'-end with a sequence complementary to the sequence of the tag;
- (B) extending the amplified molecule in the presence of a polymerase and a second primer having 5'-end complementary the 3'-end of the amplified sequence, with the 3'-end of the second primer extending to immediately adjacent said locus, in the presence of a plurality of nucleoside triphosphate derivatives each of which is: (i) capable of incorporation during transcription by the polymerase onto the 3'-end of a growing nucleotide strand; (ii) causes termination of polymerization; and (iii) capable of differential detection, one from the other, wherein there is a said derivative complementary to each possible nucleotide present at said locus of the amplified sequence;
- (C) specifically hybridizing the second primer to a tag complement having the tag complement sequence of (A); and
- (D) detecting the nucleotide derivative incorporated into the second

primer in (B) so as to identify the base located at the locus of the nucleic acid.

In another method of the invention, a biological sample containing a plurality of nucleic acid molecules is analyzed for the presence of a mutation or polymorphism at a locus of each nucleic acid molecule, for each nucleic acid molecule. This method includes steps of:

- (A) amplifying the nucleic acid molecule in the presence of a first primer having a 5'-sequence having the sequence of a tag complementary to the sequence of a tag complement belonging to a family of tag complements of the invention to form an amplified molecule with a 5'-end with a sequence complementary to the sequence of the tag;
- (B) extending the amplified molecule in the presence of a polymerase and a second primer having 5'-end complementary the 3'-end of the amplified sequence, the 3'-end of the second primer extending to immediately adjacent said locus, in the presence of a plurality of nucleoside triphosphate-derivatives each of which is: (i) capable of incorporation during transcription by the polymerase onto the 3'-end of a growing nucleotide strand; (ii) causes termination of polymerization; and (iii) capable of differential detection, one from the other, wherein there is a said derivative complementary to each possible nucleotide present at said locus of the amplified molecule;
- (C) specifically hybridizing the second primer to a tag complement having the tag complement sequence of (A); and
- (D) detecting the nucleotide derivative incorporated into the second primer in (B) so as to identify the base located at the locus of the nucleic acid;

wherein each tag of (A) is unique for each nucleic acid molecule and steps (A) and (B) are carried out with said nucleic molecules in the presence of each other.

5 Another method includes analyzing a biological sample that contains a plurality of double stranded complementary nucleic acid molecules for the presence of a mutation or polymorphism at a locus of each nucleic acid molecule, for each nucleic acid molecule. The method includes steps of:

- (A) amplifying the double stranded molecule in the presence of a pair of first primers, each primer having an identical 5'-sequence having the sequence of a tag complementary to the sequence of a tag complement belonging to a family of tag complements of the invention to form amplified molecules with 5'-ends with a sequence complementary to the sequence of the tag;

- (B) extending the amplified molecules in the presence of a polymerase and a plurality of second primers each second primer having a 5'-end complementary to a 3'-end of the amplified sequence, the 3'-end of each said second primer extending to immediately adjacent said locus, in the presence of a plurality of nucleoside triphosphate derivatives each of which is: (i) capable of incorporation during transcription by the polymerase onto the 3'-end of a growing nucleotide strand; (ii) causes termination of polymerization; and (iii) capable of differential detection, one from the other;
 - (C) specifically hybridizing each of the second primers to a tag complement having the tag complement sequence of (A); and
 - (D) detecting the nucleotide derivative incorporated into the second primers in (B) so as to identify the base located at said locus;
- wherein the sequence of each tag of (A) is unique for each nucleic acid molecule and steps (A) and (B) are carried out with said nucleic molecules in the presence of each other.

In yet another aspect, the invention is a method of analyzing a biological sample containing a plurality of nucleic acid molecules for the presence of a mutation or polymorphism at a locus of each nucleic acid molecule, for each nucleic acid molecule, the method including steps of:

- (a) hybridizing the molecule and a primer, the primer having a 5'-sequence having the sequence of a tag complementary to the sequence of a tag complement belonging to a family of tag complements of the invention and a 3'-end extending to immediately adjacent the locus;
- (b) enzymatically extending the 3'-end of the primer in the presence of a plurality of nucleoside triphosphate derivatives each of which is: (i) capable of enzymatic incorporation onto the 3'-end of a growing nucleotide strand; (ii) causes termination of said extension; and (iii) capable of differential detection, one from the other, wherein there is a said derivative complementary to each possible nucleotide present at said locus;
- (c) specifically hybridizing the extended primer formed in step (b) to a tag complement having the tag complement sequence of (a); and
- (d) detecting the nucleotide derivative incorporated into the primer in step (b) so as to identify the base located at the locus of the nucleic acid molecule;

wherein each tag of (a) is unique for each nucleic acid molecule and steps (a) and (b) are carried out with said nucleic molecules in the presence of each other.

The derivative can be a dideoxy nucleoside triphosphate.

Each respective complement can be attached as a uniform population of substantially identical complements in spacially discrete regions on one or more solid phase support(s).

5. Each tag complement can include a label, each such label being different for respective complements, and step (d) can include detecting the presence of the different labels for respective hybridization complexes of bound tags and tag complements.

10 Another aspect of the invention includes a method of determining the presence of a target suspected of being contained in a mixture. The method includes the steps of:

- (i) labelling the target with a first label;
- (ii) providing a first detection moiety capable of specific binding to the target and including a first tag;
- (iii) exposing a sample of the mixture to the detection moiety under conditions suitable to permit (or cause) said specific binding of the molecule and target;
- (iv) providing a family of suitable tag complements of the invention wherein the family contains a first tag complement having a sequence complementary to that of the first tag;
- (v) exposing the sample to the family of tag complements under conditions suitable to permit (or cause) specific hybridization of the first tag and its tag complement;
- (vi) determining whether a said first detection moiety hybridized to a first tag complement is bound to a said labelled target in order to determine the presence or absence of said target in the mixture.

Preferably, the first tag complement is linked to a solid support at a specific location of the support and step (vi) includes detecting the presence of the first label at said specified location.

- 15 Also, the first tag complement can include a second label and step (vi) includes detecting the presence of the first and second labels in a hybridized complex of the moiety and the first tag complement.

20 Further, the target can be selected from the group consisting of organic molecules, antigens, proteins, polypeptides, antibodies and nucleic acids. The target can be an antigen and the first molecule can be an antibody specific for that antigen.

The antigen is usually a polypeptide or protein and the labelling step can include conjugation of fluorescent molecules, digoxigenin, biotinylation and the like.

5 The target can be a nucleic acid and the labelling step can include incorporation of fluorescent molecules, radiolabelled nucleotide, digoxigenin, biotinylation and the like.

10 Another aspect of the invention includes detecting the presence of a target nucleic acid molecule using the Invader Assay, which is described in detail in US Patent No. 5,985,557 issued November 16, 1999, incorporated herein by reference. The sequences of the present invention are incorporated into the 3' portion of one of the two oligonucleotide probes that will eventually be cleaved by a Cleavase enzyme and captured by its complement which may be attached on a solid phase support in a microarray format.

15 Another aspect of the invention includes a method of analyzing a biological sample comprising a plurality of target nucleic acid molecules for the presence of a mutation or polymorphism at a locus of each target nucleic acid molecule using the Invader Assay. Again, the sequences of the present invention are incorporated into the 3' portion of one of the two probes that will eventually be cleaved by a Cleavase enzyme and detected by using the
20 cleaved sequence's complement, which may be attached on a solid phase support such as in a microarray format.

Another aspect of the invention incorporates the use of a second target nucleic acid sequence, wherein the second target nucleic acid sequence comprises a synthetic nucleic acid. The synthetic nucleic acid may further
25 comprise at least one hairpin loop. The construction and use of such nucleic acid sequences with hairpin loops has been described in detail in US Patent No. 5,770,365 issued June 23, 1998 and International Publication WO 01/94625A2 published December 13, 2001.

30 The present invention capitalizes on the exquisite specificity of the Invader Assay and the minimally cross-hybridizing sequences of the present invention such that simultaneous use of multiple hybridization probes in a single experiment is now possible. The methods and compositions of the present invention allow for accurate and homogenous genotyping of a plurality of distinct nucleic acid in a single experiment. The methods and
35 compositions of the present invention are flexible enough to extend to novel loci with little optimization. the features of both the Invader Assay and the sequences of the present invention lend the technology to automation.

DETAILED DESCRIPTION OF THE INVENTION

FIGURES

Reference is made to the attached figures in which,

Figures 1A and 1B illustrate results obtained in the cross-hybridization experiments described in Example 1. Figure 1A shows the hybridization pattern found when a microarray containing all 100 probes (SEQ ID NOs:1 to 100 of Table I) was hybridized with a 24mer oligonucleotide having the complementary sequence to SEQ ID NO:3 of Table I (target). Figure 1B shows the pattern observed when a similar array was hybridized with a mix of all 100 targets, i.e., oligonucleotides having the sequences complementary to SEQ ID NOs:1 to 100 of Table 1.

Figure 2 shows the intensity of the signal (MFI) for each perfectly matched sequence (indicated in Table I) and its complement obtained as described in Example 3.

Figure 3 is a three dimensional representation showing cross-hybridization observed for the sequences of Figure 2 as described in Example 3. The results shown in Figure 2 are reproduced along the diagonal of the drawing.

Figure 4 is illustrative of results obtained for an individual target (SEQ ID NO:23 of Table I, target No. 16) when exposed to the 100 probes of Example 3. The MFI for each bead is plotted.

Figure 5 illustrates generally the steps followed to obtain a family of sequences of the present invention;

Figure 6 shows the intensity of the signal (MFI) for each perfectly matched sequence (probe sequence indicated in Table II) and its complement (target at 50 fmol) obtained as described in Example 4;

Figure 7 is a three dimensional representation showing cross-hybridization observed for the sequences of Figure 6 as described in Example 4. The results shown in Figure 6 are reproduced along the diagonal of the drawing;

Figure 8 is illustrative of the results obtained for an individual target (Table II, SEQ ID No: 90, target No. 90) when exposed to the 100 probes of Example 4. The MFI for each bead is plotted.

DETAILED DESCRIPTION OF THE INVENTION

The invention provides a method for sorting complex mixtures of molecules by the use of families of oligonucleotide sequence tags. The families of oligonucleotide sequence tags are

designed so as to provide minimal cross hybridization during the sorting process. Thus any sequence within a family of sequences will not cross hybridize with any other sequence derived from that family under appropriate hybridization conditions known by those skilled in the art. The invention is particularly useful in highly parallel processing of analytes.

Families of Oligonucleotide Sequence Tags

The present invention includes a family of 24mer polynucleotides, that have been demonstrated to be minimally cross-hybridizing with each other. This family of polynucleotides is thus useful as a family of tags, and their complements as tag complements.

The oligonucleotide sequences that belong to families of sequences that do not exhibit cross hybridization behavior can be derived by computer programs (described in United States Provisional Patent Application No. 60/181,563 filed February 10, 2000). The programs use a method of generating a maximum number of minimally cross-hybridizing polynucleotide sequences that can be summarized as follows. First, a set of sequences of a given length are created based on a given number of block elements. Thus, if a family of polynucleotide sequences 24 nucleotides (24mer) in length is desired from a set of 6 block elements, each element comprising 4 nucleotides, then a family of 24mers is generated considering all positions of the 6 block elements. In this case, there will be 6^6 (46,656) ways of assembling the 6 block elements to generate all possible polynucleotide sequences 24 nucleotides in length.

Constraints are imposed on the sequences and are expressed as a set of rules on the identities of the blocks such that homology between any two sequences will not exceed the degree of homology desired between these two sequences. All polynucleotide sequences generated which obey the rules are saved. Sequence comparisons are performed in order to generate an incidence matrix. The incidence matrix is presented as a simple graph and the sequences with the desired property of being minimally cross hybridizing are found from a clique of the simple graph, which may have multiple cliques. Once a clique containing a suitably large number of sequences is found, the sequences are experimentally tested to determine if it is a set of minimally cross hybridizing sequences. This method has been used to

obtain the 100 non cross-hybridizing tags of Table I that are the subject of Example 1.

The method includes a rational approach to the selection of groups of sequences that are used to describe the blocks. For example there are n^4 different tetramers that can be obtained from n different nucleotides, non-standard bases or analogues thereof. In a more preferred embodiment there are 4^4 or 256 possible tetramers when natural nucleotides are used. More preferably 81 possible tetramers when only 3 bases are used A, T and G. Most preferably 32 different tetramers when all sequences have only one G.

Block sequences can be composed of a subset of natural bases most preferably A, T and G. Sequences derived from blocks that are deficient in one base possess useful characteristics, for example, in reducing potential secondary structure formation or reduced potential for cross hybridization with nucleic acids in nature. Sets of block sequences that are most preferable in constructing families of non cross hybridizing tag sequences should contribute approximately equivalent stability to the formation of the correct duplex as all other block sequences of the set. This should provide tag sequences that behave isothermally. This can be achieved, for example, by maintaining a constant base composition for all block sequences such as one G and three A's or T's for each block sequence. Preferably, non-cross hybridizing sets of block sequences will be comprised from blocks of sequences that are isothermal. The block sequences should be different from each other by at least one mismatch. Guidance for selecting such sequences is provided by methods for selecting primer and or probe sequences that can be found in published techniques (Robertson et al., *Methods Mol Biol*;98:121-54 (1998); Rychlik et al, *Nucleic Acids Research*, 17:8543-8551 (1989); Breslauer et al., *Proc Natl Acad Sci.*, 83:3746-3750 (1986)) and the like. Additional sets of sequences can be designed by extrapolating on the original family of non cross hybridizing sequences by simple methods known to those skilled in the art.

A preferred family of 100 tags is shown as SEQ ID NOs:1 to 100 in Table I. Characterization of the family of 100 sequence tags was performed to determine the ability of these sequences to form specific duplex structures with their complementary sequences and to assess the potential for cross hybridization. The 100 sequences were synthesized and spotted onto

glass slides where they were coupled to the surface by amine linkage. Complementary tag sequences were Cy3-labeled and hybridized individually to the array containing the family of 100 sequence tags. Formation of duplex structures was detected and quantified for each of the positions on the array. Each of the tag sequences performed as expected, that is the perfect match duplex was formed in the absence of significant cross hybridization under stringent hybridization conditions. The results of a sample hybridization are shown in Figure 1. Figure 1a shows the hybridization pattern seen when a microarray containing all 100 probes was hybridized with the target complementary to probe 181234. The 4 sets of paired spots correspond to the probe complementary to the target. Figure 1b shows the pattern seen when a similar array was hybridized with a mix of all 100 targets. These results indicate that the family of sequences which is the subject of this patent can be used as a family of non-cross hybridizing (tag) sequences.

The family of 100 non-cross-hybridizing sequences can be expanded by incorporating additional tetramer sequences that are used in constructing further 24mer oligonucleotides. In one example, four additional words were included in the generation of new sequences to be considered for inclusion as non-cross talkers in a family of sequences that were obtained from the above method using 10 tetramers. In this case, the four additional words were selected to avoid potential homologies with all potential combinations of other words: YYXW (TTAG); WYYX (GTTA); YXXW (ATAG) and WYYY (GTTT). The total number of sequences containing six words using the 14 possible words is 14^6 or 7,529,536. These sequences were screened to eliminate sequences that contain repetitive regions that present potential hybridization problems such as four or more of a similar base (e.g., AAAA or TTTT) or pairs of G's. Each of these sequences was compared to the sequence set of the original family of 100 non-cross-hybridizing sequences (SEQ ID NOs:1 to 100). Any new sequence that contained a minimal threshold of homology (that does not include the use of insertions or deletions) such as 15 or more matches with any of the original family of sequences was eliminated. In other words, if it was possible to align a new sequence with one or more of the original 100 sequences so as to obtain a maximum simple homology of 15/24 or more, the new sequence was dropped. "Simple homology" between a pair of sequences is defined here as the number of pairs of nucleotides that are matching (are the same as each other) in a comparison of two aligned sequences divided by the total number of potential matches. "Maximum simple homology" is obtained

when two sequences are aligned with each other so as to have the maximum number of paired matching nucleotides. In any event, the set of new sequences so obtained was referred to as the "candidate sequences". One of the candidate sequences was arbitrarily chosen and referred to as sequence 101. All the candidate sequences were checked against sequence 101, and sequences that contained 15 or more non-consecutive matches (i.e., a maximum simple homology of 15/24 (62.5%) or more were eliminated. This results in a smaller set of candidate sequences from which another sequence is selected that is now referred to as sequence 102. The smaller set of candidate sequences is now compared to sequence 102 eliminating sequences that contained 15 or more non-consecutive matches and the process is repeated until there are no candidate sequences remaining. Also, any sequence selected from the candidate sequences is eliminated if it has 13 or more consecutive matches with any other previously selected candidate sequence.

The additional set of 73 tag sequences so obtained (SEQ ID NOs:101 to 173 of Table 1) is composed of sequences that when compared to any of SEQ ID NOs:1 to 100 of Table I have no greater similarity than the sequences of the original 100 sequence tags of Table I. The sequence set as derived from the original family of non cross hybridizing sequences, SEQ ID NOs:1 to 173 of Table 1, are expected to behave with similar hybridization properties to the sequences having SEQ ID NOs:1 to 100 since it is understood that sequence similarity correlates directly with cross hybridization (Southern et al., Nat. Genet.; 21, 5-9: 1999).

The set of 173 24mer oligonucleotides were expanded to include those having SEQ ID NOs:174 to 210 as follows. The 4mers WXYW, XYXW, WXXW, WYYW, XYYX, YXYX, YXXY and XYXY where W=G, X=A, and Y=U/T were used in combination with the fourteen 4mers used in the generation of SEQ ID NOs:1 to 173 to generate potential 24-base oligonucleotides. Excluded from the set were those containing the sequence patterns GG, AAAA and TTTT. To be included in the set of additional 24mers, a sequence also had to have at least one of the 4mers containing two G's: WXYW (GATG), WYXW (GTAG), WXXW (GAAG), WYYW (GTTG) while also containing exactly six G's. Also required for a 24mer to be included was that there be at most six bases between every neighboring pair of G's. Another way of putting this is that there are at most six non-G's between any two G's. Also, each G nearest the 5'-end of its oligonucleotide (the left-hand side as written in Table I) was required to occupy one of the first to seventh positions (counting the 5'-

terminal position as the first position.) A set of candidate sequences was obtained by eliminating any new sequence that was found to have a maximum simple homology of 16/24 or more with any of the previous set of 173 oligonucleotides (Table 1, SEQ ID NOS:1 to 173). As above, an
 5 arbitrary 174th sequence was chosen and candidate sequences eliminated by comparison therewith. In this case the permitted maximum degree of simple homology was 16/24. A second sequence was also eliminated if there were ten consecutive matches between the two (i.e., it was notionally possible to generate a phantom sequence containing a sequence of 10 bases that is
 10 identical to a sequence in each of the sequences being compared). A second sequence was also eliminated if it was possible to generate a phantom sequence 20 bases in length or greater.

A property of the polynucleotide sequences shown in Table I is that the maximum block homology between any two sequences is never greater than 66 2/3
 15 percent. This is because the computer algorithm by which the sequences were initially generated was designed to prevent such an occurrence. It is within the capability of a person skilled in the art, given the family of sequences of Table I, to modify the sequences, or add other sequences while largely retaining the property of minimal-cross hybridization which the polynucleotides of Table I
 20 have been demonstrated to have.

There are 210 polynucleotide sequences given in Table I. Since all 210 of this family of polynucleotides can work with each other as a minimally cross-hybridizing set, then any plurality of polynucleotides that is a subset of the 210 can also act as a minimally cross-hybridizing set of polynucleotides. An
 25 application in which, for example, 30 molecules are to be sorted using a family of polynucleotide tags and tag complements could thus use any group of 30 sequences shown in Table I. This is not to say that some subsets may be found in practical sense to be more preferred than others. For example, it may be found that a particular subset is more tolerant of a wider variety of conditions
 30 under which hybridization is conducted before the degree of cross-hybridization becomes unacceptable.

It may be desirable to use polynucleotides that are shorter in length than the 24 bases of those in Table I. A family of subsequences (i.e., subframes of the sequences illustrated) based on those contained in Table I having as few as
 35 10 bases per sequence could be chosen, so long as the subsequences are chosen to retain homological properties between any two of the sequences of the family important to their non cross-hybridization.

The selection of sequences using this approach would be amenable to a computerized process. Thus for example, a string of 10 contiguous bases of the first 24mer of Table I could be selected: GATTTGTATTGATTGAGATTAAAG.

- 5 A string of contiguous bases from the second 24mer could then be selected and compared for maximum homology against the first chosen sequence:

TGATTGTAGTATGTATTGATAAAG

Systematic pairwise comparison could then be carried out to determine if the maximum homology requirement of 66 2/3 percent is violated:

Alignment	Matches
GATTTGTATT	1
ATTGATAAAG	
GATTTGTATT	0
ATTGATAAAG	
GATTTGTATT	1
ATTGATAAAG	
GATTTGTATT	1
ATTGATAAAG	
GATTTGTATT	1
ATTGATAAAG	
GATTTGTATT	1
ATTGATAAAG	
GATTTGTATT	3
ATTGATAAAG	
GATTTGTATT	1
ATTGATAAAG	
GATTTGTATT	2
ATTGATAAAG	
GATTTGTATT	2
ATTGATAAAG	
GATTTGTATT	5 (*)
ATTGATAAAG	
GATTTGTATT	3
ATTGATAAAG	
GATTTGTATT	3
ATTGATAAAG	
GATTTGTATT	2
ATTGATAAAG	
GATTTGTATT	1
ATTGATAAAG	
GATTTGTATT	1
ATTGATAAAG	
GATTTGTATT	3
ATTGATAAAG	
GATTTGTATT	1
ATTGATAAAG	
GATTTGTATT	0
ATTGATAAAG	

As can be seen, the maximum homology between the two selected subsequences is 50 percent (5 matches out of the total length of 10), and so these two sequences are compatible with each other.

5 A 10mer subsequence can be selected from the third 24mer sequence of Table I, and pairwise compared to each of the first two 10mer sequences to determine its compatability therewith, etc. and in this way a family of 10mer sequences developed.

10 It is within the scope of this invention, to obtain families of sequences containing 11mer, 12mer, 13mer, 14mer, 15mer, 16mer, 17mer, 18mer, 19mer, 20mer, 21mer, 22mer and 23mer sequences by analogy to that shown for 10mer sequences.

15 It may be desirable to have a family of sequences in which there are sequences greater in length than the 24mer sequences shown in Table I. It is within the capability of a person skilled in the art, given the family of sequences shown in Table I, to obtain such a family of sequences. One possible approach would be to insert into each sequence at one or more locations a nucleotide, non natural base or analogue such that the longer sequence should not have greater similarity than any two of the original non cross hybridizing sequences of Table I and the addition of extra bases to the tag sequences should not result in a major change in the thermodynamic properties of the tag sequences of that set for example the GC content must be maintained between 10%-40% with a variance from the average of 20%. This method of inserting bases could be used to obtain a family of sequences up to 40 bases long.

25 Given a particular family of sequences that can be used as a family of tags (or tag complements), e.g., those of Table I or Table II, or the combined sequences of these two tables, a skilled person will readily recognize variant families that work equally as well.

30 Again taking the sequences of Table I for example, every T could be converted to an A and vice versa and no significant change in the cross-hybridization properties would be expected to be observed. This would also be true if every G were converted to a C.

35 Also, all of the sequences of a family could be taken to be constructed in the 5'-3' direction, as is the convention, or all of the constructions of sequences could be in the opposition direction (3'-5').

There are additional modifications that can be carried out. For example, C has not been used in the family of sequences. Substitution of C in place of one or more T's of a particular sequence would yield a sequence

that is at least as low in homology with every other sequence of the family as the particular sequence chosen to be modified was. It is thus possible to substitute C in place of one or more T's in any of the sequences shown in Table I. Analogously, substituting of C in place of one or more A's is possible, or substituting C in place of one or T's is possible.

It is preferred that the sequences of a given family are of the same, or roughly the same length. Preferably, all the sequences of a family of sequences of this invention have a length that is within five bases of the base-length of the average of the family. More preferably, all sequences are within four bases of the average base-length. Even more preferably, all or almost all sequences are within three bases of the average base-length of the family. Better still, all or almost all sequences have a length that is within two of the base-length of the average of the family.

It is also possible for a person skilled in the art to derive sets of sequences from the family of sequences that is the subject of this patent and remove sequences that would be expected to have undesirable hybridization properties.

Methods For Synthesis Of Oligonucleotide Families

Preferably oligonucleotide sequences of the invention are synthesized directly by standard phosphoramidite synthesis approaches and the like (Caruthers et al, *Methods in Enzymology*; 154, 287-313: 1987; Lipshutz et al, *Nature Genet.*; 21, 20-24: 1999; Fodor et al, *Science*; 251, 763-773: 1991). Alternative chemistries involving non natural bases such as peptide nucleic acids or modified nucleosides that offer advantages in duplex stability may also be used (Hacia et al; *Nucleic Acids Res* ;27: 4034-4039, 1999; Nguyen et al, *Nucleic Acids Res.*;27, 1492-1498: 1999; Weiler et al, *Nucleic Acids Res.*; 25, 2792-2799:1997). It is also possible to synthesize the oligonucleotide sequences of this invention with alternate nucleotide backbones such as phosphorothioate or phosphoroamidate nucleotides. Methods involving synthesis through the addition of blocks of sequence in a step wise manner may also be employed (Lyttle et al, *Biotechniques*, 19: 274-280 (1995). Synthesis may be carried out directly on the substrate to be used as a solid phase support for the application or the oligonucleotide can be cleaved from the support for use in solution or coupling to a second support.

Solid Phase Supports

There are several different solid phase supports that can be used with the invention. They include but are not limited to slides, plates, chips, membranes, beads, microparticles and the like. The solid phase supports can also vary in the materials that they are composed of including plastic, glass, silicon, nylon, polystyrene, silica gel, latex and the like. The surface of the support is coated with the complementary sequence of the same.

In preferred embodiments, the family of tag complement sequences are derivatized to allow binding to a solid support. Many methods of derivatizing a nucleic acid for binding to a solid support are known in the art (Hermanson G., *Bioconjugate Techniques*; Acad. Press: 1996). The sequence tag may be bound to a solid support through covalent or non-covalent bonds (Iannone et al, *Cytometry*; 39: 131-140, 2000; Matson et al, *Anal. Biochem.*; 224: 110-106, 1995; Proudnikov et al, *Anal Biochem*; 259: 34-41, 1998; Zammattéo et al, *Analytical Biochemistry*; 280:143-150, 2000). The sequence tag can be conveniently derivatized for binding to a solid support by incorporating modified nucleic acids in the terminal 5' or 3' locations.

A variety of moieties useful for binding to a solid support (e.g., biotin, antibodies, and the like), and methods for attaching them to nucleic acids, are known in the art. For example, an amine-modified nucleic acid base (available from, eg., Glen Research) may be attached to a solid support (for example, Covalink-NH, a polystyrene surface grafted with secondary amino groups, available from Nunc) through a bifunctional crosslinker (e.g., bis(sulfosuccinimidyl suberate), available from Pierce). Additional spacing moieties can be added to reduce steric hindrance between the capture moiety and the surface of the solid support.

Attaching Tags to Analytes for Sorting

A family of oligonucleotide tag sequences can be conjugated to a population of analytes most preferably polynucleotide sequences in several different ways including but not limited to direct chemical synthesis, chemical coupling, ligation, amplification, and the like. Sequence tags that have been synthesized with primer sequences can be used for enzymatic extension of the primer on the target for example in PCR amplification.

Detection of Single Nucleotide Polymorphisms Using Primer Extension

There are a number of areas of genetic analysis where families of non cross hybridizing sequences can be applied including disease diagnosis, single

nucleotide polymorphism analysis, genotyping, expression analysis and the like. One such approach for genetic analysis referred to as the primer extension method (also known as Genetic Bit Analysis (Nikiforov et al, Nucleic Acids Res.; 22, 4167-4175: 1994; Head et al Nucleic Acids Res.; 25, 5065-5071: 1997)) is an extremely accurate method for identification of the nucleotide located at a specific polymorphic site within genomic DNA. In standard primer extension reactions, a portion of genomic DNA containing a defined polymorphic site is amplified by PCR using primers that flank the polymorphic site. In order to identify which nucleotide is present at the polymorphic site, a third primer is synthesized such that the polymorphic position is located immediately 3' to the primer. A primer extension reaction is set up containing the amplified DNA, the primer for extension, up to 4 dideoxynucleoside triphosphates, each labelled with a different fluorescent dye and a DNA polymerase such as the Klenow subunit of DNA Polymerase I. The use of dideoxy nucleotides ensure that a single base is added to the 3' end of the primer, a site corresponding to the polymorphic site. In this way the identity of the nucleotide present at a specific polymorphic site can be determined by the identity of the fluorescent dye-labelled nucleotide that is incorporated in each reaction. One major drawback to this approach is its low throughput. Each primer extension reaction is carried out independently in a separate tube.

Universal sequences can be used to enhance the throughput of primer extension assay as follows. A region of genomic DNA containing multiple polymorphic sites is amplified by PCR. Alternately, several genomic regions containing one or more polymorphic sites each are amplified together in a multiplexed PCR reaction. The primer extension reaction is carried out as described above except that the primers used are chimeric, each containing a unique universal tag at the 5' end and the sequence for extension at the 3' end. In this way, each gene-specific sequence would be associated with a specific universal sequence. The chimeric primers would be hybridized to the amplified DNA and primer extension carried out as described above. This would result in a mixed pool of extended primers, each with a specific fluorescent dye characteristic of the incorporated nucleotide. Following the primer extension reaction, the mixed extension reactions are hybridized to an array containing probes that are reverse complements of the universal sequences on the primers. This would segregate the products of a number of primer extension reactions into discrete spots. The fluorescent dye present

at each spot would then identify the nucleotide incorporated at each specific location.

Kits Using Families Of Tag Sequences

- 5 The families of non cross-hybridizing sequences may be provided in kits for use in for example genetic analysis. Such kits include at least one set of non cross hybridizing sequences in solution or on a solid support. Preferably the sequences are attached to microparticles and are provided with buffers and reagents that are appropriate for the application. Reagents may
- 10 include enzymes, nucleotides, fluorescent labels and the like that would be required for specific applications. Instructions for correct use of the kit for a given application will be provided.

EXAMPLES

15 EXAMPLE 1

Demonstrate Non Cross Talk Behavior

- One hundred oligonucleotide probes corresponding to a family of non-cross talking oligonucleotides from Table I were synthesized by Integrated
- 20 DNA Technologies (IDT, Coralville IA). These oligonucleotides incorporated a C₆ aminolink group coupled to the 5' end of the oligo through a C₁₈ ethylene glycol spacer. These probes were used to prepare microarrays as follows. The probes were resuspended at a concentration of 50 µM in 150 mM NaPO₄, pH 8.5. The probes were spotted onto the surface of a SuperAldehyde slide (Telechem
- 25 Int., Sunnyvale CA) using and SDDC-II microarray spotter (ESI, Toronto Ont). The spots formed were approximately 120 µM in diameter with 200 µM centre-to-centre spacing. Each probe was spotted 8 times on each microarray. Following spotting, the arrays were processed essentially as described by the slide manufacturer. Briefly, the arrays were treated with 67 mM sodium borohydride
- 30 in PBS/EtOH (3:1) for 5 minutes then washed with 4 changes of 0.1% SDS. The arrays were not boiled.

- One hundred labelled oligonucleotide targets were also synthesized by IDT. The sequence of these targets corresponded to the reverse complement of the 100 probe sequences. The targets were labelled at the 5' end with
- 35 Cy3.

Each Cy3-labeled target oligonucleotide was hybridized separately to two microarrays each of which contained all 100 oligonucleotide probes. Hybridizations were carried out at 42°C for 2 hours in a 40 µl reaction and contained 40 nM of the labelled target suspended in 10 mM TrisHCl, pH 8.3, 50

mM KCl, 0.1% Tween 20. These are low stringency hybridization conditions designed to provide a rigorous test of the performance of the family of non-cross hybridizing sequences. Hybridizations were carried out by depositing the hybridization solution on a clean cover slip then carefully positioning the microarray slide over the cover slip in order to avoid bubbles. The slide was then inverted and transferred to a humid chamber for incubation. Following hybridization, the cover slip was removed and the microarray was washed in hybridization buffer for 15 minutes at room temperature. The slide was then dried by brief centrifugation.

Hybridized microarrays were scanned using a ScanArray Lite (GSI-Lumonics, Billerica MA). The laser power and photomultiplier tube voltage used for scanning each hybridized microarray were optimized in order to maximize the signal intensity from the spots representing the perfect match.

The results of a sample hybridization are shown in Figure 1. Figure 1a shows the hybridization pattern seen when a microarray containing all 100 probes was hybridized with the target complementary to probe 181234. The 4 sets of paired spots correspond to the probe complementary to the target. Figure 1b shows the pattern seen when a similar array was hybridized with a mix of all 100 targets.

EXAMPLE 2

Tag sequences used in sorting polynucleotides

The family of non cross hybridizing sequence tags or a subset thereof can be attached to oligonucleotide probe sequences during synthesis and used to generate amplified probe sequences. In order to test the feasibility of PCR amplification with non cross hybridizing sequence tags and subsequently addressing each respective sequence to its appropriate location on two-dimensional or bead arrays, the following experiment was devised. A 24mer tag sequence was connected in a 5'-3' specific manner to a p53 exon specific sequence (20mer reverse primer). The connecting p53 sequence represented the inverse complement of the nucleotide gene sequence. To facilitate the subsequent generation of single stranded DNA post-amplification the tag-Reverse primer was synthesized with a phosphate modification (PO₄) on the 5'-end. A second PCR primer was also generated for each desired exon, which represented the Forward (5'-3') amplification primer. In this instance the Forward primer was labeled with a 5'-biotin modification to allow detection with Cy3-avidin or equivalent.

A practical example of the aforementioned description is as follows: For exon 1 of the human p53 tumor suppressor gene sequence the following tag-Reverse primer was generated:

5 222087 222063
5' -PO4-GATTGTAAGATTTGATAAAGTGTA-TCCAGGGAAGCGTGTCAACGTCGT-3'
Tag Sequence # 3 Exon 1 Reverse

10 The numbering above the Exon-1 reverse primer represents the genomic
nucleotide positions of the indicated bases.
The corresponding Exon-1 Forward primer sequence is as follows:

221873 221896

5'-Biotin-TCATGGCGACTGTCCAGCTTTGTG-3'

15 In combination these primers will amplify a product of 214 bp plus a 24 bp tag extension yielding a total size of 238 bp.

Once amplified, the PCR product was purified using a QIAquick PCR purification kit and the resulting DNA was quantified. To generate

20 single stranded DNA, the DNA was subjected to --exonuclease digestion thereby resulting in the exposure of a single stranded sequence (anti-tag) complementary to the tag-sequence covalently attached to the solid phase array. The resulting product was heated to 95°C for 5 minutes and then directly applied to the array at a concentration of 10-50 nM.

25 Following hybridization and concurrent sorting, the tag-Exon 1 sequences were visualized using Cy3-streptavidin. In addition to direct visualization of the biotinylated product, the product itself can now act as a substrate for further analysis of the amplified region, such as SNP detection and haplotype determination.

30 The present invention also includes a family of 1168 24mer polynucleotides that have been demonstrated to be minimally cross-hybridizing with each other. This family of polynucleotides is thus useful as a family of tags, and their complements as tag complements.

35 In order to be considered for inclusion into the family, a sequence had to satisfy a certain number of rules regarding its composition. For example, repetitive regions that present potential hybridization problems such as four or more of a similar base (e.g., AAAA or TTTT) or pairs of Gs were forbidden. Another rule is that each sequence contains exactly six Gs and no Cs, in

order to have sequences that are more or less isothermal. Also required for a 24mer to be included is that there must be at most six bases between every neighboring pair of Gs. Another way of putting this is that there are at most six non-Gs between any two consecutive Gs. Also, each G nearest the
 5 5'-end (resp. 3'-end) of its oligonucleotide (the left-hand (resp. right-hand) side as written in Table II) was required to occupy one of the first to seventh positions (counting the 5'-terminal (resp. 3'-terminal) position as the first position.)

The process used to design families of sequences that do not
 10 exhibit cross-hybridization behavior is illustrated generally in Figure 5). Depending on the application for which these families of sequences will be used, various rules are designed. A certain number of rules can specify constraints for sequence composition (such as the ones described in the previous paragraph). The other rules are used to
 15 judge whether two sequences are too similar. Based on these rules, a computer program can derive families of sequences that exhibit minimal or no cross-hybridization behavior. The exact method used by the computer program is not crucial since various computer programs can derive similar families based on these rules. Such a program is for
 20 example described in international patent application No. PCT/CA 01/00141 published under WO 01/59151 on August 16, 2001. Other programs can use different methods, such as the ones summarized below.

A first method of generating a maximum number of minimally cross-hybridizing polynucleotide sequences starts with any number of non-
 25 cross-hybridizing sequences, for example just one sequence, and increases the family as follows. A certain number of sequences is generated and compared to the sequences already in the family. The generated sequences that exhibit too much similarity with sequences already in the family are dropped. Among the "candidate sequences"
 30 that remain, one sequence is selected and added to the family. The other candidate sequences are then compared to the selected sequence, and the ones that show too much similarity are dropped. A new sequence is selected from the remaining candidate sequences, if any, and added to the family, and so on until there are no candidate sequences left.
 35 At this stage, the process can be repeated (generating a certain number of sequences and comparing them to the sequences in the family, etc.) as often as desired. The family obtained at the end of this method contains only minimally cross-hybridizing sequences.

A second method of generating a maximum number of minimally cross-hybridizing polynucleotide sequences starts with a fixed-size family of polynucleotide sequences. The sequences of this family can be generated randomly or designed by some other method. Many sequences in
 5 this family may not be compatible with each other, because they show too much similarity and are not minimally cross-hybridizing. Therefore, some sequences need to be replaced by new ones, with less similarity. One way to achieve this consists of repeatedly replacing a sequence of the family by the best (that is, lowest similarity) sequence among a
 10 certain number of (for example, randomly generated) sequences that are not part of the family. This process can be repeated until the family of sequences shows minimal similarity, hence minimal cross-hybridizing, or until a set number of replacements has occurred. If, at the end of the process, some sequences do not obey the similarity rules that have
 15 been set, they can be taken out of the family, thus providing a somewhat smaller family that only contains minimally cross-hybridizing sequences. Some additional rules can be added to this method in order to make it more efficient, such as rules to determine which sequence will be replaced.

20 Such methods have been used to obtain the 1168 non-cross-hybridizing tags of Table II that are also the subject of this patent application.

One embodiment of the invention is a composition comprising molecules for use as tags or tag complements wherein each molecule comprises an
 25 oligonucleotide selected from a set of oligonucleotides based on the group of sequences set out in Table IIA, wherein each of the numeric identifiers 1 to 3 (see the Table) is a nucleotide base selected to be different from the others of 1 to 3. According to this embodiment, several different families of specific sets of oligonucleotide sequences are described, depending upon
 30 the assignment of bases made to the numeric identifiers 1 to 3.

The sequences contained in Table II have a mathematical relationship to each other, described as follows.

Let S and T be two DNA sequences of lengths s and t respectively. While the term "alignment" of nucleotide sequences is widely used in the field of
 35 biotechnology, in the context of this invention the term has a specific meaning illustrated here. An alignment of S and T is a $2 \times p$ matrix A (with $p \geq s$ and $p \geq t$) such that the first (or second) row of A contains the characters of S (or T respectively) in order, interspersed with $p-s$ (or $p-t$

respectively) spaces. It assumed that no column of the alignment matrix contains two spaces, i.e., that any alignment in which a column contains two spaces is ignored and not considered here. The columns containing the same base in both rows are called *matches*, while the columns containing different bases are called *mismatches*. Each column of an alignment containing a space in its first row is called an *insertion* and each column containing a space in its second row is called a *deletion* while a column of the alignment containing a space in either row is called an *indel*. Insertions and deletions within a sequence are represented by the character '-'. A *gap* is a continuous sequence of spaces in one of the rows (that is neither immediately preceded nor immediately followed by another space in the same row), and the *length of a gap* is the number of spaces in that gap. An *internal gap* is one in which its first space is preceded by a base and its last space is followed by a base and an *internal indel* is an indel belonging to an internal gap. Finally, a *block* is a continuous sequence of matches (that is neither immediately preceded nor immediately followed by another match), and the *length of a block* is the number of matches in that block. In order to illustrate these definitions, two sequences $S = \text{TGATCGTAGCTACGCCGCG}$ (of length $s = 19$; SEQ ID NO:1169) and $T = \text{CGTACGATTGCAACGT}$ (of length $t = 16$; SEQ ID NO:1170) are considered. Exemplary alignment R_1 of S and T (with $p = 23$) is:

Alignment R_1 :

-	-	-	-	T	G	A	T	C	G	T	A	G	C	T	A	C	G	C	C	G	C	G
C	G	T	A	C	G	A	T	-	-	T	-	G	C	A	A	C	G	T	-	-	-	-

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

Columns 1 to 4, 9, 10, 12 and 20 to 23 are indels, columns 6, 7, 8, 11, 13, 14, 16, 17 and 18 are matches, and columns 5, 15 and 19 are mismatches. Columns 9 and 10 form a gap of length 2, while columns 16 to 18 form a block of length 3. Columns 9, 10 and 12 are internal indels.

A score is assigned to the alignment A of two sequences by assigning weights to each of matches, mismatches and gaps as follows:

- the reward for a match m ,
- the penalty for a mismatch mm ,
- the penalty for opening a gap og .

- the penalty for extending a gap eg .

Once these values are set, a score to each column of the alignment is assigned according to the following rules:

1. assign 0 to each column preceding the first match and to each column following the last match.
2. for each of the remaining columns, assign m if it is a match, $-mm$ if it is a mismatch, $-og-eg$ if it is the first indel of a gap, $-eg$ if it is an indel but not the first indel of a gap.

The score of the alignment A is the sum of the scores of its columns. An alignment is said to be of maximum score if no other alignment of the same two sequences has a higher score (with the same values of m , mm , og and eg). A person knowledgeable in the field will recognize this method of scoring an alignment as scoring a local (as opposed to global) alignment with affine gap penalties (that is, gap penalties that can distinguish between the first indel of a gap and the other indels). It will be appreciated that the total number of indels that open a gap is the same as the total number of gaps and that an internal indel is not one of those assigned a 0 in rule (1) above. It will also be noted that foregoing rule (1) assigns a 0 for non-internal mismatches. An internal mismatch is a mismatch that is preceded and followed (not necessarily immediately) by a match.

As an illustration, if the values of m , mm , og and eg are set to 3, 1, 2 and 1 respectively, alignment R_1 has a score of 19, determined as shown below:

Scoring of Alignment R_1

-	-	-	-	T	G	A	T	C	G	T	A	G	C	T	A	C	G	C	C	G	C	G
C	G	T	A	C	G	A	T	-	-	T	-	G	C	A	A	C	G	T	-	-	-	-

0 0 0 0 0 3 3 3 -3 -1 3 -3 3 3 -1 3 3 3 0 0 0 0 0

Note that for two given sequences S and T , there are numerous alignments. There are often several alignments of maximum score.

Based on these alignments, five sequence similarity measures are defined as follows. For two sequences S and T , and weights $\{m, mm, og, eg\}$:

- $M1$ is the maximum number of matches over all alignments free of internal indels;
- $M2$ is the maximum length of a block over all alignments;

- $M3$ is the maximum number of matches over all alignments of maximum score;
- $M4$ is the maximum sum of the lengths of the longest two blocks over all alignments of maximum score;
- 5 • $M5$ is the maximum sum of the lengths of all the blocks of length at least 3, over all alignments of maximum score.

Notice that, by definition, the following inequalities between these similarity measures are obtained: $M4 \leq M3$ and $M5 \leq M3$. Also, in order to determine $M2$ it is sufficient to determine the maximum length of a block over
 10 all alignments free of internal indels. For two given sequences, the values of $M3$ to $M5$ can vary depending on the values of the weights $\{m, mm, og, eg\}$, but not $M1$ and $M2$.

For weights $\{3, 1, 2, 1\}$, the illustrated alignment is not a maximum score alignment of the two example sequences. But for weights $\{6, 6, 0, 6\}$
 15 it is; hence this alignment shows that for these two example sequences, and weights $\{6, 6, 0, 6\}$, $M2 \geq 3$, $M3 \geq 9$, $M4 \geq 6$ and $M5 \geq 6$. In order to determine the exact values of $M1$ to $M5$, all the necessary alignments need to be considered. $M1$ and $M2$ can be found by looking at the $s+t-1$ alignments free of internal indels, where s and t are the lengths of the two sequences
 20 considered. Mathematical tools known as dynamic programming can be implemented on a computer and used to determine $M3$ to $M5$ in a very quick way. Using a computer program to do these calculations, it was determined that:

- with the weights $\{6, 6, 0, 6\}$, $M1 = 8$, $M2 = 4$, $M3 = 10$, $M4 = 6$ and $M5 = 6$;
- 25 • with the weights $\{3, 1, 2, 1\}$, $M1 = 8$, $M2 = 4$, $M3 = 10$, $M4 = 6$ and $M5 = 4$.

According to the preferred embodiment of this invention, two sequences S and T each of length 24 are *too similar* if at least one of the following happens:

- $M1 > 16$ or
- 30 • $M2 > 13$ or
- $M3 > 20$ or
- $M4 > 16$ or
- $M5 > 19$

when using either weights $\{6, 6, 0, 6\}$, or $\{6, 6, 5, 1\}$, or $\{6, 2, 5, 1\}$, or
 35 $\{6, 6, 6, 0\}$. In other words, the five similarity measures between S and T are determined for each of the above four sets of weights, and checked against these thresholds (for a total of 20 tests).

The above thresholds of 16, 13, 20, 16 and 19, and the above sets of weights, were used to obtain the sequences listed in Table I. Additional sequences can thus be added to those of Table I as long as the above alignment rules are obeyed for all sequences.

5 It is also possible to alter thresholds $M1$, $M2$, etc., while remaining within the scope of this invention. It is thus possible to substitute or add sequences to those of Table II, or more generally to those of Table IIA to obtain other sets of sequences that would also exhibit reasonably low cross-hybridization. More specifically, a set of 24mer sequences in which there are
10 no two sequences that are too similar, where too similar is defined as:

- $M1 > 19$ or
- $M2 > 17$ or
- $M3 > 21$ or
- $M4 > 18$ or
- 15 • $M5 > 20$

when using either weights $\{6,6,0,6\}$, or $\{6,6,5,1\}$, or $\{6,2,5,1\}$, or $\{6,6,6,0\}$, would also exhibit low cross-hybridization. Reducing any of the threshold values provides sets of sequences with even lower cross-hybridization. Alternatively, 'too similar' can also be defined as:

- 20
- $M1 > 19$ or
 - $M2 > 17$ or
 - $M3 > 21$ or
 - $M4 > 18$ or
 - $M5 > 20$

25 when using either weights $\{3,1,2,1\}$. Alternatively, other combinations of weights will lead to sets of sequences with low cross-hybridization.

Notice that using weights $\{6,6,0,6\}$ is equivalent to using weights $\{1,1,0,1\}$, or weights $\{2,2,0,2\}$, ... (that is, for any two sequences, the values of $M1$ to $M5$ are exactly the same whether weights $\{6,6,0,6\}$ or $\{1,1,0,1\}$ or $\{2,2,0,2\}$ or any other multiple of $\{1,1,0,1\}$ is used).
30

When dealing with sequences of length other than 24, or sequences of various lengths, the definition of similarity can be adjusted. Such adjustments are obvious to the persons skilled in the art. For example, when comparing a sequence of length $L1$ with a sequence of length $L2$ (with $L1 < L2$); they can be
35 considered as too similar when

- $M1 > 19/24 \times L1$
- $M2 > 17/24 \times L1$
- $M3 > 21/24 \times L1$

M4 > 18/24 x L1

M5 > 20/24 x L1

when using either weights {6, 6, 0, 6}, or {6, 6, 5, 1}, or {6, 2, 5, 1} or {6, 6, 6, 0}.

5 Polynucleotide sequences can be composed of a subset of natural bases most preferably A, T and G. Sequences that are deficient in one base possess useful characteristics, for example, in reducing potential secondary structure formation or reduced potential for cross hybridization with nucleic acids in nature. Also, it is preferable to have tag
10 sequences that behave isothermally. This can be achieved for example by maintaining a constant base composition for all sequences such as six Gs and eighteen As or Ts for each sequence. Additional sets of sequences can be designed by extrapolating on the original family of non-cross-hybridizing sequences by simple methods known to those skilled in the art.

15 In order to validate the sequence set, a subset of sequences from the family of 1168 sequence tags was selected and characterized, in terms of the ability of these sequences to form specific duplex structures with their complementary sequences, and the potential for cross-hybridization within the sequence set. See Example 4, below. The subset of 100 sequences was randomly
20 selected, and analyzed using the *Luminex*¹⁰⁰ LabMAP™ platform. The 100 sequences were chemically immobilized onto the set of 100 different *Luminex* microsphere populations, such that each specific sequence was coupled to one spectrally distinct microsphere population. The pool of 100 microsphere-immobilized probes was then hybridized with each of the 100 corresponding complementary sequences.
25 Each sequence was examined individually for its specific hybridization with its complementary sequence, as well as for its non-specific hybridization with the other 99 sequences present in the reaction. This analysis demonstrated the propensity of each sequence to hybridize only to its complement (perfect match), and not to cross-hybridize appreciably with any of the other oligonucleotides
30 present in the hybridization reaction.

It is within the capability of a person skilled in the art, given the family of sequences of Table II, to modify the sequences, or add other sequences while largely retaining the property of minimal cross-hybridization which the polynucleotides of Table II have been demonstrated to have.

35 There are 1168 polynucleotide sequences given in Table II. Since all 1168 of this family of polynucleotides can work with each other as a

minimally cross-hybridizing set, then any plurality of polynucleotides that is a subset of the 1168 can also act as a minimally cross-hybridizing set of polynucleotides. An application in which, for example, 30 molecules are to be sorted using a family of polynucleotide tags and tag complements could thus use
 5 any group of 30 sequences shown in Table II. This is not to say that some subsets may be found in a practical sense to be more preferred than others. For example, it may be found that a particular subset is more tolerant of a wider variety of conditions under which hybridization is conducted before the degree of cross-hybridization becomes unacceptable.

10 It may be desirable to use polynucleotides that are shorter in length than the 24 bases of those in Table II. A family of subsequences (i.e., subframes of the sequences illustrated) based on those contained in Table II having as few as 10 bases per sequence could be chosen, so long as the subsequences are chosen to retain homological properties between any two of the sequences of the family
 15 important to their non cross-hybridization.

The selection of sequences using this approach would be amenable to a computerized process. Thus for example, a string of 10 contiguous bases of the first 24mer of Table II could be selected: AAATTGTGAAAGATTGTTTGTGTA (SEQ ID NO:1).

20 The same string of contiguous bases from the second 24mer could then be selected and compared for similarity against the first chosen sequence: GTTAGAGTTAATTGTATTGATGA (SEQ ID NO:2 of Table II). A systematic pairwise comparison could then be carried out to determine if the similarity requirements are violated. If the pair of sequences does not violate any set property, a
 25 10mer subsequence can be selected from the third 24mer sequence of Table II, and compared to each of the first two 10mer sequences (in a pairwise fashion to determine its compatibility therewith, etc. In this way a family of 10mer sequences may be developed.

30 It is within the scope of this invention, to obtain families of sequences containing 11mer, 12mer, 13mer, 14mer, 15mer, 16mer, 17mer, 18mer, 19mer, 20mer, 21mer, 22mer and 23mer sequences by analogy to that shown for 10mer sequences. It may be desirable to have a family of sequences in which there are sequences greater in length than the 24mer sequences shown in Table II. It is within the capability of a person skilled in the art, given the family of sequences shown
 35 in Table II, to obtain such a family of sequences. One possible approach would be to insert into each sequence at one or more locations a nucleotide, non-natural base or analogue such that the longer

sequence should not have greater similarity than any two of the original non-cross-hybridizing sequences of Table II and the addition of extra bases to the tag sequences should not result in a major change in the thermodynamic properties of the tag sequences of that set for example the GC content must
 5 be maintained between 10%-40% with a variance from the average of 20%. This method of inserting bases could be used to obtain, for example, a family of sequences up to 40 bases long.

Given a particular family of sequences that can be used as a family of tags (or tag complements), e.g., those of Table II, a skilled person will
 10 readily recognize variant families that work equally as well.

Again taking the sequences of Table II for example, every T could be converted to an A and vice versa and no significant change in the cross-hybridization properties would be expected to be observed. This would also be true if every G were converted to a C.

15 Also, all of the sequences of a family could be taken to be constructed in the 5'-3' direction, as is the convention, or all of the constructions of sequences could be in the opposition direction (3'-5').

There are additional modifications that can be carried out. For example, C has not been used in the family of sequences. Substitution of C
 20 in place of one or more G's of a particular sequence would yield a sequence that is at least as low in homology with every other sequence of the family as was the particular sequence chosen for modification. It is thus possible to substitute C in place of one or more G's in any of the sequences shown in Table II. Analogously, substituting of C in place of one or more A's is
 25 possible, or substituting C in place of one or T's is possible.

It is preferred that the sequences of a given family are of the same, or roughly the same length. Preferably, all the sequences of a family of sequences of this invention have a length that is within five bases of the base-length of the average of the family. More preferably, all sequences are
 30 within four bases of the average base-length. Even more preferably, all or almost all sequences are within three bases of the average base-length of the family. Better still, all or almost all sequences have a length that is within two of the base-length of the average of the family, and even better still, within one of the base-length of the average of the family.

35 It is also possible for a person skilled in the art to derive sets of sequences from the family of sequences described in this specification and remove sequences that would be expected to have undesirable hybridization properties.

EXAMPLE 3 - Cross Talk Behavior of Sequence on Beads

A group of 100 of the sequences of Table I was tested for feasibility for use as a family of minimally cross-hybridizing oligonucleotides. The 100 sequences selected are separately indicated in Table I along with the numbers
5 assigned to the sequences in the tests.

The tests were conducted using the Luminex LabMAP™ platform available from Luminex Corporation, Austin, Texas, U.S.A. The one hundred sequences, used as probes, were synthesized as oligonucleotides by Integrated DNA Technologies (IDT, Coralville, Iowa, U.S.A.). Each probe included a C₆ aminolink group
10 coupled to the 5'-end of the oligonucleotide through a C₁₂ ethylene glycol spacer. The C₆ aminolink molecule is a six carbon spacer containing an amine group that can be used for attaching the oligonucleotide to a solid support. One hundred oligonucleotide targets (probe complements), the sequence of each being the reverse complement of the 100 probe sequences, were also synthesized
15 by IDT. Each target was labelled at its 5'-end with biotin. All oligonucleotides were purified using standard desalting procedures, and were reconstituted to a concentration of approximately 200 µM in sterile, distilled water for use. Oligonucleotide concentrations were determined spectrophotometrically using extinction coefficients provided by the supplier.

Each probe was coupled by its amino linking group to a carboxylated
20 fluorescent microsphere of the LabMAP system according to the Luminex¹⁰⁰ protocol. The microsphere, or bead, for each probe sequence has unique, or spectrally distinct, light absorption characteristics which permits each probe to be distinguished from the other probes. Stock bead pellets
25 were dispersed by sonication and then vortexing. For each bead population, approximately five million microspheres (400 µL) were removed from the stock tube using barrier tips and added to a 1.5 mL Eppendorf tube (USA Scientific). The microspheres were then centrifuged, the supernatant was removed, and beads were resuspended in 25 µL of 0.2 M MES
30 (2-(N-morpholino)ethane sulfonic acid) (Sigma), pH 4.5, followed by vortexing and sonication. One nmol of each probe (in a 25 µL volume) was added to its corresponding bead population. A volume of 2.5 µL of EDC cross-linker (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (Pierce), prepared immediately before use by adding 1.0 mL of sterile ddH₂O
35 to 10 mg of EDC powder, was added to each microsphere population. Bead mixes were then incubated for 30 minutes at room temperature in the dark with periodic vortexing. A second 2.5 µL aliquot of freshly prepared EDC

solution was then added followed by an additional 30 minute incubation in the dark. Following the second EDC incubation, 1.0 mL of 0.02% Tween-20 (BioShop) was added to each bead mix and vortexed. The microspheres were centrifuged, the supernatant was removed, and the beads were resuspended in 1.0 mL of 0.1% sodium dodecyl sulfate (Sigma). The beads were centrifuged again and the supernatant removed. The coupled beads were resuspended in 100 μ L of 0.1 M MES pH 4.5. Bead concentrations were then determined by diluting each preparation 100-fold in ddH₂O and enumerating using a Neubauer BrightLine Hemacytometer. Coupled beads were stored as individual populations at 2-8°C protected from light.

The relative oligonucleotide probe density on each bead population was assessed by Terminal Deoxynucleotidyl Transferase (TdT) end-labelling with biotin-ddUTPs. TdT was used to label the 3'-ends of single-stranded DNA with a labeled ddNTP. Briefly, 180 μ L of the pool of 100 bead populations (equivalent to about 4000 of each bead type) to be used for hybridizations was pipetted into an Eppendorf tube and centrifuged. The supernatant was removed, and the beads were washed in 1x TdT buffer. The beads were then incubated with a labelling reaction mixture, which consisted of 5x TdT buffer, 25mM CoCl₂, and 1000 pmol of biotin-16-ddUTP (all reagents were purchased from Roche). The total reaction volume was brought up to 85.5 μ L with sterile, distilled H₂O, and the samples were incubated in the dark for 1 hour at 37°C. A second aliquot of enzyme was added, followed by a second 1 hour incubation. Samples were run in duplicate, as was the negative control, which contained all components except the TdT. In order to remove unincorporated biotin-ddUTP, the beads were washed 3 times with 200 μ L of hybridization buffer, and the beads were resuspended in 50 μ L of hybridization buffer following the final wash. The biotin label was detected spectrophotometrically using SA-PE (streptavidin-phycoerythrin conjugate). The streptavidin binds to biotin and the phycoerythrin is spectrally distinct from the probe beads. The 10mg/mL stock of SA-PE was diluted 100-fold in hybridization buffer, and 15 μ L of the diluted SA-PE was added directly to each reaction and incubated for 15 minutes at 37°Celsius. The reactions were analyzed on the Luminex¹⁰⁰ LabMAP. Acquisition parameters were set to measure 100 events per bead using a sample volume of 50 μ L.

The results obtained are shown in Figure 2. As can be seen the Mean Fluorescent Intensity (MFI) of the beads varies from 277.75 to 2291.08, a

range of 8.25 -fold. Assuming that the labelling reactions are complete for all of the oligonucleotides, this illustrates the signal intensity that would be obtained for each type of bead at this concentration if the target (i.e., labelled complement) was bound to the probe sequence to the full extent possible.

The cross-hybridization of targets to probes was evaluated as follows. 100 oligonucleotide probes linked to 100 different bead populations, as described above, were combined to generate a master bead mix, enabling multiplexed reactions to be carried out. The pool of microsphere-immobilized probes was then hybridized individually with each biotinylated target. Thus, each target was examined individually for its specific hybridization with its complementary bead-immobilized sequence, as well as for its non-specific hybridization with the other 99 bead-immobilized universal sequences present in the reaction. For each hybridization reaction, 25 μ L bead mix (containing about 2500 of each bead population in hybridization buffer) was added to each well of a 96-well Thermowell PCR plate and equilibrated at 37°C. Each target was diluted to a final concentration of 0.002 fmol/ μ L in hybridization buffer, and 25 μ L (50 fmol) was added to each well, giving a final reaction volume of 50 μ L. Hybridization buffer consisted of 0.2 M NaCl, 0.1 M Tris, 0.08% Triton X-100, pH 8.0 and hybridizations were performed at 37°C for 30 minutes. Each target was analyzed in triplicate and six background samples (i.e. no target) were included in each plate. A SA-PE conjugate was used as a reporter, as described above. The 10 mg/mL stock of SA-PE was diluted 100-fold in hybridization buffer, and 15 μ L of the diluted SA-PE was added directly to each reaction, without removal of unbound target, and incubated for 15 minutes at 37°C. Finally, an additional 35 μ L of hybridization buffer was added to each well, resulting in a final volume of 100 μ L per well prior to analysis on the Luminex¹⁰⁰ LabMAP. Acquisition parameters were set to measure 100 events per bead using a sample volume of 80 μ L.

The percent hybridization was calculated for any event in which the NET MFI was at least 3 times the zero target background. In other words, a calculation was made for any sample where $(\text{MFI}_{\text{sample}} - \text{MFI}_{\text{zero target background}}) / \text{MFI}_{\text{zero target background}} \geq 3$.

A "positive" cross-talk event (i.e., significant mismatch or cross-hybridization) was defined as any event in which the net median fluorescent

intensity ($MFI_{\text{sample}} - MFI_{\text{zero target background}}$) generated by a mismatched hybrid was greater than or equal to the arbitrarily set limit of 10% that of the perfectly matched hybrid determined under identical conditions. As there are 100 probes and 100 targets, there are $100 \times 100 = 10,000$ possible different interactions possible of which 100 are the result of perfect hybridizations. The remaining 9900 result from hybridization of a target with a mismatched probe.

The results obtained are illustrated in Figure 3. The ability of each target to be specifically recognized by its matching probe is shown. Of the possible 9900 non-specific hybridization events that could have occurred when the 100 targets were each exposed to the pool of 100 probes, 6 events were observed. Of these 6 events, the highest non-specific event generated a signal equivalent to 10.2 % of the signal observed for the perfectly matched pair (i.e. specific hybridization event).

Each of the 100 targets was thus examined individually for specific hybridization with its complement sequence as incorporated onto a microsphere, as well as for non-specific hybridization with the complements of the other 99 target sequences. Representative hybridization results for target 16 (complement of probe 16, Table I) are shown in Figure 4. Probe 16 was found to hybridize only to its perfectly-matched target. No cross-hybridization with any of the other 99 targets was observed.

The foregoing results demonstrate the possibility of incorporating the 210 sequences of Table I, or any subset thereof, into a multiplexed system with the expectation that most if not all sequences can be distinguished from the others by hybridization. That is, it is possible to distinguish each target from the other targets by hybridization of the target with its precise complement and minimal hybridization with complements of the other targets.

Methods For Synthesis Of Oligonucleotide Families

Preferably oligonucleotide sequences of the invention are synthesized directly by standard phosphoramidite synthesis approaches and the like
 5 (Caruthers et al, Methods in Enzymology; 154, 287-313: 1987; Lipshutz et al, Nature Genet.; 21, 20-24: 1999; Fodor et al, Science; 251, 763-773: 1991). Alternative chemistries involving non natural bases such as peptide nucleic acids or modified nucleosides that offer advantages in duplex stability may also be used (Hacia et al; *Nucleic Acids Res* ;27: 4034-4039, 1999; Nguyen et
 10 al, *Nucleic Acids Res.*;27, 1492-1498: 1999; Weiler et al, *Nucleic Acids Res.*; 25, 2792-2799:1997). It is also possible to synthesize the oligonucleotide sequences of this invention with alternate nucleotide backbones such as phosphorothioate or phosphoroamidate nucleotides. Methods involving synthesis through the addition of blocks of sequence in a stepwise manner may
 15 also be employed (Lyttle et al, *Biotechniques*, 19: 274-280 (1995). Synthesis may be carried out directly on the substrate to be used as a solid phase support for the application or the oligonucleotide can be cleaved from the support for use in solution or coupling to a second support.

20 Solid Phase Supports

There are several different solid phase supports that can be used with the invention. They include but are not limited to slides, plates, chips, membranes, beads, microparticles and the like. The solid phase supports can also vary in the materials that they are composed of including plastic,
 25 glass, silicon, nylon, polystyrene, silica gel, latex and the like. The surface of the support is coated with the complementary tag sequences by any conventional means of attachment.

In preferred embodiments, the family of tag complement sequences is derivatized to allow binding to a solid support. Many methods of
 30 derivatizing a nucleic acid for binding to a solid support are known in the art (Hermanson G., *Bioconjugate Techniques*; Acad. Press: 1996). The sequence tag may be bound to a solid support through covalent or non-covalent bonds (Iannone et al, *Cytometry*; 39: 131-140, 2000; Matson et al, *Anal. Biochem.*; 224: 110-106, 1995; Proudnikov et al, *Anal Biochem*; 259: 34-41, 1998;
 35 Zammattéo et al, *Analytical Biochemistry*; 280:143-150, 2000). The sequence tag can be conveniently derivatized for binding to a solid support by incorporating modified nucleic acids in the terminal 5' or 3' locations.

A variety of moieties useful for binding to a solid support (e.g., biotin, antibodies, and the like), and methods for attaching them to nucleic acids, are known in the art. For example, an amine-modified nucleic acid base (available from, eg., Glen Research) may be attached to a solid support (for example, Covalink-NH, a polystyrene surface grafted with secondary amino groups, available from Nunc) through a bifunctional crosslinker (e.g., bis(sulfosuccinimidyl suberate), available from Pierce). Additional spacing moieties can be added to reduce steric hindrance between the capture moiety and the surface of the solid support.

10

Attaching Tags to Analytes for Sorting

A family of oligonucleotide tag sequences can be conjugated to a population of analytes most preferably polynucleotide sequences in several different ways including but not limited to direct chemical synthesis, chemical coupling, ligation, amplification, and the like. Sequence tags that have been synthesized with primer sequences can be used for enzymatic extension of the primer on the target for example in PCR amplification.

15

Detection of Single Nucleotide Polymorphisms Using Primer Extension

20

There are a number of areas of genetic analysis where families of non-cross-hybridizing sequences can be applied including disease diagnosis, single nucleotide polymorphism analysis, genotyping, expression analysis and the like. One such approach for genetic analysis, referred to as the primer extension method (also known as Genetic Bit Analysis (Nikiforov et al, Nucleic Acids Res.; 22, 4167-4175: 1994; Head et al Nucleic Acids Res.; 25, 5065-5071: 1997)), is an extremely accurate method for identification of the nucleotide located at a specific polymorphic site within genomic DNA. In standard primer extension reactions, a portion of genomic DNA containing a defined polymorphic site is amplified by PCR using primers that flank the polymorphic site. In order to identify which nucleotide is present at the polymorphic site, a third primer is synthesized such that the polymorphic position is located immediately 3' to the primer. A primer extension reaction is set up containing the amplified DNA, the primer for extension, up to 4 dideoxynucleoside triphosphates (each labeled with a different fluorescent dye) and a DNA polymerase such as the Klenow subunit of DNA Polymerase 1. The use of dideoxy nucleotides ensures that a single base is added to the 3' end of the primer, a site corresponding to the polymorphic site. In this way the identity of the nucleotide present at a specific

25

30

35

polymorphic site can be determined by the identity of the fluorescent dye-labeled nucleotide that is incorporated in each reaction. One major drawback to this approach is its low throughput. Each primer extension reaction is carried out independently in a separate tube.

- 5 Universal sequences can be used to enhance the throughput of primer extension assay as follows. A region of genomic DNA containing multiple polymorphic sites is amplified by PCR. Alternatively, several genomic regions containing one or more polymorphic sites each are amplified together in a multiplexed PCR reaction. The primer extension reaction is carried out
- 10 as described above except that the primers used are chimeric, each containing a unique universal tag at the 5' end and the sequence for extension at the 3' end. In this way, each gene-specific sequence would be associated with a specific universal sequence. The chimeric primers would be hybridized to the amplified DNA and primer extension is carried out as described above. This
- 15 would result in a mixed pool of extended primers, each with a specific fluorescent dye characteristic of the incorporated nucleotide. Following the primer extension reaction, the mixed extension reactions are hybridized to an array containing probes that are reverse complements of the universal sequences on the primers. This would segregate the products of a number of
- 20 primer extension reactions into discrete spots. The fluorescent dye present at each spot would then identify the nucleotide incorporated at each specific location. A number of additional methods for the detection of single nucleotide polymorphisms, including but not limited to, allele specific polymerase chain reaction (ASPCR), allele specific primer extension (ASPE)
- 25 and oligonucleotide ligation assay (OLA) can be performed by someone skilled in the art in combination with the tag sequences described herein.

Kits Using Families Of Tag Sequences

- The families of non cross-hybridizing sequences may be provided in kits
- 30 for use in for example genetic analysis. Such kits include at least one set of non-cross-hybridizing sequences in solution or on a solid support. Preferably the sequences are attached to microparticles and are provided with buffers and reagents that are appropriate for the application. Reagents may include enzymes, nucleotides, fluorescent labels and the like that would be
- 35 required for specific applications. Instructions for correct use of the kit for a given application will be provided.

EXAMPLES

EXAMPLE 4 - Cross Talk Behavior of Sequence on Beads

A group of 100 sequences, randomly selected from Table II, was tested for feasibility for use as a family of minimally cross-hybridizing oligonucleotides. The 100 sequences selected are separately indicated in Table II along with the numbers assigned to the sequences in the tests.

The tests were conducted using the Luminex LabMAP™ platform available from Luminex Corporation, Austin, Texas, U.S.A. The one hundred sequences, used as probes, were synthesized as oligonucleotides by Integrated DNA Technologies (IDT, Coralville, Iowa, U.S.A.). Each probe included a C₆ aminolink group coupled to the 5'-end of the oligonucleotide through a C₁₂ ethylene glycol spacer. The C₆ aminolink molecule is a six carbon spacer containing an amine group that can be used for attaching the oligonucleotide to a solid support. One hundred oligonucleotide targets (probe complements), the sequence of each being the reverse complement of the 100 probe sequences, were also synthesized by IDT. Each target was labelled at its 5'-end with biotin. All oligonucleotides were purified using standard desalting procedures, and were reconstituted to a concentration of approximately 200 µM in sterile, distilled water for use. Oligonucleotide concentrations were determined spectrophotometrically using extinction coefficients provided by the supplier.

Each probe was coupled by its amino linking group to a carboxylated fluorescent microsphere of the LapMAP system according to the Luminex¹⁰⁰ protocol. The microsphere, or bead, for each probe sequence has unique, or spectrally distinct, light absorption characteristics which permits each probe to be distinguished from the other probes. Stock bead pellets were dispersed by sonication and then vortexing. For each bead population, five million microspheres (400 µL) were removed from the stock tube using barrier tips and added to a 1.5 mL Eppendorf tube (USA Scientific). The microspheres were then centrifuged, the supernatant was removed, and beads were resuspended in 25 µL of 0.2 M MES (2-(N-morpholino)ethane sulfonic acid) (Sigma), pH 4.5, followed by vortexing and sonication. One nmol of each probe (in a 25 µL volume) was added to its corresponding bead population. A volume of 2.5 µL of EDC cross-linker (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (Pierce), prepared immediately before use by adding 1.0 mL of sterile ddH₂O to 10 mg of EDC powder, was added to each microsphere population. Bead mixes were then incubated for 30 minutes at room temperature in the dark with periodic vortexing. A second 2.5 µL aliquot

of freshly prepared EDC solution was then added followed by an additional 30 minute incubation in the dark. Following the second EDC incubation, 1.0 mL of 0.02% Tween-20 (BioShop) was added to each bead mix and vortexed. The microspheres were centrifuged, the supernatant was removed, and the beads were resuspended in 1.0 mL of 0.1% sodium dodecyl sulfate (Sigma). The beads were centrifuged again and the supernatant removed. The coupled beads were resuspended in 100 μ L of 0.1 M MES pH 4.5. Bead concentrations were then determined by diluting each preparation 100-fold in ddH₂O and enumerating using a Neubauer BrightLine Hemacytometer. Coupled beads were stored as individual populations at 8°C protected from light.

The relative oligonucleotide probe density on each bead population was assessed by Terminal Deoxynucleotidyl Transferase (TdT) end-labelling with biotin-ddUTPs. TdT was used to label the 3'-ends of single-stranded DNA with a labeled ddNTP. Briefly, 180 μ L of the pool of 100 bead populations (equivalent to about 4000 of each bead type) to be used for hybridizations was pipetted into an Eppendorf tube and centrifuged. The supernatant was removed, and the beads were washed in 1x TdT buffer. The beads were then incubated with a labelling reaction mixture, which consisted of 5x TdT buffer, 25mM CoCl₂, and 1000 pmol of biotin-16-ddUTP (all reagents were purchased from Roche). The total reaction volume was brought up to 85.5 μ L with sterile, distilled H₂O, and the samples were incubated in the dark for 1 hour at 37°C. A second aliquot of enzyme was added, followed by a second 1 hour incubation. Samples were run in duplicate, as was the negative control, which contained all components except the TdT. In order to remove unincorporated biotin-ddUTP, the beads were washed 3 times with 200 μ L of hybridization buffer, and the beads were resuspended in 50 μ L of hybridization buffer following the final wash. The biotin label was detected spectrophotometrically using SA-PE (streptavidin-phycoerythrin conjugate). The streptavidin binds to biotin and the phycoerythrin is spectrally distinct from the probe beads. The 10mg/mL stock of SA-PE was diluted 100-fold in hybridization buffer, and 15 μ L of the diluted SA-PE was added directly to each reaction and incubated for 15 minutes at 37°Celsius. The reactions were analyzed on the *Luminex*¹⁰⁰ LabMAP. Acquisition parameters were set to measure 100 events per bead using a sample volume of 50 μ L.

The results obtained are shown in Figure 6. As can be seen the Mean Fluorescent Intensity (MFI) of the beads varies from 840.3 to 3834.9, a range of 4.56-fold. Assuming that the labelling reactions are complete for all of the oligonucleotides, this illustrates the signal intensity that would be

obtained for each type of bead at this concentration if the target (i.e., labelled complement) was bound to the probe sequence to the full extent possible.

The cross-hybridization of targets to probes was evaluated as follows.

5 100 oligonucleotide probes linked to 100 different bead populations, as described above, were combined to generate a master bead mix, enabling multiplexed reactions to be carried out. The pool of microsphere-immobilized probes was then hybridized individually with each biotinylated target. Thus, each target was examined individually for its specific hybridization with its

10 complementary bead-immobilized sequence, as well as for its non-specific hybridization with the other 99 bead-immobilized universal sequences present in the reaction. For each hybridization reaction, 25 μ L bead mix (containing about 2500 of each bead population in hybridization buffer) was added to each well of a 96-well Thermowell PCR plate and equilibrated at 37°C. Each target

15 was diluted to a final concentration of 0.002 fmol/ μ L in hybridization buffer, and 25 μ L (50 fmol) was added to each well, giving a final reaction volume of 50 μ L. Hybridization buffer consisted of 0.2 M NaCl, 0.1 M Tris, 0.08% Triton X-100, pH 8.0 and hybridizations were performed at 37°C for 30 minutes. Each target was analyzed in triplicate and six background samples (i.e. no target)

20 were included in each plate. A SA-PE conjugate was used as a reporter, as described above. The 10 mg/mL stock of SA-PE was diluted 100-fold in hybridization buffer, and 15 μ L of the diluted SA-PE was added directly to each reaction, without removal of-unbound target, and incubated for 15 minutes at 37°C. Finally, an additional 35 μ L of hybridization buffer was

25 added to each well, resulting in a final volume of 100 μ L per well prior to analysis on the *Luminex*¹⁰⁰ LabMAP. Acquisition parameters were set to measure 100 events per bead using a sample volume of 80 μ L.

The percent hybridization was calculated for any event in which the NET MFI was at least 3 times the zero target background. In other words, a

30 calculation was made for any sample where $(\text{MFI}_{\text{sample}} - \text{MFI}_{\text{zero target background}}) / \text{MFI}_{\text{zero target background}} \geq 3$.

The net median fluorescent intensity ($\text{MFI}_{\text{sample}} - \text{MFI}_{\text{zero target background}}$) generated for all of the 10,000 possible target/probe combinations was calculated. As there are 100 probes and 100 targets, there are $100 \times 100 =$

35 10,000 possible different interactions possible of which 100 are the result of perfect hybridizations. The remaining 9900 result from hybridization of a target with a mismatched probe. A cross-hybridization event is then defined as a non-specific event whose net median fluorescent intensity exceeds 3

times the zero target background. In other words, a cross-talk calculation is only be made for any sample where $(MFI_{\text{sample}} - MFI_{\text{zero target background}}) / MFI_{\text{zero target background}} \geq 3$. Cross-hybridization events were quantified by expressing the value of the cross-hybridization signal as a percentage of the perfect match hybridization signal with the same probe.

The results obtained are illustrated in Figure 7. The ability of each target to be specifically recognized by its matching probe is shown. Of the possible 9900 non-specific hybridization events that could have occurred when the 100 targets were each exposed to the pool of 100 probes, 6 events were observed. Of these 6 events, the highest non-specific event generated a signal equivalent to 5.3% of the signal observed for the perfectly matched pair (i.e. specific hybridization event).

Each of the 100 targets was thus examined individually for specific hybridization with its complement sequence as incorporated onto a microsphere, as well as for non-specific hybridization with the complements of the other 99 target sequences. Representative hybridization results for target (complement of probe 90, Table II) are shown in Figure 8. Probe 90 was found to hybridize only to its perfectly-matched target. No cross-hybridization with any of the other 99 targets was observed.

The foregoing results demonstrate the possibility of incorporating the 1168 sequences of Table II, or any subset thereof, into a multiplexed system with the expectation that most if not all sequences can be distinguished from the others by hybridization. That is, it is possible to distinguish each target from the other targets by hybridization of the target with its precise complement and minimal hybridization with complements of the other targets.

EXAMPLE 5 - Tag sequences used in sorting polynucleotides

The family of non cross hybridizing sequence tags or a subset thereof can be attached to oligonucleotide probe sequences during synthesis and used to generate amplified probe sequences. In order to test the feasibility of PCR amplification with non cross hybridizing sequence tags and subsequently addressing each respective sequence to its appropriate location on two-dimensional or bead arrays, the following experiment was devised. A 24mer tag sequence can be connected in a 5'-3' specific manner to a p53 exon specific sequence (20mer reverse primer). The connecting p53 sequence represents the inverse complement of the nucleotide gene sequence. To facilitate the subsequent generation of single stranded DNA post-amplification the tag-Reverse primer can be synthesized with a phosphate

modification (PO₄) on the 5'-end. A second PCR primer can also be generated for each desired exon, represented by the Forward (5'-3') amplification primer. In this instance the Forward primer can be labeled with a 5'-biotin modification to allow detection with Cy3-avidin or equivalent.

A practical example of the aforementioned description is as follows: For exon 1 of the human p53 tumor suppressor gene sequence the following tag-Reverse primer (SEQ ID NO:1171) can be generated:

222087	222063
5'-PO4-ATGTTAAAGTAAGTGTGAAATGT -TCCAGGGAAGCGTGTACCGTCGT-3'	
Tag Sequence # 3	Exon 1 Reverse

The numbering above the Exon-1 reverse primer represents the genomic nucleotide positions of the indicated bases.

The corresponding Exon-1 Forward primer sequence (SEQ ID NO:1172) is as follows:

221873	221896
5'-Biotin-TCATGGCGACTGTCCAGCTTTGTG-3'	

In combination, these primers will amplify a product of 214 bp plus a 24 bp tag extension yielding a total size of 238 bp. Once amplified, the PCR product can be purified using a QIAquick PCR purification kit and the resulting DNA can be quantified. To generate single stranded DNA, the DNA is subjected to λ -exonuclease digestion thereby resulting in the exposure of a single stranded sequence (anti-tag) complementary to the tag-sequence covalently attached to the solid phase array. The resulting product is heated to 95°C for 5 minutes and then directly applied to the array at a concentration of 10-50 nM. Following hybridization and concurrent sorting, the tag-Exon 1 sequences are visualized using Cy3-streptavidin. In addition to direct visualization of the biotinylated product, the product itself can now act as a substrate for further analysis of the amplified region, such as SNP detection and haplotype determination.

The Invader Assay is described in detail in US Patent No. 5,846, 717 and 5,985,557. Briefly, the ability of the Invader technology to identify target nucleic acid sequences and in particular single base pair changes is dependent on the proper structure being formed, followed by subsequent

recognition and cleavage of this structure by the Cleavase enzyme. For recognition by Cleavase III, the target sequence must be complementary to the primary probe, and there must be at least a 1 base "invasion" (overlap) of this structure by an upstream oligonucleotide. Cleavable "flaps" can be created by invasion of an upstream oligonucleotide without primer extension, and the site of cleavage is determined by the extent to which the upstream oligonucleotide overlaps the 5' region of the downstream oligonucleotide. Cleavage by the Cleavase enzyme is dependent on this invaded structure and is sensitive to single-base mismatches is positioned immediately upstream of the cleavage site. By adding overlapping pairs of oligonucleotide probes complementary to a predetermined region of target DNA, the cleavage of the downstream probes become a sensitive indicator of the presence of the target sequence. Further, reaction conditions have been established that allow multiple copies of the downstream oligonucleotide probe to be cleaved for each target sequence without temperature cycling, so as to amplify the cleavage signal and allow quantitative detection of target DNA at sub-attomole levels. Incorporation of the minimally cross-hybridizing sequences of the invention described herein into the probe that will be cleaved by the Cleavase enzyme allows detection of multiple target DNA sequences in a single experiment.

DEFINITIONS

Non-cross-hybridization: Describes the absence of hybridization between two sequences that are not perfect complements of each other.

Cross-hybridization: The hydrogen bonding of a single-stranded DNA sequence that is partially but not entirely complementary to a single-stranded substrate.

Homology or Similarity: How closely related two or more separate strands of DNA are to each other, based on their base sequences.

Analogue: The symbols A, G, T/U, C take on their usual meaning in the art here. In the case of T and U, a person skilled in the art would understand that these are equivalent to each other with respect to the inter-strand hydrogen-bond (Watson-Crick) binding properties at work in the context of this invention. The two bases are thus interchangeable and hence the designation of T/U. A chemical, which resembles a nucleotide

base is an analogue thereof. A base that does not normally appear in DNA but can substitute for the ones, which do, despite minor differences in structure. Analogues particularly useful in this invention are of the naturally occurring bases can be inserted in their respective places where
 5 desired. Such an analogue is any non-natural base, such as peptide nucleic acids and the like that undergoes normal Watson-Crick pairing in the same way as the naturally occurring nucleotide base to which it corresponds.

10 **Complement:** The opposite or "mirror" image of a DNA sequence. A complementary DNA sequence has an "A" for every "T" and a "C" for every "G". Two complementary strands of single stranded DNA, for example a tag sequence and its complement, will join to form a double-stranded molecule.

15 **Complementary DNA (cDNA):** DNA that is synthesized from a messenger RNA template; the single- stranded form is often used as a probe in physical mapping.

20 **Oligonucleotide:** Refers to a short nucleotide polymer whereby the nucleotides may be natural nucleotide bases or analogues thereof.

Tag: Refers to an oligonucleotide that can be used for specifically sorting analytes with at least one other oligonucleotide that when used together do not cross hybridize.

25 **Similar Homology:** In the context of this invention, pairs of sequences are compared with each other based on the amount of "homology" between the sequences. By way of example, two sequences are said to have a 50% "maximum homology" with each other if, when the two sequences are aligned side-by-side
 30 with each other so to obtain the (absolute) maximum number of identically paired bases, the number of identically paired bases is 50% of the total number of bases in one of the sequences. (If the sequences being compared are of different lengths, then it would be of the total number of bases in the shorter of the two sequences.) Examples of determining maximum homology are as follows:

35 Example 1:

* *

A-A-B-B-C-C

B-D-C-D-D-D (2 out of 4 paired bases are the same)

* *

A-A-B-B-C-C

B-D-C-D-D-D (2 out of 3 paired bases are the same)

5 In this case, the maximum number of identically paired bases is two and there are two possible alignments yielding this maximum number. The total number of possible pairings is six giving $33 \frac{1}{3} \% (2/6)$ homology. The maximum amount of homology between the two sequences is thus $1/3$.

10 Example 2:

* * *

A-A-B-B-C-A

A-A-D-D-C-D (3 out of 6 paired bases are the same)

15

In this alignment, the number of identically paired bases is three and the total number of possibly paired bases is six, so the homology between the two sequences is $3/6 (50\%)$.

20

*

A-A-B-B-C-A

A-A-D-D-C-D (1 out of 1 paired bases are the same)

25

In this alignment, the number of identically paired bases is 1, so the homology between the two sequences is $1/6 (16 \frac{2}{3} \%)$.

The maximum homology between these two sequences is thus 50%.

30

Block sequence: Refers to a symbolic representation of a sequence of blocks. In its most general form a block sequence is a representative sequence in which no particular value, mathematical variable, or other designation is assigned to each block of the sequence.

35

Incidence Matrix: As used herein is a well-defined term in the field of Discrete Mathematics. However, an incidence matrix cannot be defined without first defining a "graph". In the method described herein a subset of general graphs called simple graphs is used. Members of this subcategory are further defined as follows.

A simple graph G is a pair (V, E) where V represents the set of vertices of the simple graph and E is a set of un-oriented edges of the simple graph. An edge is defined as a 2-component combination of members of the set of vertices.

5 In other words, in a simple graph G there are some pairs of vertices that are connected by an edge. In our application a graph is based on nucleic acid sequences generated using sequence templates and vertices represent DNA sequences and edges represent a relative property of any pair of sequences.

10 The incidence matrix is a mathematical object that allows one to describe any given graph. For the subset of simple graphs used herein, the simple graph $G=(V,E)$, and for a pre-selected and fixed ordering of vertices, $V=\{v_1, v_2, \dots, v_n\}$, elements of the incidence matrix $A(G) = [a_{ij}]$ are defined by the following rules:

15 (1) $a_{ij}=1$ for any pair of vertices $\{v_i, v_j\}$ that is a member of the set of edges; and

(2) $a_{ij}=0$ for any pair of vertices $\{v_i, v_j\}$ that is not a member of the set of edges.

20 This is an exact unequivocal definition of the incidence matrix. In effect, one selects the indices: $1, 2, \dots, n$ of the vertices and then forms an $(n \times n)$ square matrix with elements $a_{ij}=1$ if the vertices v_i and v_j are connected by an edge and $a_{ij}=0$ if the vertices v_i and v_j are not connected by an edge.

To define the term "class property" as used herein, the term
25 "complete simple graph" or "clique" must first be defined. The complete simple graph is required because all sequences that result from the method described herein should collectively share the relative property of any pair of sequences defining an edge of graph G , for example not violating the threshold rule that is, do not have a "maximum simple homology" greater than a predetermined amount,
30 whatever pair of the sequences are chosen from the final set. It is possible that additional "local" rules, based on known or empirically determined behavior of particular nucleotides, or nucleotide sequences, are applied to sequence pairs in addition to the basic threshold rule.

35 In the language of a simple graph, $G=(V, E)$, this means in the final graph there should be no pair of vertices (no sequence pair) not connected by an edge (because an edge means that the sequences represented by v_i and v_j do not violate the threshold rule).

Because the incidence matrix of any simple graph can be generated by the above definition of its elements, the consequence of defining a simple complete graph is that the corresponding incidence matrix for a simple complete graph will have all off-diagonal elements equal to 1 and all diagonal elements equal to 0. This is because if one aligns a sequence with itself, the threshold rule is of course violated, and all other sequences are connected by an edge.

For any simple graph, there might be a complete subgraph. First, the definition of a subgraph of a graph is as follows. The subgraph $G_s = (V_s, E_s)$ of a simple graph $G = (V, E)$ is a simple graph that contains the subsets of vertices V_s of the set V of vertices and inclusion of the set V_s into the set V is immersion (a mathematical term). This means that one generates a subgraph $G_s = (V_s, E_s)$ of a simple graph G in two steps. First select some vertices V_s from G . Then select those edges E_s from G that connect the chosen vertices and do not select edges that connect selected with non selected vertices.

We desire a subgraph of G that is a complete simple graph. By using this property of the complete simple graph generated from the simple graph G of all sequences generated by the template based algorithm, the pairwise property of any pair of the sequences (violating/non-violating the threshold rule) is converted into the property of all members of the set, termed "the class property".

By selecting a subgraph of a simple graph G that is a complete simple graph, this assures that, up to the tests involving the local rules described herein, there are no pairs of sequences in the resulting set that violate the threshold rule, also described above, independent of which pair of sequences in the set are chosen. This feature is called the "desired class property".

The present invention thus includes reducing the potential for non cross-hybridization behavior by taking into account local homologies of the sequences and appears to have greater rigor than known approaches. For example, the method described herein involves the sliding of one sequence relative to the other sequence in order to form a sequence alignment that would accommodate insertions or deletions. (Kane et al., Nucleic Acids Res.; 28, 4552-4557: 2000).

Table I

SEQ ID NO (1)	Sequence	No. Assigned in Example 3
1	GATTTGTATTGATTGAGATTAAAG	1
2	TGATTGTAGTATGTATTGATAAAG	2
3	GATTGTAAGATTTGATAAAGTGTA	3
4	GATTTGAAGATTATTGGTAATGTA	4
5	GATTGATTATTGTGATTGGAATTG	5
6	GATTTGATTGTAAAAGATTGTTGA	6
7	ATTGGTAAATTGGTAAATGAATTG	7
8	ATTGGATTTGATAAAGGTAAATGA	
9	GTAAGTAATGAATGTAAAAGGATT	8
10	GATTGATTGATTGATTGATTGAT	
11	TGATGATTAAAGAAAGTGATTGAT	
12	AAAGGATTTGATTGATAAAGTGAT	
13	TGTAGATTTGTATGTATGTATGAT	10
14	GATTTGATAAAGAAAGGATTGATT	
15	GATTAAAGTGATTGATGATTTGTA	11
16	AAAGAAAGAAAGAAAGAAAGTGTA	12
17	TGTAAGGATTGATTTGTATGTA	
18	AAAGTGTAGATTGATTAAAGAAAG	
19	AAAGTTGATTGATTGAAAAGGTAT	
20	TTGATTGAGATTGATTTTGAGTAT	
21	TGAATTGATGAATGAATGAAGTAT	15
22	GTAATGAAGTATGTATGTAAGTAA	
23	TGATGATTTGAATGAAGATTGATT	16
24	TGATAAAGTGATAAAGGATTAAAG	17
25	TGATTTGAGTATTTGAGATTTTGA	18
26	TGTAGTAAGATTGATTAAAGGTAA	
27	GTATAAAGGATTGATTTTGAAAAG	
28	GTATTTGAGTAAGTAATTGATTGA	19
29	GTAAAAAGTTGAGTATTGAAAAAG	
30	GATTTGATAAAGGATTTGTATTGA	
31	GATTGTATTGAAGTATTGTAAAAG	20
32	TGATGATTTTGATGAAAAAGTTGA	
33	TGATTTGAGATTAAAGAAAGGATT	21
34	TGATTGAATTGAGTAAAAAGGATT	22
35	AAAGTGTAAAAGGATTTGATGTAT	
36	AAAGGTATTTGAGATTTGATTGAA	
37	AAAGTTGAGATTTGAATGATTGAA	23
38	TGTATTGAAAAGGTATGATTGAA	
39	GTATTGTATTGAAAAGGTAATTGA	24
40	TTGAGTAATGATAAAGTGAAGATT	
41	TGAAGATTTGAAGTAATTGAAAAG	25
42	TGAAAAAGTGTAGATTTTGAGTAA	26
43	TGTATGAATGAAGATTTGATTGTA	
44	AAAGTTGAGTATTGATTTGAAAAG	27
45	GATTTGTAGATTTGTATTGAGATT	
46	AAAGAAAGGATTTGTAGTAAGATT	29
47	GTAAAAAGAAAGGTATAAAGGTAA	30
48	GATTAAAGTTGATTGAAAAGTGAA	31
49	TGAAAAAGGTAATTGATGTATGAA	
50	AAAGGATTAAAGTGAAGTAATTGA	33

51	ATGAATTGGTATGTATATGAATGA	34
52	TGAAATGAATGAATGATGAAATTG	35
53	ATTGATTGTGAATGAAATGAATTG	36
54	ATTGAAAGATGAAAAGATGAAAAG	37
55	ATTGTTGAAAAGTGTAAATGATTGA	38
56	ATGATGTAATGAAAAGATTGTGTA	39
57	AAAGATTGAAAGATGATGTAATTG	
58	ATTGATGAGTATATTGCTGTAGTAA	41
59	AAAGATTGTGTAATTGATGATGAA	
60	AAAGGTATATTGTGTAATGAGTAA	
61	TGTAATGAGTATTGTAATTGAAAAG	43
62	GTATAAAGAAAGATTGGTAAATGA	44
63	TTGAGTAATTGAATTGTGAAATGA	45
64	TGTATTGAATGAATTGTTGATGTA	46
65	TGTAATTGGTAAATGAGTAAAAAG	
66	TGAATGAAATTGATGAGTATAAAG	
67	GTAAGTAAATTGAAAGATTGATGA	49
68	GTAAATGATGATATTGGTATATTG	50
69	ATTGTTGATGATTGATTGAAATGA	51
70	ATTGTGAAGTATAAAGATGATTGA	52
71	ATGAAAAGTTGAGTAAATTGTGAT	
72	ATGAATTGAAAGTGATTGAAAAAG	54
73	GTAAATTGATGAAAAGTTGATGAT	
74	AAAGTGATGTATATGAGTAAATTG	56
75	GTAATGATAAAGATGATGATATTG	57
76	TTGAAAAGATTGGTAAATGATATGA	
77	AAAGTGAAAAGATTGATTGATGA	59
78	ATTGATGAGATTGATTATTGTGTA	
79	ATGAGATTATTGGATTGTAGATT	60
80	TGAAGATTATGAATTGGTAAGATT	61
81	ATTGGATTATGAGATTATGATTGA	62
82	ATTGTTGAATTGGATTAAAGATGA	
83	AAAGATGAGTAAGTAAATTGGATT	
84	AAAGGTAAGATTATTGATGAAAAG	65
85	ATTGATGAGATTAAAGTTGAATTG	
86	GATTATTGGATTATGAAAAGGATT	
87	GATTTGTAATTGTTGAGTAAATGA	67
88	AAAGAAAAGATTGTTGAGATTATGA	68
89	GTATAAAGGATTTTGAATTGATGA	
90	TTGAGATTGTAAATGAATTGTTGA	
91	GTATATTGATTGTGTAATGAAAAG	
92	TGATATGAATTGGATTATTGGTAT	70
93	ATGAATGATGAATGATGATTATTG	
94	ATGAATTGATTGGATTGTAATGAT	71
95	GATTGTAATTGAGTAAATTGATGA	
96	GATTATTGGATTAAAGGTAAATGA	72
97	ATTGTTGAATTGATGAGATTGAT	73
98	GATTATGAGTAAATTGATTGTGAT	
99	GATTATTGTTGATGAATGATATTG	
100	TGTAAGAGATTGAAAGGTATGATT	75
101	GTATTTAGATGAGTTTGTTAGATT	76
102	TGAAGTTATGTAATAGAAAGTGAT	
103	GTATGTATTGTATGTAGTTAATTG	77
104	TGATATAGATAGTTAGATAGATAG	78
105	ATGATGATGTATTGTAGTTATGAA	79

106	TTAGTGAATGTATTAGTTGATGTA	
107	GTTAGTTAGATTATTGTTAGTTAG	80
108	GTTAATTGTGTAGTTTGTATTGA	
109	GTTATGAAATAGTGATATTGTTAG	
110	ATTGTTAGAAAGTGTAGATTAAAG	81
111	ATGAGTATGTTATTAGTGTATGTA	82
112	TGTAATAGTGAAGTTAGATTGTAT	83
113	ATTGATAGATGATTAGTTAGTTGA	84
114	ATGAGTTTGTATTATGAGATTAAAG	
115	TGATGTTTGATTATGATGTAGTAT	85
116	ATGAGTTAGTTATGAATTAGATGA	
117	ATTGTTAGTGATGTTAGTAATTAG	86
118	TGATGTAAAGTATTGATGTTAGTTT	87
119	GATTGTAAATAGAAAGTGAAGTAA	88
120	ATTGTGTATGAAGTATTGTATGAT	
121	ATAGTGATGTTATGAAGATTGTTA	
122	TTAGATGAATTGTGAAGTATTTAG	90
123	GTAAGTTATGATTGATGTTATGAA	91
124	GTATTGATGTTTAAAGTGTAATAG	92
125	GATTGTAAAGTAAGATTGTATATTG	
126	GTTTGTATTTAGATGAATAGAAAG	93
127	GTTTGATTTGTAATAGTGATTGTA	
128	TGTATGTAGTATTTAGAAAGATGA	
129	ATGAATTGTGATAAAGAAAGTTAG	
130	TTAGTGTAGTAAGTTTAAAGTGTA	95
131	GTATGATTGTTTGTAAATTAGTGAT	
132	GTTTAAAGTTAGTTGAGTTAGTAT	96
133	ATAGTGTATGTAGATTATGAGATT	97
134	TTGAATGATTAGTTGAGTATGATT	98
135	GTATGTAAAGTTAGTATGATTTGAA	
136	TGTAGTATATTGTTGAATTGTGAT	
137	ATAGTGATTGTATGTATGATAAAG	
138	TTAGTGATTGATGTATATTGAAAG	
139	GTAAGATTATGAGTTATGATGTAA	
140	GTTATGAAATTGTTAGTGTAGATT	99
141	GTTAGATTTGTAGTTTAAAGATAG	100
142	TTAGTGATTGAAATGATGTAGATT	
143	AAAGTGTAGTTATTAGTTAGTTAG	
144	AAAGAAAGTGTATGATGTTATTAG	
145	GATTGTATATTGTGTATGATGATT	
146	TTGAGATTGTTATGATATGAGTAT	
147	ATGAGTATGATTGTTATGATGTTT	
148	TGATTTAGTGAAATTGTGTATTAG	
149	TGAATGTATGTAGTATGTTTGTTA	
150	GTTAGTATTGATGATTATGAGTTA	
151	GTATATTGTGATTTAGTTGAGATT	
152	GTTAGTTTAAAGTTGAGATTGTTT	
153	GTATATTGTTAGATGAGATTTGTA	
154	TGATGTATGTTAGTTTATGAATGA	
155	TGTAGTATGTAATGTAGTATTTGA	
156	ATGAGTTATGTATTGAGTTAGTAT	
157	TGTATGATGATTATAGTTGAGTAA	
158	ATTGATGAATGAGTTTGTATAAAG	
159	TTGAGTTTATGATTAGAAAGAAAG	
160	TGATATTGATGAGTTAGTATTGAA	

161	ATAGAAAAGTGAAATGAGTATGTTA	
162	TTGATGTAGATTTGATGTATATAG	
163	TTGAGATTATAGTGTAGTTTATAG	
164	TGATGTTAGATTGTTTGATTATTG	
165	TGTATTAGATAGTGATTTGAATGA	
166	GATTATGATGAATGTAGTATGTAA	
167	TGAATGATTGATATGAATAGTGTA	
168	GTAATGATTTAGTGTATTGAGTTT	
169	TGTAGTAATGATTTGATGATAAAG	
170	TGAAGATTGTTATTAGTGATATTG	
171	GTATTTGAATGATGTAATAGTGTA	
172	GTATATGATGTATTAGATTGAAAG	
173	AAAGTTAGATTGAAAGTGATAAAG	
174	GTAAGATGTTGATATAGAAGATTA	9
175	TAATATGAGATGAAAGTGAATTAG	
176	TTAGTGAAGAAGTATAGTTTATTG	13
177	GTAGTTGAGAAGATAGTAATTAAT	
178	ATGAGATGATATTTGAGAAGTAAT	
179	GATGTGAAGAAGATGAATATATAT	
180	AAAGTATAGTAAGATGTATAGTAG	14
181	GAAGTAATATGAGTAGTTGAATAT	
182	TTGATAATGTTTGTGTTTGTAG	28
183	TGAAGAAGAAAGTATAATGATGAA	
184	GTAGATTAGTTTGAAGTGAATAAT	32
185	TATAGTAGTGAAGATGATATATGA	
186	TATAATGAGTTGTTAGATATGTTG	
187	GTTGTGAAATTAGATGTGAAATAT	
188	TAATGTTGTGAATAATGTAGAAAG	40
189	GTTTATAGTGAAATATGAAGATAG	42
190	ATTATGAAGTAAGTTAATGAGAAG	47
191	GATGAAAGTAATGTTTATTGTGAA	
192	ATTATTGAGATGTGAAGTTTGTGTT	48
193	TGTAGAAGATGAGATGTATAATTA	53
194	TAATTTGAGTTGTGTATATAGTAG	
195	TGATATTAGTAAGAAGTTGAATAG	
196	GTTAGTTATTGAGAAGTGTATATA	55
197	GTAGTAATGTTAATGAATTAGTAG	58
198	GTTTGTGTTGATGTGATTGAATAAT	
199	GTAAGTAGTAATTTGAATATGTAG	64
200	GTTTGAAGATATGTTTGAAGTATA	
201	ATGATAATTGAAGATGTAATGTTG	
202	GTAGATAGTATAGTTGTAATGTTA	66
203	GATGTGAATGTAATATGTTTATAG	69
204	TGAAATTAGTTTGTGAAGATGTGTA	74
205	TGTAGTATAAAGTATATGAAGTAG	63
206	ATATGTTGTTGAGTTGATAGTATA	89
207	ATTATTGAGTAGAAAGATAGAAAG	94
208	GTTGTTGAATATTGAATATAGTTG	
209	ATGAGAAGTTAGTAATGTAAATAG	
210	TGAAATGAGAAGATTAATGAGTTT	

Table II

Sequence	SEQ ID NO:	No. in Ex 4
A A A T T G T G A A A G A T T G T T T G T G T A	1	1
G T T A G A G T T A A A T T G T A T T T G A T G A	2	-
A T G T T A A A G T A A G T G T T G A A A T G T	3	-
T G A T G T T A G A A G T A T A T T G T G A A T	4	-
T T T G T G T A G A A T A T G T G T T G T T A A	5	-
A T A A G T G T A A G T G A A A T A A G A A G A	6	-
A A G A G T A T T T T G T T G T G A G T T A A A T	7	-
G T G T T T A T T T G T T A T G T G A A G T T T	8	-
A A A G A G A A T A G A A T A T G T G T A A G T	9	-
T A T G A A A G A G T G A G A T A A T G T T T A	10	-
A T G A G A A A T A T G T T A G A A T G T G A T	11	-
T T A G T T G T T G A T G T T T A G T A G T T T	12	-
G T A A A G A G T A T A A G T T T G A T G A T A	13	-
A A A G T A A G A A T G A T G T A A T A A G T G	14	-
G T A G A A A T A G T T T A T T G A T G A T T G	15	-
T G T A A G T G A A A T A G T G A G T T A T T T	16	2
A A A T A G A T G A T A T A A G T G A G A A T G	17	-
A T A A G T T A T A A G T G T T A T G T G A G T	18	-
T A T A G A T A A A A G A G A T G A T T T G T T G	19	-
A G A G T T G A G A A T G T A T A G T A T T A T	20	-
A A G T A G T T T G T A A G A A T G A T T G T A	21	-
T T A T G A A A T T G A G T G A A G A T T G A T	22	-
G T A T A T A A A T T G T T A T G T T G A G	23	-
G A A T T G T A T A A A A G T A T T A G A T G T G	24	4
T A G A T G A G A T T A A A G T G T T A T T T G A	25	-
G T T A A G T T T G T T T A T G T A T A G A A G	26	-
G A G T A T T A G T A A A G T G A T A T G A T A	27	-
G T G A A T G A T T T T A G T A A A T G A T T G A	28	-
G A T T G A A G T T A T A G A A A T G A T T A G	29	-
A G T G A T A A A T G T T A G T T G A A T T G T	30	-
T A T A T A G T A A A T G T T T G T G T G T T G	31	-
T T A A G T G T T A G T T A T T T G T T G T A G	32	-
G T A G T A A T A T G A A G T G A G A A T A T A	33	-
T A G T G T A T A G A A T G T A G A T T T A G T	34	-
T T G T A G A T T A G A T G T G T T T G T A A A	35	-
T A G T A T A G A G T A G A G A T G A T A T T T	36	-
A T T G T G A A A G A A A G A G A A G A A A T T	37	7
T G T G A G A A T T A A G A T T A A G A A T G T	38	-
A T A T T A G T T A A G A A A G A G A G T T G	39	-
T T G T A G T T G A G A A A T A T G T A G T T T	40	-
T A G A G T T G T T A A A G A G T G T A A A T A	41	-
G T T A T G A T G T G T A T A A G T A A T A T G	42	-
T T T G T T A G A A T G A G A A G A T T T A T G	43	10
A G T A T A G T T T A A A G A A G T A G T A G A	44	-
G T G A G A T A T A G A T T T A G A A A G T A A	45	-
T T G T T T A T A G T G A A G T G A A T A G T A	46	-
A A G T A A G T A G T A A T A G T G T G T T A A	47	-
A T T T G T G A G T T A T G A A A G A T A A G A	48	-
G A A A G T A G A G A A T A A A G A T A A G A A	49	-
A T T T A A G A T T G T T A A G A G T A G A A G	50	-
G T T T A A A G A T T G T A A G A A T G T G T A	51	-
T T T G T G A A G A T G A A G T A T T T G T A T	52	-

Table II

Sequence	SEQ ID NO:	No. in Ex 4
TGTGTTT TAGAATT TAGTATGTGTA	53	-
GATAATTGATTATAGAAAGTGTTTG	54	-
GTTATTTTGTAAAGTTAAGATAGTAG	55	-
AGTTTATTGTAAAGAGTTTGAATAG	56	-
TTGTGTTTTATTGTGTAGTTTAAAG	57	-
ATTGTGTGAGAAAGATATGAAAGTTAT	58	-
TGAGAAATGTAAAGAAATGTTTATTG	59	13
ATGTGAAAGTTATGATGTTAATTG	60	-
GTTTTAGTATTAGTTGTTAAGATTG	61	-
GATTGTATATTTGAATGTTTGTTTG	62	14
TGAAATTGAAAGTGTAAATGTTGTAT	63	-
GATTGTATTTGTGTGAGAAATAGAAATA	64	-
AAATTTTGAGATTTTGTGTATAGAGTA	65	-
GTAATTTAGATTTTGTTTGTGTGT	66	-
GTTTGTATTTGTTAGTGAATATAGT	67	-
ATGTAGTAGTAGTAGATTGTTTATGAAAT	68	-
TGTTTAAAGATGATTGAAAGAAATG	69	-
TGTGATAAATGATGTTATTTGTGTA	70	-
ATAGTTGTGTGAGAAATTTGTAAATTAG	71	-
ATAGATGTAAAGAGAAATTTGTGAAA	72	-
AGATTAAAGAGAAAGTTAATAGAGTA	73	-
GAAAGTAAAGATTGTGAATGAAAGAAA	74	-
AATGTAAAGAAAGAAAGATTGTTGTA	75	-
TTTGATTTTATGTGTTATGTTGAGT	76	-
GTATTTGAGAAATTTGAAGAAATGAA	77	-
GAAATTGTATGAATAATGAATTGTAAG	78	-
TATTTGTAGAAAGTAAAGTTAGAAAGT	79	-
TTTATATGTAAATGATAAAGTGTAGTTG	80	-
ATATATAGTTTGAAATTTGTGTATAGTGT	81	-
ATAAGAAATTTAGAGAGTTTGTAAAG	82	-
GAAATTGTGAAATGTGATTGATATA	83	-
AAATAAAGTAGTTTAAATGAGAGAAAG	84	-
GATTAAAGAAAGTAAAGTGAAATGTTT	85	-
TATGTGTGTGTTGTTTAGTGTATTATA	86	-
GAGTTTATATGTAGTTTAGAGTTATA	87	-
GAAAGAAAGAAAGTGTTAAGTTTAAA	88	-
TAGTATTAGTAAAGTATGTTGATTGT	89	-
TTGTGTGTGATTGAATATTTGTGAAAT	90	-
ATGTGAAAGAGTTTAAAGTGATTAAA	91	-
GATTGAAATGATTGAGATATGTAAA	92	-
AAGATGATAGTTTAAAGTGTAAGTTA	93	17
TAGTTGTATTATGAGAAATTTAGAAAG	94	-
TTTATATAGTGAATTTATGAGTGAAAG	95	-
GATAGATTTTAGAAATGAATTTAAGTG	96	18
TTTGAAGAAAGAGATTTTGAATAATTGA	97	-
ATGAATAAAGAGTTGTATAAATGTGA	98	-
TGTTTATGTAGTGTAGATTGAAATT	99	-
TTTAAAGTGAGTTATAGAAAGTAGTA	100	19
GATTTTATGTGTTTGAAGTTAAGAT	101	-
TAGTTAGAGAAAGTGATAAAGTTA	102	-
GTAAATGATAAATGAAGTGATATATAG	103	-
AATGAAGTGTTAGTATATAGATAGTA	104	-
TAAATTGAGTTTGTTTTGATTGTAG	105	-
TAAATGAAGAAATAAGTATGAGTGT	106	-

Table II

Sequence	SEQ ID NO:	No. in Ex 4
A A A T G T A A T A G T G T T G T T A G T T A G	107	-
A G A G T T A G T G A A A T G T T G T T A A A T	108	-
G A A A T A G A A A T G T A T T G T T T G T G A	109	-
A G T T A T A A G T T T G T G A G A A T T A A G	110	-
G A G T T T A T A G T T T A G A A T A T G T T G T	111	-
A G A G T T A T T A G A A G A A G A T T T A A G	112	-
G A G T T A A A T G A A A T A A G T A T T T G T G	113	-
A T G A T G A A A T A G T T G A A G T A T A T A G	114	-
A T A G A T A T G A G A T G A A A G T T A G T A	115	-
T A T G T A A A G A A A G T G A A A G A A G A A	116	-
T G A A T G T A G A A A A T G A A T G T T G A A A	117	-
A A T T G A A A T A G T G T G T G A G T T T A A T	118	-
A G A T A T T T G T T T T G A T T A A T G A A G A G	119	-
A A A G T T T G T A A A G T T G A A G A T A A A G	120	-
G T T A A G A G A T T A T G A G A T G T A T T A	121	-
A G A A G A T A T A A G A A G A T T G A A T T G	122	-
G T A G A A A A T T T G A A T T G A T G T G A A A	123	-
A A G A G T A G A T T G A T A A G T A T A T G A	124	-
T G A T A T A G T A G T G A A G A A A T A A G T	125	22
A G A T A A A T G A T G A G A A A T G A A G A T A	126	-
A T G T G A A A G T A T T T G T G A T A T A G T	127	-
A A T A A G A G A A T T G A T A T G A A G A T G	128	23
T A A G T G T A T T T A G T A G A A T G A A G T	129	-
T A T G T T A G A T T T T G T T G A G A T T G A T	130	-
A G T T T G T A T G A A G A G A T A G T A T T T	131	-
G A G A A A T G T T A T G T A T T T A G T A G T	132	-
T A T G T G A G A A T G T G T T T G A T T T A A	133	-
G T A T G T T T T G T T T A T A G A A T G T A T G	134	-
G A G T A T A T A T A G A A G A A A G A A A T T T G	135	-
A T G A G T G A A A G T A A A T G T A G T T A T T	136	-
T T A A G A A A G T G A G T T A T T G T G A T A T	137	-
A T G A A A T G A G A A T A T T G T T G T T T G	138	-
G A T T A A A T G A T T A T G T G A A T T G A T G	139	-
G A A A T G T T A A A G A T A T G A A A G T A G	140	-
T A T T T G T T G A T T T T G A T A T T A G T G T G	141	-
T T T A T G T T T T G T G T A T G T A A G T A G T	142	-
A A T T G A A A G A A T T G T G T G A A T T G A	143	-
T G A G T T T T G A A T T T G T T T G A G T A A T	144	-
G A T G T T A T A A T G A T G T G T G T A A A T T	145	-
A T G T G A G A G A A G A A A T T T G T T T A T T	146	-
G T G A T A A A A G T A T T G T T G A T A G A A A	147	-
G A A G T A G A A A T A G A A A G T T A A T A G A	148	-
T T G T G T A G T T A A A G A G T T G T T T A A T	149	24
T A G T A G T A A A G T T G T T A G A A T A G T T	150	-
A A T T T T G A A A G T A T A A T G A A T G T G T G	151	-
T A G A A A A T T G T A G T A T T T T G A G A G A A	152	-
T G T A T A T G T T A A A T G A G A T G T T G T A	153	25
T A T T T T G A T A A G A G A A T G A A G A A G T	154	26
T T G A A T A G T G T A A A T G A A T A T G A T G	155	-
G T A G T T T T G T G A A A T A G A A T T A G T T T	156	-
A A A G A T G A T T T G T A A T T T G T G T G A A	157	-
G A A G A T T T G T T G A G T T A A T A G A T A A	158	-
A G A T T A T G T A G T G A T G T A A A T G T T	159	-
G A A T T T T A G A T G T A G A T A T G A A T G T	160	-

Table II

Sequence	SEQ ID NO:	No. in Ex 4
G A T A G A A G T G T A T T A A G T A A G T T A	161	-
T A T G A A T T A T G A G A A G A A T A G A G T	162	-
T T T G T T A T G A A G T G A T T T T G T T T G T	163	-
G T A A A G A T T G T G T T A T A T G A A A T G	164	-
T T G T G A T A G T A G T T A G A T A T T T G T	165	28
G A A T T A A G A T A A A G A A G A A G T A	166	-
G A T T G T A G A A T G A A T T T G T A G T A T	167	-
A A A T A A G A G A G A G A A T G A T T T A G T	168	-
A A T T A T G T G A A T A G A T T G T T G A A G	169	-
T T A A G A T T T A T G T G A T A G T A G A G T	170	-
T T A A A G A T A G T G T T T G T T G T G T T A	171	-
T A T T G A T T T A T G A A G A G T A T A G T G	172	-
A A A T T T G A T G A G T A G T T T A A G A G A	173	-
A T A A A G T T G T T T G A T G T T T G A A T G	174	-
G A T T G T G A T G A A T A A T G T T A T T G A	175	-
G A T G A A G A A A T A T G A T A T G A A T A G	176	-
T T A A A G T T A T T G A A A G T G A A G T T G A	177	-
T T G T A A G A A A T A G A G A T T T G T G T T	178	-
G A G A T T G A G T T T A A G T A T T A G A T T	179	-
A G T G A T A A T A G A A T G A T A A A A T G T G	180	-
G A T A A T A G T G A A T T T G A A G T T G T A T	181	-
A G A T A T T T G T A G T A G A A G T A T G T	182	-
G T T A T G A A T G T T G A A T T T G A A T G T	183	-
A T G A A A G A T T T A G T T G T G A G A T A T	184	30
A A A T A G A G A A G T T A T G A T G T G A T A	185	-
T T A G T G A G A A A T G T T T A A A T G T G A T	186	-
T G A A G A A T A T G T G A A A T T A G T T T G	187	-
G T T T G A T A G T T T A A T G A G T A T T G A	188	-
G T T G T A A G T A A T G A T A A A G T A T G A	189	-
T A A G A G T A G T A A T T G T T G T T T A G A	190	-
T T T G A G A G A G T A T G T A T G A T T A T T	191	-
A T T G A T T G T G A A T T A G A T A G A A G A	192	-
G A T T A G T A T T T A G T A G T A A A T A G A G	193	31
T A T G T A T T A G A G A T A T T G A A A A G T G	194	-
T A T G T G A A A G T A A T G A T A A A A T G A G	195	-
G T A A T T A G T A A A G A T T T G A A A T G A G	196	-
G T T T A T T G T A A A G A T G T A A G T G A A	197	-
T A G T A G A A T T G T T G T T A A A G A A T G	198	32
T A T T G T T A G T T A T G T A G T G T G T A A	199	-
G A G T G A A A G T T A T A T G A A A G T A T A	200	-
A T A T A G A A G T T G A T G A G T T T A T G A	201	-
T T T A G A A G T A A G A A T A A G T G A G T A	202	-
T G T G T A T A A G A T A T T T G T A A G A A G	203	-
T A G A A G A G T T G T A T T G T T A T A A A G T	204	-
G T G T T A T T A G T T T A A A G T T A G A G T A	205	-
A A T A T A G T G A T G T G A A A T T G A A T G	206	-
T T A G A G A A T A G A G T G A T T A T A G T T	207	-
G A A G T G A G T T A A T G A T T T G T A A A T	208	-
A A T G T A A A G T A A A G A A A G T G A T G A	209	33
G T T A G T T A T G A T G A A T A T T G T G T A	210	34
A A A T G A G T T A G A G T A G A A T T A T G T	211	-
G A T A T A G A A G A T T A G T T A G T G A T A	212	-
A T A G T T T G T T G A G A T T T A T G A G T A	213	-
T A G A A T A G T T A G T A G T A A G A G T A T	214	-

Table II

Sequence	SEQ ID NO:	No. in Ex 4
G A A T T T G T A T T G T G A A G T T T A G T A	215	-
G T A G T A A G A A G A G A A T T A G A T T A A	216	-
A A T G T G T T A T G T A T G T A A A T A G T G	217	-
G A A T T A G T T A G A G T A A A A T T G T T T G	218	-
G A A A T T G A A G A T A G T A A A G A A A T G A	219	-
G T G T A T T A T G T G A T T T A T G A T A G A	220	-
T A T T A T G A G A A A G T T G A A T A G T A G	221	35
T A T G T A T T G T A T T G A G T A G A T G A A	222	-
G T G A T T G A A T A G T A G A T T G T T T A A	223	36
A G T A A G T T G T T T G A T T G A A A T T T G	224	-
G A A G T T T G A T T T A A G T T T A A G A A G	225	-
G A G A A G A T A A A T G A T A T T G T T A T G	226	-
A T G A T G A G T T G T T A A T A G T T A G T T	227	-
T A T G A T A T T T G A A G A G T G T T A A G A	228	-
G A G A T G A T T A A A G T G A T T T A T G A A	229	-
A T A G T T A A G A G T G A T G A G A A T A A A	230	-
T T T A T T G T T A G A T A A A G A G T T G A G	231	-
A G A A T A T T G A T A G T T G A A G T T G A A	232	-
T A G T G T A A A G T G T A G A T T G T A A A T	233	-
A G T A G T G A T A T G A T T T G A A T A T T G	234	-
T G T A T T G A A T T A G A A T A G T G A G A A	235	-
T G A T A T G A G A T A G A A G T T T A A T G T	236	-
G A A G A A G T A A G T A T A A A G T A A A T G	237	-
T T T A A G T G T G A T A A G A A A G A T A G A	238	-
T A T T G T T G A A T G T G T T T A A A G A G A	239	38
G A A T A A T G A T G A G A T G A T T A T T G A	240	-
T A G A G A A A G A G A G A A T T G T A T T A A	241	39
A T G T A T A A T G A G A T A T G T T T G T G A	242	-
A A T A G A T A A G A T T G A T T G T G T T T G	243	40
T T T G A T G A T A A T A G A A G A G A A T G A	244	-
A G A T G A A T A A G T T G T G A A T G T T T A	245	-
A G A T G A A A G A A A G T G T A G A A T A T T	246	-
T G T T A A A T G T A T G T A G T A A T T G A G	247	41
T A G T A G T G T G A A G T T A T T T G T T A T	248	-
A G T G A A T G T T T G T A A A G A G T T T A A	249	-
G A T A A A T G A A A A T T G A A G T A A T T G T	250	-
T G A T G A G A A A A T T G T T T A A G T G T T T	251	-
A A A T A A G T A G T G T G A G T A A T A G T A	252	-
T A T G A A A T A T G T G A T A G T A A G A G A	253	-
A T T G T A A G A G T G A T T A T A G A T G A T	254	-
A G A G T A A G A A T G A A A G A G A T A A T A	255	-
T A A G T A A G T A G A T G T T A A A G A G A T	256	-
A A A T A G A A A G A A T T G T A G A G T A G T	257	-
A T A G A T T T A A G T G A A G A G A G T T A T	258	42
G A A T G T T T G T A A A T G T A T A G A T A G	259	43
A A A T A G A A T G A G T A G T G A A A T A T G	260	-
T T G A A T T A T G T A G A G A A A G T A A A G	261	-
T A G T A A A T T G A G A G T A G T T G A A T T	262	-
T G T A A A G T G T T T A T A G T G T G T A A T	263	-
A T A T G A T T T G A G A T G A G A A T G T A A	264	-
A A T A T T G A T A T G T G T T G T G A A G T A	265	-
A G T G A G A T T A T G A G T A T T G A T T T A	266	44
T T G T A T T A G A T A G T A G A T T A T G	267	-
A T A G A A A T G A A A G A T A G A T A G A A G	268	-

Table II

Sequence	SEQ ID NO:	No. in Ex 4
G A T T G T A T A T G T A A A G T A G T T T A G	269	-
T A T G A A T G T T A T T G T G T G T T G A T T	270	45
G A T A T T A G T A G A G T A A A G T A T A T T G	271	-
T G A G A T G A A T T T G T G T T A T G A T A T	272	-
T A T G A A T G A A G T A A A G A G A T G T A A	273	-
G A G T G A A T T T G T T G T A A T T T G T T T	274	-
A G A A A T T G T A G A G T T A A T T G T G T A	275	-
G T G T T A A T G A A A G T T G T G A A T A A T	276	-
T G T G A T T T G T T A A G A A G A T T A A T G	277	-
A G T A G T A T T G T A A A G T A T A A A G A G	278	-
T G A T T G T T G T A T A G T T A T T G T G T A	279	-
G A T T G T A G T T T A A T G T T A A G A A T G	280	-
A T G A A A T A A G A A A T T G A G T A G A G A	281	-
T A T G A T G A T A T T T G T T G T A T G T G T	282	-
T T T A G A G T T T G A T T A G T A T G T T T G	283	-
A A T A A G A G A T T G T G A T G A G A A A T A	284	-
A A T G A A T A G A A T A G A G A A T G T A G A	285	-
G T A G T A G T A A T T T G A A T G T T T G A A	286	47
A G T G A G T A A T T G A T T G A T T G T T A A	287	-
G A A T A A T G T T T A G T G T T T G A A A	288	-
A A T A G A A A G T A G A G A A A G T G T T A T	289	-
T G A G T T A T T G T A T T T A G T T T G A A G	290	-
T A G T T G A G T T T A A A G T T G A A A G A A	291	-
T A A A G A G T G A T G T A A A T A G A A G T T	292	-
T G T A G T G T T T A G A G T A A G T T A T T A	293	-
A G A G A T T A A T G T G T T G A A A G A T T A	294	-
G T A A T A A G T T G T G A A A G A A G A T T A	295	-
G A G A T G T T A T A G A T A A T G A A A G A A	296	-
T T T A G T T G A T T G T T G A A T A G A G T A	297	-
A T T A T T G A A A G T A G A T G T T A G A T G	298	-
T T T A T G T G T G A T T G A G T G T T T A A T	299	-
T A T T T A G T T A G A T A G A T A G A G A G T	300	-
A T G T G T T T A T G T G A A A G A T T T G T A	301	-
A T A G T A A T T A G A A G A G A A G A A T G T	302	-
T A T G A G T G A T T T A G A A T T G T A T T T G	303	-
T T A A T G T A T T G T T T A A A G A G T G T G	304	-
A T A G A G A A T T A A G A A T T G T T T G A G	305	-
G T T A T A A G T A G A A A T G T A T A G A A G	306	-
A G T A A T T A G T T T G A A A T G T G T A G T	307	-
G A A A G A T T A T G A T T G T A A A G T G A T	308	-
G T A A G A T T A G A A G T T A A T G A A G A A	309	48
G A G A A T G T T G A A T A A G A A G T A A T T	310	-
T T A A G A G T G T T T G A A T A G T G T T T A	311	-
A T A A A G A A A G A G T A T G A G A T T A T G	312	-
A G T T A T T G A T T G A A G A T G A G A A A T	313	-
G T T T G T G T T T G T A T A A G T T G T T A A	314	50
T T G T A T G T G A G T T T A G A T T A A T G A	315	-
T A G T T A A A G T A T A G T T G T T T G A G T	316	-
A A A T T T G T G T T G A G A T T T G T A T A G	317	-
T A T T A G T G T T A T G A T A A A G A G A A G	318	-
T A T A A G A A G A G T A A T T T G A G A A G A G T	319	-
T A A G T T G A G A T G T T T G T T T G A T A A	320	-
G T G T A G A T T T A T G A A T T G A G T A A T	321	-
T A T A G A G A A G T G T T T A G T T G T A T A	322	-

Table II

Sequence	SEQ ID NO:	No. in Ex 4
ATAAAGAAAGAAATAGTTTGTGTGTGTATA	323	-
AGATTGTGAAATAAGATTAGAAAGTTTG	324	-
GTTGTATTATAAGAAATAGTTTGTGTG	325	-
AGAAATAGAGTAAAGAGTTGTTTTAAA	326	-
AGAGATAGTAGTAAATAGTTATTG	327	-
AAATGATTGTGTAAAGTTATGTATG	328	-
AAGAAAGTAAAGAGAGAAATTTGAAAT	329	-
GTGTGTATTTTAGTTTGAATAATTGAT	330	-
ATTGTTTGTTTGTGTGAGAAATGTATT	331	-
AGATAAAGTTTAAAGTAAAGAGAAATG	332	-
TAGTTTGAAGTTTAGTTTAAAGTGTTA	333	-
AGTAAGAAATGTAAATATGATGATAG	334	-
ATGAGATTGTAAAGATTTTATGAATG	335	-
TGATTGTAAATTAGAGAGAAATGTATA	336	-
AGTTAGTAAAGAGAAATATAGTGAAT	337	-
ATTAAAGATTGTATAGTTTAGTGAATG	338	-
GAGATAAAGAAATTTGAAATAGAAAGA	339	-
AGAGTAAATGTTTAAAGAAAGAAAGTT	340	-
AAAGTTTGTTTATGTGTGAAGAAATT	341	-
ATTGTGTTTAAAGAAATATGATGAG	342	-
TATTGAAATGAGATGTATGTAGTT	343	-
ATTTGTGTGATGTTTGAATAATGA	344	-
TAAGATAAATAGTGAAGAGAAATTTGA	345	-
ATTTATGATTAGTGTAAAGTGTGTGT	346	-
GATTAAAGAAATAAAGTGTGAAGAAAT	347	-
GTAATTGATGAAGAGTTAGTTTAT	348	-
TGTGTTATGTTTATAAGAAAGTGATA	349	-
AGAGAAATTTGAATTTAGAAATGTG	350	-
TTATTGAATGTGAGAAAGTATTTTG	351	-
TGTTAAATGAGAAAGATAAATGATAGT	352	-
GAAAGTATTTTGTGTGATTATTGTGTG	353	-
TAGTTTATGTTAGTTTAAATTTGTGTGAG	354	-
GTTGAAAGATAGTTTGTATATGTAT	355	-
TTAGAAGATAGATTATTTGAGAAAG	356	-
AATAGATGTTGTGAATAGATGTGA	357	56
AGTAAGAAAGTTTAAAGTTTAGTTAG	358	-
TAGTTTAAATGAGATGTTTGTATATG	359	-
TTAAAGATGTTTAAAGAAATGAGTGA	360	-
AAAGTGTGTATATGTTTAGAAAGTA	361	-
ATTAAAGTTATGTTGTTTATGTTGTG	362	-
TTTGAAGAAAGTGTTTGTATTTATGT	363	-
TGTTAAAGAAAGTTTAGTTTAAAGTTG	364	-
TTTAAAGTATAAAGATTGTGTGAGAT	365	-
AGATATTTTGTATAGATAGAAAGAAAG	366	-
ATTTAGAGTTTGTAAAGAAATATTG	367	-
GAGAAATTTGTAAATTTGTTAGAGTAT	368	-
GAAAGTATATGTTTAAAGATGTAAATAG	369	-
AATATTGAAAGATGTAGTGAAGTTAT	370	-
GAGTTTTAGAAATGATAAAGAAATTG	371	-
TAGAAATGAGTTTATATGTTTGAGGA	372	60
TTGATATTAAGAAAGTTGTGATTAAGT	373	-
AAGTGTTTTAAATGTAGAAATGAA	374	61
GTTGTGAGAAATGTAGAAATAGTATA	375	-
TTTAGTTTGAATGTGTTTATGAGAT	376	-

Table II

Sequence	SEQ ID NO:	No. in Ex 4
G T A A T T G A A A G T A T G A G T A G T A A T	377	-
T A G T T G A A T A A G A T T G A G A G A A A T	378	-
T T A A G T G A A G T G T T G T T T A T T G A A	379	-
A T T G A T T T T G T T G A A A T A A G T G T T G	380	-
T G A A T T G T T G A T A A G T T A T G A A G A	381	-
G T T T G T T A T T G A G T A A G T T G A A T T	382	-
T G A T T T A G T A T G T A T T A G A G T T G A	383	-
T A A A T A G A G A T G A G A A T A A G A A A G	384	-
A G A A T G T T A T A T G T A G A G A A A T T G	385	-
A T T T A T G T A G T T T G A G A G T G A T A A A	386	-
G T A A A G A T A G T T T T G A G T A A T T T G A	387	-
G A A A T A G T A T A A T G T T A A G T G A G A	388	-
A T T G T A T A T T G T G T T G A A G A A A G T	389	-
G A G T T A A G T G T A A A T G A A A T G T A A	390	-
A T A G A T T G T G T G A A A G A A A G A A T T	391	-
T T A A T A G A A G T T T G T A G T A T G A T G	392	-
T T G T A T G T G A G A A T A A A G T T T A G T	393	-
G T G A T T A G A T A T G A T G A T A T G A A T	394	-
T G A A G A A G A A T T T A G A T T T G T A A G	395	-
T G T A T G A T T A T T G A T T A G T G T G T T	396	-
T G T G A A A G A G A A T G A T A G A T A T T T	397	-
A A T T G A A A T G A A G T G T T T A A G A A	398	-
A T T A T A G A G T T A G T T T A G A A T G A G	399	-
A A A G A T A G A A A T T G A G T G T A T G A T	400	-
G T A G T T T G T T A A T G T T G T A T A A T G	401	-
A G A G A T A T T A G A A T G T A A G A A T A G	402	64
A G A A G T T T T G A A A T A T G A T A G A A T G	403	-
T A G A A T G T A A A G T T T A G T A T A G A G	404	-
A G T A G A T G T A T G T T A A T G T G A A T A	405	-
T G A A A G T G A A A T A T G A A A T G T T G T	406	-
A T A G T A T A T T G A G T T T G T A T G A A G	407	-
G A A G A A A T G T T T G T A G A A T A A G T A	408	-
A A T G A G T A T T G A A G A A A T G T A T A G	409	-
G T G A T A G A A T T T G T G T T T A A T G A A	410	66
T G T A G T A T G A A G A A T A A T G A A A T G	411	-
A T A G A A G T T A A T G A T A A T T G T G T G	412	-
G T G A T T G T A A G T A A G T A A A G A T A A	413	-
T A T G T A G T T T G T G T T A T T T G A A G A	414	-
T G A G T A A G T T T G T A T G T T T A A G T A	415	67
T A A A T G T A T G A G T G T G T A A A G A A A	416	-
G T A A G A G T A T T G A A A T T A G T A A G A	417	68
G T T G A G T G T A A A G A T T A T T G A T A A	418	-
A G T A T G A G T T A T T A G A T A A A G T G A	419	-
A T T T G T T A T A G A G T T G T G T T G T A T	420	-
T A A T T A G T A G T G T G T T G A A A T T T G	421	-
T G T A T T G A G A T T G T T A T T G T A T T G	422	-
G T T A T T A G A A G A G A T A A T T G A G T T	423	-
T T G A G T T G T G A T T A A G T A G T A T A T	424	-
G A T A G T A T A A T G A T T G A A G T A A T G	425	-
G T G A A A G A T A T T T G A G A G A T A A A T	426	-
A G T T A T G A T T T T G A A G A A A T T G T T G	427	-
G T A A G T A T T T G A A T T T G A T G A G T T	428	-
T A A T A G T G T T A T A A G T G A A A G A G T	429	-
A A A T G A A T T G A T G T G T A T A T G A A G	430	-

Table II

Sequence	SEQ ID NO:	No. in Ex 4
A G A A A G T G A G T T G T T A A G T A T T T A	431	-
T T T A T G T G T G A A T T G T G T A T A T A G	432	-
G T A A T A T G A T A G A A A T G T A A A G A G	433	-
G A G A A T T G T T T A A A G A T A G T T G T A	434	-
G A A T T T G T T A A A A T G A G T T T G A T	435	-
A T A G T G A T G A T T A A A G A G A A T T T G	436	-
A T A G A T G T T T A G T T G A G A T T A T T G	437	-
A A G A G T G T A A A T A G A A A G T G A T A T	438	-
T G T G T A T T G A T T G T T G A G A T A A A T	439	-
T A G T A T A G T G A G A A A G A G T T A A A T	440	-
A A A G A T A A G A A A G A G A T G A T G T T T	441	-
G A A G T T A T T G A A A T A G A G A A G T A T	442	-
A T G T A T G T A T A G A A A G A G T A A A T G	443	-
G A T G T T T G T A A A G A T T G A A A T T G A	444	-
A A T T T T A G A G A G T A T T T G T G T T G T A	445	-
A A T T T T G T T T G A A A G A A A G T A A G T G	446	-
A A A G A G T A G T G T T A T T G T T A G A T A	447	-
G T A T G T T G T A T A T G T T G T T G A T A T	448	-
G T A G A A T T T T G T T G A G T A T T T T G T A A	449	-
A T G A A T T T A G T T A G T G T A A G A A A G	450	-
A T G A T A A G A A A T A G T T G A A A G T A	451	-
T T G A T G A T G A A G A T A A T G T A G A T A	452	-
A G A T G A T A T G A T A T A G A T T A G A T G	453	-
T T G A A A G T T A G A A A G A T A G A T G T T	454	-
G T T T A A T G T T A G T T A G A A A G T A A G	455	-
G A G A T T T A A G T T T G A A G T G A A A T A	456	-
T T T G T T A G T A G T T T G T T A T A A G A G A	457	-
T A T G A G A A T A G T T T T G T T A G T G A A T	458	-
T T G A A A G T T T A A A G A A G A G A T A A G	459	-
A A G T G A G T T G A A A A T G A A A T A T G T T	460	-
G T T A G A A A T G A A A A T G A G T A G T T A T	461	-
T A A G T A T T G T A T T T G T G T G T G T A T	462	-
T G T A T T A G T A A A G A A G A G A G A A T A	463	-
G A G A A G A G A A A A T A A G T T G A A A T A A	464	-
G T A A A G T A G A A A T A G A A T T G A G T T	465	-
G T G T G T T A T T T T G T T T G T A A A G T A T	466	69
T T T G A T G T A T G A A T A T A G T A T G A G	467	-
A A G A T T G T G T G A A T A G T T G A A A T T	468	-
T A T A A A G T T T G A A G A T G A G T G A T A	469	-
A G A T A A A G A G A T T T A A G A T G T A T G	470	71
G A A G A A T T A A G T T G A G A A T T A A G A	471	-
T A G A G A A A T T T G A T A A A G A A A G A G	472	-
A A A G T T T A T G A A G T T A T T G A G T A G	473	-
A A A T A G T G T A A G T A A A G A G A T G A T	474	-
T A T G A T G A T T T A G T T A T A A G A G T G	475	-
T A G A T A A A T G T T A T G A T G A G T A A G	476	-
A G A T T G A T T G T G A T G A T T T G T A T A	477	-
T T A A G A A G A A T T G T A T A T G A G A G T	478	73
G T A G A A T G T T T A G A G T T G A A T A T A	479	-
G A G A A A T A G T A A G A A G T A A A T A G A	480	-
A T T G A A A G T G T T A T G T G A A A G A T T T	481	-
T A A A T G T T G T T A G A G T A A A T T A G A	482	-
A A A T A A G A G T T T G A G A A G T T G T T T	483	-
A G T T G T A A T A A G A A G T G A T T T A A G	484	-

Table II

Sequence	SEQ ID NO:	No. in Ex 4
G T T A G A A T G T A T A T A G A G T T A G A T	485	74
T T G A T A T T G A A A G A G A A A G T T A T G	486	-
T T A A A G A G A G A A A T G T T T G A T T A G	487	-
T G T G A A T T T T G A G T A T T A G T A A G A A	488	-
T A A T T T T G A A T G T G A A A G T T G T T A G	489	-
A T G T G T T T T G A A A G A T G A T G A T T T A	490	-
A A G T T A T G T T G A T A T T G A G T G A A A	491	-
T A G A T A A A G A A G A T A G A G A T T T A G	492	-
G A T G A A T G T A G A T A T A T G T A A T G A	493	-
G A A G A A T A G T T T A T G T A A A T G A T G	494	-
G T A G T A T A T A G T T A A A G A T G A G T T	495	-
G T T A T T T T G T G T A T G A T T A T G A T T G	496	-
A G A G A T T A G A A A T T G A G A G A A T T A	497	-
G T A T G A T A G A G T T T A T A G T G A T A A	498	-
G T T A G A A A G A A T G A A A T T G A A G T A	499	-
A A G A A T G A G A A T A T A G A G A T G A A T	500	-
A A A G A G A A T A G T G T T T A A G A A G A T	501	-
G A T G T G T T A T T G A T A G A A A T T A G A	502	-
T A G A G T T A T A G A G A T A T T G T A T G A	503	-
G A G A G T T G A A T A A G T T A A A G A T A T	504	-
A G A T A T G A A A T A G A T T G T T A G A G A	505	-
G A G T G A A T A G A A A G A T A T G T T A A T	506	-
A A A G A G A T A T T G A A G A G A A T A A A G	507	-
G T T A T A G A A T A A G T T G T A A A G T G T	508	-
T G A T A G T A T G A T A A T G T G T T T A T G	509	-
T T T G T T G T T A A G T A T G T G A T T T A G	510	77
T A A A G T G T T G T G T T A A A G A T T A A G	511	-
T G T G T T T G A T T G A T T A A T G T T A T G	512	-
A T T A A T G A A T G A G T G T T G T A A T G T	513	-
T A G A T G T T T G T G A G T T T G A T A T T A	514	-
G A A T G A A T A G T A A T A G A T G A T T T G	515	-
A A T A G T G T G T T G T T A T A T G A T T A G	516	-
T A G A T T A G A A G A T G T T G T G T A T T A	517	-
A A T G T G T G T G T T A A A T G A A T T T G T	518	-
G A A T T A A G T A T A T G A G T G T A G A A A	519	-
T T A T T G T G T G T A A G T A G T G T A A A T	520	-
G T A G T A A A G A G A A T T G T T T A G T A T	521	80
A A G T T T G T A A G A A G T A G T T G A A T A	522	-
A G T T A T A G T A T A G T A G T A T A G A G A	523	-
G A A A G A A A T G T G T A T A G T T T A A T G	524	-
T T G T G A G T A A T G A A T G A T G T A T T A	525	-
G T A G A G T T G T A A A T A G A G A A T A A A	526	-
A T T A A T G T A G A T T G T A A A G A G A T A G	527	-
T T A G T G T G T T T G T A G A T A G A A T T A	528	-
A G A G A G T T T G T G T A T A T G T A T A A A	529	81
T T A A G T T T A G T G A G A T T T G T T A A G	530	-
A T G A A G T T T A T T G A A T A G T A G T G A	531	-
A T A T T T G T T G T T G T A T G A T T T G T G A A	532	-
A A A G T G T T T A T A G A A G A T T T G A T G	533	-
A A G A G A T A T G A T T T G T T A G T T G T A	534	-
A A G A A G A A A T G A G T G A T A A T G T A A	535	-
T A G T G T T T G A T A T G T T A A G A A G T T	536	-
G T A G A A A G T G A T A G A T T A G T A A T A	537	-
G A T A A A T G T T A A G T T A G T A T G A T G	538	-

Table II

Sequence	SEQ ID NO:	No. in Ex 4
AGATTAGAAAGAAATTGTTTAGAAATG	539	-
ATATTTTGAGAAAGTGTGAAATGAAAT	540	-
TGAGTAAATAGTTTATGAGTAGTA	541	-
TTAGAGAGTAGATAAAGATTGAT	542	-
ATTGTTTAAAGTTGTGTGATAAGATG	543	-
GTTGTAAAGTTAAAGTGTGAAATTT	544	-
ATAGATTGTGTGTGTGTATAGTA	545	-
GTAAGTTTATTGAGAAATGATAAATAG	546	-
TAGATTAGTTGATAAAGTGTGTAAT	547	83
AAATGTAAATGAAGAGTGTGTTGTT	548	-
GATAGAAAGAAATGTATATAGTGAT	549	-
TATAGAGTGTATGTATATGATAAAG	550	-
TATGAAGTGAATAAGATGAAGAAAT	551	-
TGTTTGAGAAATAGTAAGAGAAATTTA	552	-
TAGATAAATGTGAAGTAATAAGTGA	553	84
GTATTATGATGATAGTAGTAAGTA	554	-
AGATATGATTTAGTATTGAAATGTG	555	-
AATTAAGTTTTGTAGAGTGAATTTGA	556	-
AAGAAATAGATGTAGTAAGATGTT	557	-
TTGAGAAAGTTGTGTGTAATAAGAAAT	558	-
AGTGTGAAATAAGTGAAGTTTAAAA	559	-
TTTATGTAGTATTTATGTTGAAG	560	-
ATTAATGAGAAATTAGTGTGTTAG	561	-
ATGTTAATAGTGAATAGTAAGTGA	562	-
TATGTTTGATAAAATGATTATGAGTG	563	-
TTATTAGAGTTGTGTGTGATATAT	564	-
TGTTTGTTATGATTGAGTTAGAAATA	565	-
AAATTTGAGTTTAAAGAAAGTGTAA	566	-
AAAGATAAAAGTTAAAGTGTGTTGTAG	567	88
TGTTTGAGATGATAATTGTATAAGTT	568	-
TAAATAAGTGAATGAGTTATAGAGT	569	-
ATAGATGTTATGATAGTTAGTTAG	570	-
GTTAAGTGAAGATATGTATTGTTTA	571	-
TAAAGAAAGTAAAGTTTGTAGATGT	572	-
AAGAGAAAGTTTGTGATTGAATAAAG	573	-
ATATTGAGATGTGAGTTATATGTGT	574	-
AGTTTGAGTTTATGATATTGTGAAATA	575	-
ATGTTAATAATGAGAGATTGTGTATA	576	-
TAAATGTTTGATTAATTGTGAGAT	577	-
TAAAGAAATTGAAGTAAGAGTTATTG	578	-
AGAGATAGAAATTAAGTTTGTGAT	579	-
GAAGAAATGTTAAGAAATATGTAAG	580	-
TATTTGTGATTAAAGAAAGTTGAGAA	581	-
AGTTTAGAAATTTGTGTAGTAGAATT	582	-
AAAGTTTATTGTTGATGTTGTATTG	583	-
GAAATGAGTTTAAAGAGTTTATAGTA	584	-
AGTGAAAGATTGTATGTAGTATAAAA	585	-
AGTTTGAAATGAGTATTAAAGTAATG	586	-
ATGTGTATTATTGAGATGAGTAATT	587	-
AAATAGTGTGTTGATGAAGTTGTTAT	588	-
GTAGAGTAAAGATATATGTAGTTTA	589	-
GAGAGTATTTGTATGAATGATTATA	590	-
GAGTATAAAGTTTAGTGTATATTGA	591	-
ATAAATGTGATTATTGATGAGAGA	592	-

Table II

Sequence	SEQ ID NO:	No. in Ex 4
T T A G T T G T T A T G T G A G A G T A A T A A	593	-
A A A T G A G T A T A T T G A A T T G T G A T G	594	-
A A T T A G A A G T A A A G T A G A G T T T A A G	595	3
T G T A A G T T T A A A G T A A G A A A T G T G	596	5
G A A A T G A T A A G T T G A T A T A A G A A G	597	-
A A T G A G T A G T T T G T A T T T G A G T T T	598	-
A G T G A A T G T A A G A T T A T G T A T T T G	599	6
G T A A T T G A A T T G A A A G A T A A G T G T	600	8
T A T G T T T A A G T A G T G A A A T A G A G T	601	-
G T A T T G A A A T T G A A T T A G A A G T A G	602	-
A A T A T G T A A T G T A G T T G A A A G T G A	603	-
T G A A T A T T G A G A A T T A T G A G A G T T	604	-
T A G T G T A A A T G A T G A A G A A A G T A T	605	-
G T A T G T G T A A A G A A A T T T G A T G T A	606	-
A A T T G T T T G A A A G T T T T G T T G A G A A	607	-
A A T T G T T T G A G T A G T A T T A G T A G T	608	-
T A A T T G A G T T T G A A T A A G A G A G T T	609	-
T G T T G A T T G T A A G T G T T T A T T G T T	610	-
G A A A T T T G T G A G T A T G T A T T T G A A	611	-
T A A G A A T G A A T G T G T G A A G T G A A T A T	612	-
T A A G A G T G A A G T T T G T G A A A G A T A T	613	-
T T G T A T A T G A A A G T A A G A A G A A G T	614	-
T A G A G A G A A G A A G A A A T A A G A A T A	615	-
A T T T G A A A T G T T A A T G A G A G A G A T	616	-
T T G T G T G T A T A T A G T A T T A G A A T G	617	-
A T T G T T A G T A T T G A T G T G A A G T T A	618	-
T G T T T G T A T T T T G A A T G A A A T G A A G	619	-
T G T T A G A T T G T G T T A A A A T G T A G T T	620	-
T A T A G A G T A T T G T A T A G A G A G A A A	621	-
A A A T A G T A A G A A T G T A G T T G T T G A	622	-
T G A G T G T G A T T T A T G A T T A A G T T A	623	-
A G A A T T T G T T G T A G T G T T A T G A T T	624	-
G A T T G A A G A A A G A A A T A G T T T G A A	625	-
G A T A A T A G A G A A T A G T A G A G T T A A	626	-
G A T T T G A A A T T T G T A G T T A T A G T G A	627	-
G A T T T T A A G A A G A T G A A T A A T G T A G	628	-
T T T G A G A G A A A G T A G A A T A A G A T A	629	-
G A T T A A G A G T A A A T G A G T A T A A G A	630	-
T T T G A T A G A A T T G A A A T T T G A G A G	631	-
T G A A G A A G A G T G T T A T A A G A T T T A	632	-
G T G A A A T G A T T T A G A G T A A T A A G T	633	-
A A A T A A G A A T A G A G A G A G A A A G T T	634	9
G T T G T A A A G T A A T A G A G A A A T T A G	635	-
A G T G A T T T A G A T T A T G T G A T G A T T	636	-
A G A G T A T A G T T T A G A T T T A T G T A G	637	-
A T G A T T A G A T A G T G A A A T T G T T A G	638	-
A T G A A A T G T A T T A G T T T A G A G T T G	639	-
A T A T T G A G T G A G A G T T A T T G T T A A	640	-
A G A T G T G T A T T G A A T T A A G A A G T T	641	-
T A A T G T G T T T G A T A G A A T A G A G A T A	642	-
A A A T T A G T T T G A A A G T A T G A G A A A G	643	11
T T T A G A G T T G A A G A A A T G T T A A T G	644	-
G A T T G T T G A T T A T T G A T G A A T T T G	645	-
T G T T G T T G T T G A A T T G A A G A A T T A	646	-

Table II

Sequence	SEQ ID NO:	No. in Ex 4
A T T A A G T A A G A A T T G A G A G T T T G A	647	12
G T A T G T T G T A A T G T A T T A A G A A A G	648	15
T A G T T G T G A T T T A T G T A A T G A T T G	649	-
T G A T A A T G A A A G T T T A T A G A G A G A	650	-
G T A A G A T T G T T T G T A T G A T A A G A T	651	-
T T G A A T T A A G A G T A A G A T G T T T A G	652	-
A A G T G T T T G T T T A G A G T A A A G A T A	653	-
A G A G A G A T A A A G T A T A G A A G T T A A	654	-
A T T A T G A A T A G T T A G A A A G A G A G T	655	-
T T G T T G A T A T T A G A G A A T G T G T T T	656	-
T T T A T T G A G A G T T T G T T A T T T G T G	657	-
A G T G T T A A G A A G T T G A T T A T T G A T	658	-
G A G A A A T G A T T G A A T G T T G A T A A T	659	-
G A T A A G T A T T A G T A T G A G T G T A A T	660	-
T T T G A T T T A A G A G T G T T G A A T G T A	661	16
A A G T T A G T A A A T A G A G T A G A A A G A	662	-
G T A A A G T A T G A A T A T G T G A A A T G T	663	-
T A A T A A G T G T G T T G T G A A T G T A A T	664	-
A A A G A T T T A G A G T A G A A A G A G A A T	665	-
T T A G T T T G A G T T G A A A T A G T A A A G	666	-
T A A T A G T A T G A G T A A G A T T G A A A G	667	-
G A A G A T T A G A T T G A T G T T A G T T A A	668	-
T A A A G A G A G A A G T T A G T A A A T A G A A	669	-
T A A G T A T G A G A A A T G A T G T G T T A T	670	-
G A G T T T G T T T G T T A G T T A T T G A T A	671	-
A A G T A A A G A A A T G T T A A G A G T A G T	672	-
A T G A G A A T T G T T G T T G A A A T G T A A	673	-
T T A G A T T A G A G T A G T A G A A G A A T A	674	-
T A G T G A T G A A G A A G T T A G A A A T T A	675	-
T A A T G T A G T A A T G T G A T G A T A A G T	676	-
T T G A G A A A G A A T A A G T A G T G T A A A	677	-
T A A T G A G T G A G A T T A T A G A T T G T T	678	-
G T A T A A G A A A T G T G T G T T T G A T T A	679	-
G T G A A T G T G T T A A T G A A G A T A T A T	680	-
G A A A G T T A T T A G T A G T T A A A G A T G	681	-
T A G A A T T G T G T T T G A T A A G T G A T A	682	-
T G A T T T A G A T T G A G A G T T A A A T G A	683	-
A T T A T T G A G T T T G A A T G T T G A T A G	684	-
A T A G T A G T T A T G T T T G A T T T A G T G	685	-
A T A G A A G A A G A A T A A A G T T A G A G A	686	-
G A T G T T G A A A G T A A T G A A T T T G T A	687	-
G A G A T T G A T A G T A G A A A T G A T A A A	688	-
T G A G A G A A T A A A G T A T G A A T T T G A	689	-
T A T A A A G A T G A T G T G A A T T A G T A G	690	-
T T A T G T A A G A A T G T T T G A G A G A A A	691	-
A G T A A A T G A T G A A T G A T A T G A T G A	692	-
G A A A T T T G T G T T A A A G T T G A A T G A	693	-
G A T G A A T G A T T G T G T T T A A G T A T A	694	-
G A A A T A A G T G A G A G T T A A T G A A A T	695	-
T G T T G A A A T A G T T A T T A G T T T G T G	696	-
T T T G A G A G T A T A T T G A T A T G A G A A	697	-
A T T G T G T T G T A A A G T A A G A T T T A A G	698	-
T A T A G T T T G A A G T G T G A T G T A T T T	699	-
G T G A A G T T A T A G T G T A T A A A G A A T	700	-

Table II

Sequence	SEQ ID NO:	No. in Ex 4
G T A T G T T G A A T A G T A A A T A G A T T G	701	-
T T A G A A A G T G T G A T T T G T G T A T T T	702	-
T T T A G T A A T A T G T A A G A G A T G T G A	703	-
A G T A T G T A T A G A T G A T G T T T G T T T	704	-
A T T T A A G T A A A G T G T A G A G A T A A G	705	20
A T T T G T G T T G A A T T G T A A A G T G A A	706	-
A T G T T A T T A G A T T G T G A T G A A T G A	707	-
T A G T A G T A G A A T A T G A A A T T A G A G	708	-
T T T A A T G A G A A G A G T T A G A G T A T A	709	-
A A A G T T T A G T A G A G T G T A T G T A A A	710	-
A T A T A T G A T A G T A G A G T A G A T T A G	711	-
T G A G A A A G T T A A T T G T A T A G A T T G A	712	-
T A T A G A G A T G T T A T A T G A A G T T G T	713	-
A A A T T T G T T A A G T T G T T G T T G T T G	714	-
T T G T T G A A G A T G A A A G T A G A A T T A	715	-
A A G A G A T A A A G T A G T G T T T A T G T T T	716	-
A A T A A G A A A G A A G T G A A A G A T T G A T	717	-
T A A G T T A A A A G T T G A T G A T T G A T A G	718	-
A T A T A A G A T A A G A G T G T A A G T G A T	719	-
G T T A A A A T G T T G T T G T T T A A G T G A T	720	-
G A G T T A A A G T T A T T A G T T A A G A A G T	721	-
T A T T A A A G T T T T G A G A A T A A G T A G T	722	21
T A A T G T T G T T A T T G T G T T A G A T G T T	723	-
G A A A G T T G A T A G A A T G T A A T G T T T	724	-
T G A T A G A T G A A T T G A T T G A T T A G T	725	-
A T G A T A G A G T A A A G A A T A A G T T G T	726	-
A G T A A G T G T T A G A T A G T A T T G A A T	727	27
A T G T A G A T T A A A G T A G T G T A T G T T	728	-
T T A T T G A T A A A T G A G A G A G T T A A A G	729	-
A T T T G T T A T G A T A A A T G T G T A G T G	730	29
T T G A A G A A A T A A G A G T A A T A A G A G	731	-
T G T G T A A T A A A G T A G T A A G A T T A G A	732	-
A T G A A A G T T A G A G T T T A T G A T A A G	733	37
A T T A G T T A A A G A G A G T T T G T A G A T T	734	-
T G T A G T A T T G T A T G A T T A A A G T G T	735	-
A G T T G A T A A A A G A A G A A G A G T A T A T	736	-
G T A A A T G A G A T A A A A G A G A G A T A A T T	737	-
T G T G T T G A A G A T A A A G A T T T A T G A T	738	-
A A G A A G A G T A G T A G A A T T G A T T A	739	-
G A A T G A A G A T G A A G T T T G T T A A T A	740	-
A A A T T G T T G A G A T A A G A T A G T G A T	741	-
T G A T T G T T T A A A T G A T G T G T G A T T A	742	-
A T G A A G T A T T G T T G A G T G A T T T A A	743	-
G T G T A A A T G T T T T G A G A T G T A T A T T	744	46
A A T T G A T G A G T T T T A A A G A G T T G A T	745	-
T T T G T G T A A T A T G A T T G A G A G T T T	746	-
G T A G T A G A T G A T T A A G A A G A T A A A	747	-
T T T A A A T G T G A A A T T T G T T G T G A G T	748	-
G T A A A G A A T T A G A T A A A G A G T G A T	749	-
A A T A G T T A A A G T T T A A G A G T T G T G T	750	-
G T G T G A T G T T T A T A G A T T T G T T A T	751	-
G T A T A G T G T G A T T A G A T T T G T A A A	752	49
G T T G T A A G A A A G A T A T G T A A G A A A	753	-
A T A T T A G A T T G T A A A G A G A G T G A A	754	-

Table II

Sequence	SEQ ID NO:	No. in Ex 4
G A G T G A T A T T G A A A T T A G A T T G T A	755	-
T A A G A A G T T A A A G A A G A G A G T T T A	756	-
G A T G T T A G A T A A A G T T T A A G T A G T	757	-
G T G A T T G T A T G A G A A A T G T T A A A T	758	-
T G A T T A T T G T A A G A A A G A T T G A G A	759	-
A A G A A T T G T G T A A G A T T T A T G A G T A	760	-
T T G T A T T T A G A A G A T T T G T A G A T G	761	-
T A T A T G T T T G T G T A A G A A G A A A T G	762	-
G A T A A T G T G T G A A T T T G T G A A T A A	763	-
T T A G A A A T G T G A G A T T T A A G A G T T	764	-
A G T G T A G A A T T T G T A T T T A G T T G T	765	-
T A G T T A A G A T A G A G T A A A T G A T A G	766	-
G A A G T G A T A T T G T A A A A T T G A T A A G	767	-
G T A A T T G T G T T A G A T T T A A G A A G T	768	-
T G A T A T T T G T G A A T T G A T A G T A T G	769	-
A A G T A A A G A G A T A T A G T T A A G T T G	770	-
A T T A G T T A A G T T A T T T G T G A G T G A	771	-
A G A T G A A G T A G T T T A T G A A T T A G A	772	-
T G A G T T A G T T A A G T G A T A G T T A A A	773	-
T T A T T G T A G A T T T A G A G A A G A T G A	774	-
T A T T T G T G T T T G T T G A T T A G A T A G	775	-
G T A T T A A G T G T G T G A A A G T T A T A A	776	-
T A T A T G T T G A G T A T A A A G A G A G A A	777	-
T T A G T T A G T T T A A A G A T T G T G A G T	778	-
T T T A G A A T A A G T G A T G T G A T G A A A	779	-
A G A G T A A T G T G T A A A A T A G T T A G A T	780	-
T G T G A T A A A G A G A A A A T T A G T T G T T	781	-
G A A T T T A G T G A A A T G T T T G A G A T T A	782	-
T G T G A T G T G T A A G T A T A T G A A A A T T	783	-
T T G T G A A T G A T T A A A T G A A T A G A A G	784	51
A A T G T T G T T T A G A T T G A G A A A G T T	785	-
A G A T T G T G T T A G T A T T A G T A T A A G	786	-
T T G A T G T A T T A G A A A G T T T A T G T G	787	-
T A T G A T T G T G T G T T A G A G A A T T T A	788	-
T A G T T T A G A T A T T T T G A T A G T T A T G	789	52
A G T T T A A G T G T G T T T A G T T G T T A T G	790	-
T G T G T A A A G T A G A A A G T A A A G A T T	791	-
G T T A T G A T A T A G T G A G T T G T T A T T	792	53
T T T G A T T G A A A T G T T A A A T A G T G T G T	793	-
A G A G T A T T A G T A G T T A T T G T A A G T	794	54
T A A G T A G A A A G A A G A A G A T A T T T G	795	-
A G A A A G A G A A T T A T G T A A T G A A A G	796	-
T T A G A T T T G T T A G T G T G A T T T A A G	797	-
G A T G A T T A A G A T A T A G A G A T A G T T	798	-
A T A T T T G A G T G A T T A A G A G T A A T G	799	-
T G T A T T G T G A G T T A A G T A T A A G T T	800	-
A A T T T A G T A G A A A G T G T T G T G T T T	801	-
G T T A G A A G A T T A A G T T G A A T A A T G	802	-
T A A A G T A T G T G A G A T G A T T T A T G T	803	-
T G A A A T G A T T A A A G A T G A A G A T G A	804	-
T T A T T A G A T G T T G A G T G T T T G T T T	805	-
T A G T G T T T A A A G A G T A G T A T A T G A	806	-
A G T T A T A A G T A A A A T G A T G T T G A T G	807	-
T T A A G A G A G A A A T A A G T G T A T T G T	808	-

Table II

Sequence	SEQ ID NO:	No. in Ex 4
G A T A T T G A A A T G T G T A A A T G A T G A	809	-
A T G A T G A A T T A A G A A A G A A A G A G A	810	-
G A A T A G T T T G A T T T G T G T T T G T T A	811	-
A G T T G T T T A G A T T T G A T T T G T A A G	812	-
G T A T G A G A T T T T G A T A T A A G A T T A G	813	-
T T T A T A G T G A G T A T A G T G A T G A T T	814	-
T A T A T G T G A A G A T A T A A G T G T T T G	815	-
A T T G A T A G A T G A T A G T A A A T T G A G T	816	-
T G A T A G A T G T G A A G A A T T T G A T T T	817	-
G A A G A T A T T G A A A G A A T T T G A T G T	818	55
G A T G T T T A G T G T A G A T A T A G A T T T	819	-
G A A T A T T G A G T T A T A A G T A G T A G T	820	-
A G T G A G T A A G T A A T A G A A A G A T T T	821	-
G T A G A A T A A G T A A T T T T G T G A G A T A	822	-
G A G T T A T T T T G A G A T T T A G A T G T T T	823	-
G A A A T G A T G A T T G A A T T T A G A G A T	824	-
A A A T A G T G T G A G A A T A G T T A A G T A	825	-
A T G T G T T A A G T T G T A G A A G A A T A A	826	-
A T A A T G A G T T A A T A G T G T A A G A A G	827	-
A T A A G A G A T G T T T T A A G T T A G A A A G	828	-
T G T T A G T G T T A G A A A T A T G A A A G A	829	-
T T T A G A A A G A T T G T T A G A T A A G T T G	830	-
G T G T A A T A G T A T A A G A T A G T T A A G T	831	-
T A T T A G A G A G A A A T T G T A G A G A T T	832	57
T A G T G A G A T A A A G T A A A G T T T A T G	833	-
T T G T G A A A G T T A A G T A A G T T A G T T	834	-
A A A G T G T A A G T T G A A G A A T A T T G A	835	-
G A A T A G A G T G T T A T T T T G A A A T A G A	836	-
T A T A A G A G A G A G A T A A A G T A A T A A G	837	-
T G A G T G A A A T T G A T A G A G T A A A T T	838	-
G A T G A A T A A G T T T A A A G T G A G A A A T	839	-
G T G T G A T A T G T T T A T T G A T T A A G T	840	-
T A A A G T G A G T G T A A A A T G A T A A T G A	841	-
G T A G A G T T T T G A T T T T G A A A G A A T A T	842	-
G A A T A T T G T T A T G T T T T G T T A T G A G	843	-
G T G T A A T A A G A T G T A T T G T T G T T T	844	-
T A A A T T G A T T G T G A G T T G A A G A A T	845	-
T G A G A T A G T T A T A G T T A A A G T T T A G	846	-
A G T T T T G T T A A G A T T A T G T A G A A A G	847	-
G A A T G T G T A G A A T A A G A G A T T A A A	848	-
G T A T T A T G A A A G A A G T T G T T G T T T	849	-
G T G T T A T A G A A G T T A A A A T G T T A A G	850	58
T T A A G A G T A G T G A A T A T G A T A G T A	851	-
A A T G T T A T A A G A T G A G A G T T T A G T	852	-
A T A T A A G A T T T T G A T G T A G T G T A G T	853	-
T A T G T T T T G T T G T T G T T A A A G T T T G A	854	-
G A T A G T T T T A G T A T A G A A G A T A A A G	855	-
G T T G A A T A T A G A G A T A G T A A A A T A G	856	-
A G A G A A G A T T T A G T A A A G A A T G A T A	857	-
T G A A T G A G A A A G A T A T T G A G T A T T	858	-
T G A A G A T T A T A G T A G T T G T A T A G A	859	-
G A T T A G T A G T A T T T G A A G A T T A T G T	860	-
T G A A A T G T G T A T T T G T A T G T T T A G	861	59
A T T A A A G T T G A T A T G A A A G A A G T G	862	-

Table II

Sequence	SEQ ID NO:	No. in Ex 4
A A T G T A G A G A T T G T A G T G A A T A T T	863	62
T T A T T T G T T G A G T G T A A A T G T G A T	864	-
A T G T A A T T T G T G A A T A A T G T A T G T G	865	63
G A T T T T G T A T A G A G A T T A G T A A G T A	866	-
A A T A T T G T T T G T T T A G A G A A A G A A G	867	-
A T G A T G A T G T A T T T T G T A A A G A G T A	868	-
A A T G T A T T T T G T G T G A T T G T G T A A A	869	-
A G T G T T A T G A A G A A T A G T A A G A A T	870	-
G T T A T G T A G A G A T G A A A G A A A T T A	871	65
G T T T G T A T T A G A T A A A T G A G T T G T	872	-
T G A T T T A T G A G A T T A A G A G A A A G A	873	-
T T T G T G T G T T A T T G T A A T T G A G A T	874	70
G A T G T G T G A T A T G A T T A A A G A A A T	875	-
A G A T T A T A G A T T T T G T A G A G A A A G T	876	-
G A A G A G T A T G T A A T A G T A T T G T A T	877	-
T T T G T A A A T G T T G T T G A G T T T A A G A	878	-
A G T A A A T A G T A G T A T G A A T A A G A G	879	-
G A A T G T T G A A A T T G A A A T A T G A G T T	880	-
A G T A G T T A A A T T G A T A G T A A G T T T G	881	-
A G T G T A A A G A A A T G A A T G A A T A A G	882	-
T G T T A G A T A T T T G T G A A A T G T G A A	883	-
T G T A T G T T G A G T T T G A A A T T G T T A T	884	-
T G A G T G A A T T A G T T A T G T T G T T A T	885	-
G A A G A A A G A A A T G A G A A A G A T T A T	886	-
T T A A G T A A G T T G T G T T G A T A T T A G	887	-
A T G A T G T G T T T G A T T T G A A T T G A A	888	72
A A G T A A A G T G A A A T T G T T G T T T G A A	889	-
A T G A A G T G T A A A A G T T T G A A A G A A A	890	-
A G A G A G T A A A G A T A A T T G T A T A G T A	891	-
T T T A T G A G A T A G A T G A A A T A A G T G	892	-
A G A A A T T A G T A G T A A T G A T T T G T G	893	-
G A T T T T G A G A T T G A A T G A G A A T A T A	894	-
G A T T A G A A A G A T G A A T A A A G A T G A	895	-
T A G A T A G A A A A G T A T A T G T T G T A G T	896	-
G A A G A T A G T A A A A G T A A A G T A A G T T	897	-
A A A T G T G T G T T T A G T A G T T G T A A A A	898	75
T T G T T G A A A G T A A G A G A T G A A T A A A	899	-
T A T T T G A G A G A A A G A A A G A G T T T A	900	-
T A T T T A G T G A T G A A T T T G T G A T G T	901	-
T T A T A G T G A T G A T G A T A A G T T G A T	902	-
T A A A G A T A A A T T G T A G A A A G T A G T G	903	-
G T T T A G T A T T G A T A T T G T G T G T A A	904	-
G T G T T G T G A A T A A G A T T G A A A T A T	905	-
A A A G A A A G T A T A A A A G T G A G A T A G A	906	-
T A T T T T G T A A A G A A G T G T A G A T A T T G	907	-
T A G A A G A T G A A A A T T G T G A T T T G T T	908	-
A T A A T A G T A A A G T G A A T G A T G A G A T	909	-
A A T G T G A A T A A A G A T A A A G T G T G T A	910	-
A T T G A A G A T A A A G A T G T T G T T T A G	911	-
T G A A A T A G A A A G T G A G A T T A T A G T A	912	76
A G T T A T T G T G A A A A G A G T T T A T G A T	913	-
A A A T A G T A G T G A T A G A G A A G A T T T	914	-
A G T G T A T G A A A G T G T A A T A A G A T T A	915	-
T G A T T A A G A A T T G T G T A G T G T T A T A	916	-

Table II

Sequence	SEQ ID NO:	No. in Ex 4
AGTTTATGATATTTGTAGATGAGT	917	-
TATGTGTATGAAAGATTATAGTTAG	918	78
GAAATTTGTGTATAGAGTGATATA	919	-
TAGAAATAGTTTAAAGTATAGTGTG	920	-
TGATTTTAGATGTTTATTGTGAGAA	921	-
AAGTTGATATTTGTGTTAGATGA	922	-
TGATGTGATAATGAGAAATAAAGAA	923	79
AAAGTTTGTAGTTTGTATTAGTAGAG	924	-
AGTTTGTATGTGATAGTAAATAGAA	925	-
AAGTGTTATTGAAATGTGATGTTAT	926	-
AAATTGAAAGTGTGATAATGTTTGT	927	-
GTTTGTAGTGATTTAAAGATAGATTAG	928	82
ATAAGTGTATAAAGAGAAAGTGTAA	929	-
ATGAAATTTGTGTTGTGATGAAGTTA	930	-
AAAGAAATTTGAGAAATAAGAAAGTTAG	931	-
AGTGTAAGAGGTATAAAGGTATTTGA	932	-
GAAATTAAGATTGTTTATATGTGAGT	933	-
TATGAAAGTGTGTTGTTTAAAGTAAAGA	934	-
TAAAGTATAATTGATTGATGAGAGAA	935	-
AAAGATATTGATTGAGATAGAGTTT	936	-
AAGTGATATGAATAATGTGAGAAAT	937	-
AAATAGAGTTTGTATAATGTAAAGTG	938	-
GATTTAGATGAGTTTAAAGAAATTTAG	939	-
TTGTAAATGAGTGTGAAATAATTGTA	940	-
AGTAGTGTATTTGTAGGATAAATAGAA	941	-
TGAGTTTAAAGAGTTTGTGATATTTT	942	-
AAAGAGTGTATTTAGAAATAAGTTTG	943	-
GTTTGTAGTTATTTGTATGAGATAAATG	944	-
AAGTGTAATAATGAATAAAGAGTTGT	945	-
AATAAAGTGTAGTAAAGTGTAAATT	946	-
TATTTGAGTTTGTGTAAAGAAAGATA	947	-
TTTATAGTTTGTGTTGTGAAAGTTT	948	-
ATGAAATATGATTGTGTTTGTGTTGT	949	-
AAAGAGATGTAAAGTGAAGTTATTA	950	-
TTGAAGAAAGTTTAGATGATGAATT	951	-
ATGTTATTTGTTTAGTTTGTGTGA	952	-
AAATATGAATTTTGAAGAGAAAGTGA	953	-
GATTAGATATAGAAATAATTGAAGAG	954	-
TTAGAAATAAGAGAAATAATGTATGTGT	955	-
TTTATGAAAGAGAAAGTGTATTTATG	956	-
GTAAGTATTTAAGTGTGATTTTAGTA	957	-
ATAAAGAGAAAGTAAAGAGTAAAGT	958	-
ATTGTTAATTGAAAGTGTATGAAAG	959	-
TATATAGTTTGAAGTTGAGTAAAGATT	960	-
TAGATGAGATAATATGAAAGATAGT	961	-
ATAAGAAAGATGATTTGTGTAAATG	962	-
TTAGTAATAAGAAAGATGAAGAGAA	963	-
GATTTGTGAGTAAAGTAAATAAGAA	964	-
AAATAGATGTAGAAATTTGTGTGTTT	965	-
GAAATTAGTGTGTTGTGTTATTTAT	966	-
ATTTGAGTATGATGAGAAAGATTGTT	967	-
ATAGAGTTTGAAGTATGTAAAGTTT	968	-
TAAATTTGTGAATGTTGTTATTTGTG	969	-
TTAGTTTATGAGAGTGAAGATTTA	970	-

Table II

Sequence	SEQ ID NO:	No. in Ex 4
GTTGTTAGAGGTGTTTATGAATAATT	971	-
TTTATTGTGTGATGTGAAATTAAGAGA	972	-
GTAAGTAAATA TAGTAGTGAATAAG	973	-
TGAGATGATGTATATGTAGTAATA	974	-
AATTGAGAAAGAGATAAATGATAG	975	85
TTTGAAGTGAATGTTAGAAATGTTTA	976	-
AGTTGTGTGTGTAATTTGTTAGTAAA	977	-
ATAGTGTAGAAAGTGTATAAGATATTT	978	-
GTGTGATAAAGTAAATTTGAGTTTAAAT	979	-
TAGTTTATTGTTTTGTGAAATTTGAGA	980	-
ATAGTTTGAATAGTAAATTTTGAAGAG	981	-
ATGTTTGTGTGTTTTGAATAGAGAAATA	982	-
TGATAAAGATATATGAGAGATTTGTAA	983	-
TAAAGATGAGATGTTTGTAAAGTTT	984	-
AAGTGAATAATTTGTAAAGAAATTAGTG	985	-
GAAATGTAGAGAGTTTATTTGATAGTTTA	986	-
TTTGTAAATAATGAGATATAGTGTTAG	987	-
GTTAATTTGTGTATATTTGTATTAGTG	988	-
AGAGTGTGTGATAAAGATGTTTATA	989	-
AATTGTGAGAAATTTGATAGAAAGA	990	-
TTAAAGAGAAATTTGAGAAAGAGAAAT	991	-
TTGTTAGAAAGAAATTTGAAATGTATGT	992	-
AGTTAAGATATGTGTGTATGTTTAA	993	-
TGAGTTATGTGTGTAATAAGAAATTG	994	-
TTAGATAAAGTTTTAGAGATTTGAGAA	995	-
ATGAGTAATAAAGAGTATTTTGAAGT	996	-
TGTTTAAAGTGTAAATGATTTTGTTAG	997	-
TTGAAGAAAGATTTGTATTTGTGAA	998	-
TATAGAAAGATTTAAAGAGTGAATG	999	-
TAAATTTGTTAGAAATAATTTGAGTGTG	1000	-
ATTGTTAGTGTGTGTTATTTGATTTATG	1001	-
GAGAAATTTATGTGTGAAATATAGAAA	1002	-
TTGATTGTATAAAGTAAAGAGTGTAT	1003	-
GTGTGTAAATAATGAAATATGTTAAATG	1004	-
AAAGTAAAGAAAGAAAGTTTGAAGAG	1005	-
TTTAGTTTGAAGAAATAGAAAGAAAG	1006	-
GTGTAAATAAAGAGTGAATAGTAAATT	1007	-
TATTTGAAATAAAGAGAGATTTGTGA	1008	-
ATGAGAAAGAAAGAAAGTTTAAAGATTT	1009	-
AAGAGTGTAGATATATTTGTAAAGAA	1010	-
TTTGTAAAGTGTATGATGTAAAGATA	1011	-
GATGTTATGTGTATGAAATATGTAT	1012	-
GTAGAAATAAAGTGTAAAGTGTATA	1013	-
AAAGAGTATGTGTGTATGATATTTT	1014	-
AAAGATTAAGAGTTAGTAAATTTGTG	1015	-
AAGAAATTAAGAGAAATAAGTGTGATA	1016	-
GATAAGAAAGTGTAAATAATTTG	1017	86
GATGAAAGATGTTTAAAGTTTTGT	1018	-
AGTTGTAAAGTAAATAAGTTTTGAAGAA	1019	-
GTTGAGAAATTTAGAAATTTGATAAAG	1020	87
TTAAGAAATTTTGTATGTTGTGTTT	1021	-
AGAAGATTTTAGATGAAATGAGTTT	1022	-
TAAAGTTTGAAGATAAAGATGATATG	1023	-
TGAGATAGTTTGTAAATAATGTTTGT	1024	-

Table II

Sequence	SEQ ID NO:	No. in Ex 4
A G T T T G A A A T T G T A A G T T T G A T G A	1025	-
T A G A A T T G A T T A A T G A T G A G T A G T	1026	-
A G A G A T T T G T A A T A A G T A T T G A A G	1027	-
A T A A T G A T G T A A A T G T A A G T A G T G T	1028	-
T G A A A T T T G A T G A T G A G A T A T G T T A	1029	-
T G T G T A A A G T A T A G T T T A T G T T A G	1030	-
T G A A T A A G T G A A A T A G A A T G A A T G	1031	-
A A A G A A A G A T T G T A A T A A G T A G A G	1032	-
A A T G A A A T A G T G T T A A A T G A G T G T	1033	89
G T A G A T A A A G A T G T G A A T T A T G A T	1034	-
G A T A G T A T A T G T G T G T A T T T G T T T	1035	-
A T G T T T G T A G A A A T G T T T G A A G A T	1036	-
A A A T T T G T A G A G A G A A A T T T G T T G	1037	-
T A G A A T A A G A T T A G T A A G T G T A G A	1038	-
T G A T T T A G A G A A A T A T G A G T A G A A	1039	-
A A T A G A G T A T G T T G T T T A T G A G A A	1040	-
G A T G A T G A A G A G A G T T T A T T G T A A A T	1041	-
A A G T A A A G A A A G A A A A T G T G T T A	1042	-
T T G A A G A A T T A A A G T G T T T A G T G T A	1043	-
A G A A A G A A T G T T G A T T T A T G A T G T	1044	-
G A T T A A A G A G A T G T T G A T T G A A A T	1045	-
A A T G A T A A T T G T T G A G A G A G T A A T	1046	-
G T T T G T T G A A A G T G T A A A G T A T A T	1047	90
T G A G T T A T A T G A G A A A G T G T A A T T	1048	-
T T G T G A G A A A G A A G T A T A T A G A A T	1049	-
G T A A G T T T A G A G T T A T A G A G T T T A	1050	-
G A T A G A T A G A T A A A G T T A A T T G A A G	1051	-
A G A G A T G A T T G T T T A T G T A T T A T G	1052	-
A A A G T T A A G A A A T T G T A G T G A T A G	1053	-
T T T G A T A T T G T T T G T G A G T G T A T A	1054	-
A T T T G T A G A A A G T T G T T A T G A G T T	1055	-
G A T T T G A G T A A G T T T A T A G A T G A A	1056	-
A A G A T A A A G T G A G T T G A T T T A G A T	1057	-
G A T A T T G T A A G A T A T G T T G T A A A G	1058	-
G T A A G A G T G T A T T G T A A G T T A A T T	1059	-
T G T G T A T A G T A A T G T A A G T A T T T A	1060	91
G T A A G A A A G A T T A A G T G T T A G T A A	1061	-
A G T A G A A A G T T G A A A T T G A T T A T G	1062	92
T A A G A G A A G T T G A G T A A T G T A T T T	1063	-
G T T A A G A A A T A G T A G A T A A G T G A A	1064	-
T A A G T A A A T T G A A A G T G T A T A G T G	1065	-
A A G A T G T A T G T T T A T T G T T G T G T A	1066	-
A T T T A G A A T A T A G T G A A G A G A T A G	1067	-
G T T A T G A A A G A G T A T G T G T T A A A T	1068	93
T A T T A T G T G A A G A A G A A T G A T T A G	1069	-
T A A T A A G T T G A A G A G A A T T G T T G T	1070	-
T G A T G T T T G A T G T A A T T G T T A A A G	1071	-
G T G A A A G A T T T G A G T T T G T A T A A T	1072	-
A G A G A A T A T A G A T T G A G A T T T G T T	1073	-
T T T G A G A T G T G A T G A T A A A G T T A A	1074	-
G T T G T A A A T T G T A G T A A A G A A G T A	1075	94
T G T G T A T G A T G T T G T T A G T A T T A T	1076	-
A T T A T T G T G T A G A T G T A T T A A G A G	1077	-
G T T A G A A A G A T T T A G A A G T T A G T T	1078	-

Table II

Sequence	SEQ ID NO:	No. in Ex 4
T T G T G T A T T A A G A G A G T G A A A T A T	1079	-
G T T T A A G A T A G A A A G A G T G A T T T A	1080	-
A A T G A G A A A T A G A T A G T T A T T G T G	1081	-
T G A A T T G A A T A A G A A T T T G T T G T G	1082	95
A A T A A G A T T G A A T T A G T G A G T A A G	1083	-
A A T G T T T G A G A G A T T T A G T A A A G A	1084	-
A G T T T A G A A T A G A A A T G T G T T T G A	1085	-
T A T A A G T A A G T G T T A A G A T T T G A G	1086	-
G T A G T G A A T A A G T T A G T G T T A A T A	1087	-
A A G T G T G T T A A A G T A A A T G T A G A T	1088	-
A G A G A T G T T T A T G T T G T G A A T T A A	1089	-
A G T T G A A T A T T T G A T G A T A A G A A G A	1090	-
T G A A T G T G A G A T G T T T A G A A T A A T	1091	-
A A T A A T G A T G T A A G T T T G A G T T T G	1092	-
A A A G A G T G A A T A G A A A T A A G A G A A	1093	-
A A T A A A G T T A T T G A G A G A G T T T A G	1094	-
A G T A G T G T T G T A G T T T A G T A T A T A	1095	-
G T A A G A A T G T A T T A G A T A T T T G T G	1096	-
G A T A A A T G T T T T G A T A A A G T A G T T G	1097	-
A T A G A T A T G T A T G T G T A G A G A T T T A	1098	-
A T G A A T G T A G A G T G A T T A G T T T A A	1099	-
G T A G T A T T T T A G T G A T G T A A G A A T A	1100	-
A G A A T T G T A T T G A A G A A G A A T A T G	1101	-
T T T A T A G A A T T G A G A G A A G T T A A G	1102	-
A A A G T A G T A G A G A T T T T G A G A A T T A	1103	-
T T T A A A G A A A G T A T T T G T A A G A G T G	1104	-
A A A T T G A G A A A G T G A A T G A A G T T T	1105	-
A A G A A A T A A A G T A T G A T A G T A G T A G	1106	-
A T T T T G A A T T G T A T T G T A G T T T G T G	1107	-
A A G A G A A T A A T G T A G A G A T A T A A G	1108	-
T G T G T A A T A G T T G T T A A T G A G T A A	1109	-
T A T A G T T G T A G T T T A G A T G A A T G T	1110	-
A T T G T G T T A G A A T G A T G T T A A T A G	1111	-
G T T T G T A T A G T A T T T G A T T T G A T G T	1112	-
A G A G T A A A G T A T G A G T T A T G A A T A	1113	-
G A A A G T T T A A G T G A T G T A T A T T G T	1114	96
T T A A A T G A T A A A G A G T A G T G A A G T	1115	-
T T A A A T G T G T G A G A A G A T G A A T A A	1116	-
A T T T T G T A T A A A G T G A A G A A G A G A A	1117	97
T G A T T A G T A T T T T G T G A A G A G A T T T	1118	-
T T T G A A T G A A A T T G A T G A T A G A T G	1119	-
A G A G T A A G A T T A A G A A T A A G A A A G	1120	-
A T T G A A T T G A G A A G T G A A G T A A A T	1121	-
T T T A G A G A A G T A T T G T T T G A A A G A	1122	-
T A A A G T G A A A G A T T T G A A A T G A T G	1123	-
G A A A G T T A G A G A A A T G T A G A A A T T	1124	-
G T G A A T A A T G A A G A A G T T A T G T T A	1125	98
T T G T G A A T A A A G T A G A T G T G T T A T	1126	-
T T A T A T G A T A T G A G T T T G T G T T G A	1127	-
T T G A T T T G T G T G A G T A T T A G T T A T	1128	-
A A A G T G A T T A A G T T A G T T T T G A G A T	1129	-
T T G T A T T T T G T A T A A T G T T G A A G A G	1130	-
G T T T G A A A T T A G T G T G A G A A A T A T	1131	-
A A T G T T G A G A T T G A T A A T G T T G A A	1132	-

Table II

Sequence	SEQ ID NO:	No. in Ex 4
T A G T A G T A G T A T T G T T G T A A T A A G	1133	-
G T T G T A A T T T G A G T G T T A G T T A T T	1134	-
T G A A T A T G A T A G T T A G T A A T T G T G	1135	-
T G A T A G T A T G T T T G T G A T T A A A G A	1136	-
G A T G T A T A A A G A G T A T G T T A T A A G	1137	-
A G T G A G A T T T T A G A A G A T G T T A T T A	1138	-
A T G A G A A T T T T G T T A A A G A G A A A G T	1139	-
A A A G A A T T A G T A T G A T A G A T G A G A	1140	99
T A G A G T T G T A T A G T T T A T A G T T G A	1141	-
G T A G A A T G A T T G T T T A G A A A G A T T T	1142	-
G T T T A T G T T T G A G A A A G A G T T A T T T	1143	-
T A G A A G T T T T G A A A A G T T A T T G A T T G	1144	-
G A T G A A G A G T A T T T G T T A T A T G T A	1145	-
G A T G A A T A T A G T A A G T A T T G A G T A	1146	100
T A G T G A T G A A A T T T G A G A T A G A T A	1147	-
G A A A G A A A T T G A A G A G T T T G A T A T	1148	-
A T T T G A G T A T T T G T G T A T T G A A T G	1149	-
A T G A G T T G A A A T T T G A A G T A T T G T	1150	-
T T A A T A G T G A G A G A G T A T A T G T A A	1151	-
A T T A A G A G A G T G A G T A A A T G T A A A	1152	-
A A G A A T A G A T G A G A T T A G A A A T A G	1153	-
A G T T T A A A A G A G T T A G A A T T G A A A G	1154	-
G T A A G A T T T G T T G A A T A A A G A A G A	1155	-
A G A G A A A G A A A G T T A A A G T G A T A T T	1156	-
T A A T A G A G A A A G A G A T G T A T G A A T A	1157	-
T T A T T A G T G A T A A A G T G A A G T T T A G	1158	-
A T A A T G T A A A A G A T G A G T T T A T G A G	1159	-
T T G A T T T G A G A G T T G A T A A A G A T T T	1160	-
A T G A T T A T T G T G T G T A G A A T T A G A	1161	-
T A T A A A G A T A T A G T A G A T G A T G T G	1162	-
T T T A G T T G A G A T G A A G T T A T T A G A	1163	-
A T T G A A T T G A T A T A G T G T A A A G T G	1164	-
G A A G A A A G A T T A T T G T A T T G A G T T	1165	-
A A T G A G T G T A G T G A T T T A G A A A T A	1166	-
A A T A A A G T G T T T A A A G A G T A G A G T A	1167	-
G T A G A G A T A A T T G A T G T G T A A T T T	1168	-